Investigating the role of sex and the right ventricle in the development and treatment of experimental pulmonary hypertension by Griffin, Sinead Gael
 
 
 
 
 
 
 
Griffin, Sinead Gael (2020) Investigating the role of sex and the right 
ventricle in the development and treatment of experimental pulmonary 
hypertension. PhD thesis. 
 
http://theses.gla.ac.uk/81645/  
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
 
 
 
 
Investigating the role of sex and the right ventricle 
in the development and treatment of experimental 
pulmonary hypertension 
 
Sinéad Gael Griffin 
BSc (Hons), MRes 
 
Submitted in fulfilment of the requirements for the degree of Doctor of 
Philosophy in the Institute of Cardiovascular and Medical Sciences, University of 
Glasgow 
 
 
Institute of Cardiovascular and Medical Sciences 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
September 2020
  
ii 
 
Author’s Declaration 
I declare that this thesis has been written entirely by myself and is a record of 
the work performed by me, except where acknowledgement has been made. 
Margaret Nilsen and Dr. Craig Docherty provided assistance during the 
Anastrozole and FK506 in vivo studies. The protein expression analysis in rat 
pulmonary artery smooth muscle cells was generated by Dr. Katie Harvey. 
Development of the pulmonary artery banding model was carried out in 
collaboration with Margaret Nilsen and Michael Dunne. This thesis has not 
previously been submitted for a higher degree. The research was carried out in 
the Institute of Cardiovascular and Medical Sciences, College of Medical, 
Veterinary and Life Sciences at the University of Glasgow under the supervision 
of Prof. Stuart A. Nicklin and Dr. Christopher M. Loughrey. 
        Sinéad G. Griffin 
        January 2020 
 
  
iii 
 
Acknowledgements 
 
Firstly, I would like to thank my supervisors Prof. Stuart Nicklin and Dr. 
Christopher Loughrey for their support and advice throughout my PhD studies, 
particularly during my final year in the lab. I also have to thank them for their 
continued encouragement and support in ensuring I completed my thesis.  
I would also like to thank all my fellow lab members from Lab 427 - Lynn, Mags, 
Craig, Kirsty, Nina, Gerry, Teja, Afshan, Katie, Dawid, Alasdair and Claire. You 
all taught me so much and helped me develop as a scientist. As well as all the 
great laughs and nights out! A special thanks to Mags for her help with all things 
in vivo! Also, thank you to Mags and Mike for all their help with developing the 
PAB model. Thanks to the Nicklin and Loughrey groups for all their support 
during the final year when I was trying to learn a lot of new techniques and I had 
no idea where to start.  
I don’t look back on my PhD studies with many fond memories but the 
experience allowed me to work with some great people and gave me amazing 
friends and for that I am very grateful! To my lab mum Lynn, thank you so much 
for your friendship and all your support within and out with the lab. I couldn’t 
have done it without you and I will be eternally grateful to you (so will my 
mum!). Steph, you were a constant support and a great friend to me throughout 
Undergrad, Masters and PhD, thank you so much. I’m incredibly proud of you and 
the courage you’ve shown. I know you’ll be absolutely amazing in your new 
venture! 
The final thanks go to my family - Mum, Dad, Seán and Niamh - and my husband 
Chris. I would not have managed this had it not been for your absolute faith in 
me. I feel very lucky to have a family and husband that whole heartedly believe I 
can achieve anything I put my mind to. You would not let me give up and you 
gave me the courage I needed to keep going. You have been there for me in so 
many ways throughout this whole journey and for that I can’t thank you enough. 
Chris, you’ve been by my side throughout my whole university career, your 
support has been unwavering and you’ve done your very best to keep me sane 
during it all! Thank you.  
iv 
 
Table of Contents 
AUTHOR’S DECLARATION ................................................................. II 
TABLE OF CONTENTS ..................................................................... IV 
LIST OF FIGURES ........................................................................... XI 
LIST OF TABLES ........................................................................... XIV 
LIST OF PUBLICATIONS, PRESENTATIONS AND AWARDS .......................... XV 
DEFINITIONS/ABBREVIATIONS .......................................................... XVI 
SUMMARY .................................................................................. XX 
CHAPTER 1 ................................................................................... 1 
1 INTRODUCTION ........................................................................ 1 
1.1 Pulmonary circulation ............................................................. 2 
1.2 The right ventricle ................................................................. 3 
1.3 Pulmonary Hypertension ......................................................... 5 
1.3.1 WHO Classifications ........................................................... 5 
1.3.2 Clinical definitions ............................................................ 8 
1.3.3 Epidemiology ................................................................... 8 
1.3.4 Pathophysiology ................................................................ 9 
1.3.4.1 Pulmonary artery remodelling ......................................... 9 
1.3.4.2 Right ventricular remodelling and failure ........................... 13 
1.4 Genetic predisposition ........................................................... 16 
1.4.1 Bone morphogenetic protein receptor signalling ........................ 16 
1.4.2 Bone morphogenetic protein receptor 2 mutations as a risk factor for 
PAH  .................................................................................. 18 
1.5 PAH Therapeutics ................................................................. 19 
1.5.1 Current PAH therapeutics ................................................... 19 
v 
 
1.5.1.1 Calcium channel blockers .............................................. 21 
1.5.1.2 Prostacyclin Analogues ................................................. 21 
1.5.1.3 Prostacyclin IP receptor agonist ...................................... 22 
1.5.1.4 Endothelin Receptor Antagonists ..................................... 22 
1.5.1.5 Phosphodiesterase 5 Inhibitors ........................................ 23 
1.5.2 Potential therapeutics ....................................................... 23 
1.5.2.1 FK506 ..................................................................... 23 
1.5.2.2 Aromatase inhibitors ................................................... 26 
1.6 Estrogen ............................................................................. 28 
1.6.1 Estrogen biosynthesis and metabolism .................................... 28 
1.6.2 Estrogen signalling ........................................................... 31 
1.6.2.1 Nuclear signalling ....................................................... 32 
1.6.2.2 Non-genomic estrogen signalling ..................................... 32 
1.7 Sex differences in the cardiovascular system ............................... 33 
1.7.1 Downstream effects of estrogen in the cardiovascular system ........ 33 
1.7.2 Sex differences in pulmonary hypertension .............................. 33 
1.7.3 Estrogen in Pulmonary Hypertension ...................................... 34 
1.7.3.1 Estrogen in the pulmonary vasculature .............................. 34 
1.7.3.2 Estrogen in the right ventricle ........................................ 34 
1.7.4 Sex differences in BMPR2 in pulmonary hypertension .................. 35 
1.8 Animal models of pulmonary hypertension + right ventricular 
dysfunction ................................................................................. 36 
1.8.1 Chronic hypoxia model ...................................................... 37 
1.8.2 Sugen Hypoxia model ........................................................ 37 
1.8.3 Monocrotaline model ......................................................... 38 
1.8.4 Pulmonary artery banding model .......................................... 39 
1.9 Hypothesis and Aims ............................................................. 40 
CHAPTER 2 .................................................................................. 42 
2 MATERIALS AND METHODS ......................................................... 42 
2.1 Chemicals and Reagents ......................................................... 43 
vi 
 
2.2 Ethical Approval ................................................................... 43 
2.3 Animals .............................................................................. 43 
2.3.1 Animal welfare ................................................................ 43 
2.3.2 Sprague Dawley Rats ......................................................... 44 
2.3.3 Wistar Rats .................................................................... 44 
2.3.4 C57Bl/6 mice .................................................................. 44 
2.4 Animal Models of Pulmonary Hypertension .................................. 44 
2.4.1 Hypobaric Hypoxic Chamber ................................................ 44 
2.4.2 Chronic Hypoxia Rat Model .................................................. 45 
2.4.3 Chronic Hypoxia Mouse Model .............................................. 45 
2.5 Preparation of drugs .............................................................. 45 
2.5.1 FK506 ........................................................................... 45 
2.5.2 Anastrozole .................................................................... 46 
2.6 Administration of Drugs .......................................................... 46 
2.6.1 FK506 administration ........................................................ 46 
2.6.2 Anastrozole administration ................................................. 48 
2.7 Assessment of Pulmonary Hypertension Phenotype ....................... 48 
2.7.1 Anaesthesia .................................................................... 48 
2.7.2 Haemodynamic Measurements ............................................. 49 
2.7.2.1 Right Ventricular Pressure ............................................. 49 
2.7.2.2 Systemic Arterial Pressure and Left Ventricular Pressure ........ 51 
2.7.2.3 Volume calibration ...................................................... 53 
2.7.2.4 Analysis of haemodynamic measurements .......................... 54 
2.7.3 Tissue collection .............................................................. 54 
2.7.3.1 FK506 rat study .......................................................... 54 
2.7.3.2 Anastrozole mouse study ............................................... 55 
2.7.4 Right ventricular hypertrophy .............................................. 55 
2.7.5 In vivo studies acknowledgements ......................................... 56 
2.8 Histology ............................................................................ 57 
2.8.1 Tissue Processing ............................................................. 57 
2.8.2 Elastin picrosirius red staining .............................................. 59 
2.8.3 Pulmonary artery remodelling .............................................. 59 
vii 
 
2.9 Cell Culture ........................................................................ 60 
2.9.1 Primary cell isolations ....................................................... 60 
2.9.1.1 Adult rat cardiomyocyte isolation .................................... 60 
2.9.1.2 Neonatal rat cardiac cell isolation ................................... 63 
2.9.1.3 Adult rat pulmonary artery smooth muscle cell isolation ........ 66 
2.9.2 Passaging and plating cells .................................................. 66 
2.9.2.1 Charcoal stripped serum ............................................... 68 
2.9.3 Estrogen Stimulations of Neonatal Cardiac Fibroblasts ................. 68 
2.9.4 Migration Assay ............................................................... 69 
2.10 Analysis of RNA ................................................................. 70 
2.10.1 RNA extraction ................................................................ 70 
2.10.2 Quantification of RNA ........................................................ 70 
2.10.3 Complementary DNA preparation .......................................... 71 
2.10.4 Quantitative Polymerase Chain Reaction (qPCR) ........................ 73 
2.11 Western Blotting ................................................................ 76 
2.11.1 Protein Extraction ............................................................ 76 
2.11.2 Quantification of protein .................................................... 76 
2.11.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis ........ 76 
2.11.4 Protein transfer and visualisation .......................................... 77 
2.11.5 Immunoblotting ............................................................... 77 
2.12 Development of the Pulmonary Artery Banding Surgical Model ...... 80 
2.13 Statistical Analysis ............................................................. 80 
CHAPTER 3 .................................................................................. 81 
3 THE EFFECT OF FK506 TREATMENT ON PARAMETERS OF EXPERIMENTAL 
PULMONARY HYPERTENSION. ........................................................... 81 
3.1 Introduction ........................................................................ 82 
3.2 Results ............................................................................... 85 
3.2.1 Hypoxia but not treatment with FK506 significantly affects the body 
weight gain of male rats ............................................................... 86 
viii 
 
3.2.2 Hypoxia or treatment with FK506 does not significantly affect the 
body weight gain of female rats ...................................................... 88 
3.2.3 Treatment with FK506 had no significant effect on RVSP in male rats . 
  .................................................................................. 90 
3.2.4 Treatment with FK506 had no significant effect on RVSP in female 
rats  .................................................................................. 92 
3.2.5 FK506 did not reverse pulmonary artery remodelling in hypoxic male 
rats  .................................................................................. 94 
3.2.6 FK506 did not reverse pulmonary artery remodelling in hypoxic 
female rats ............................................................................... 96 
3.2.7 Systemic blood pressure in male rats is not influenced by treatment 
with FK506 ................................................................................ 98 
3.2.8 Systemic blood pressure in female rats is not affected by treatment 
with FK506 but hypoxia significantly influenced the systemic circulation ... 100 
3.2.9 Treatment with FK506 had no effect on LVSP in male rats housed in 
normoxic or hypoxic conditions ..................................................... 102 
3.2.10 Treatment with FK506 had no effect on LVSP in female rats housed in 
normoxic or hypoxic conditions ..................................................... 104 
3.3 Discussion ......................................................................... 106 
CHAPTER 4 ................................................................................ 110 
4 SEX DIFFERENCES IN RIGHT VENTRICLE IN EXPERIMENTAL PULMONARY 
HYPERTENSION AND THE EFFECT OF FK506 TREATMENT. ...................... 110 
4.1 Introduction ...................................................................... 111 
4.2 Results ............................................................................. 113 
4.2.1 The effect of hypoxia and FK506 treatment on right ventricular 
hypertrophy in male rats ............................................................. 114 
4.2.2 The effect of hypoxia and FK506 treatment on right ventricular 
hypertrophy in female rats .......................................................... 116 
4.2.3 Sex differences in right ventricular remodelling in experimental 
pulmonary hypertension .............................................................. 118 
4.2.4 Identification of an appropriate housekeeping gene for RV gene 
expression analysis .................................................................... 118 
ix 
 
4.2.5 The effect of hypoxia on the expression of genes involved in Bmpr2 
and Tgfβ pathway in RV tissue from male rats ................................... 121 
4.2.6 The effect of hypoxia on the expression of genes involved in cardiac 
remodelling in RV tissue from male rats ........................................... 123 
4.2.7 The effect of hypoxia on the expression of genes involved in Bmpr2 
and Tgfβ pathway in RV tissue from female rats ................................. 125 
4.2.8 The effect of hypoxia on the expression of genes involved in cardiac 
remodelling in RV tissue from female rats ........................................ 127 
4.2.9 The effect of FK506 treatment on the expression of Bmpr2 and Tgfβ1 
in RV tissue from male and female rats ............................................ 129 
4.2.10 The effect of FK506 treatment on the expression of cardiac 
remodelling associated genes in the male RV ..................................... 131 
4.2.11 Differential gene expression between the male and female normoxic 
RV.  ................................................................................ 133 
4.2.12 Differential gene expression between the male and female hypoxic 
RV.  ................................................................................ 135 
4.2.13 Development of in vitro models to investigate the role of sex in the 
right ventricle. ......................................................................... 137 
4.2.14 Investigation of neonatal rat cardiac fibroblasts ...................... 137 
4.3 Discussion ......................................................................... 140 
CHAPTER 5 ................................................................................ 144 
5 THE ROLE OF SEX AND ESTROGEN IN THE DEVELOPMENT OF 
EXPERIMENTAL PULMONARY HYPERTENSION AND THEIR EFFECT IN THE RV 144 
5.1 Introduction ...................................................................... 145 
5.2 Results ............................................................................. 148 
5.2.1 Investigation of the effect of Anastrozole on RVSP and BMPR2 
expression in the female mouse lung .............................................. 150 
5.2.2 Treatment with Anastrozole had no significant effect on RV or LV+S 
mass in the chronic hypoxia female mouse model ............................... 152 
5.2.3 Anastrozole does not significantly affect RV or LV+S mass in male 
chronic hypoxia mice ................................................................. 154 
5.2.4 Expression studies in the male and female mouse RV. ............... 156 
x 
 
5.2.5 Protein expression of Id1 and Id3 is significantly different between 
the male and female normoxic RV .................................................. 156 
5.2.6 CYP1b1, ER-α and Aromatase are expressed in the male and female 
mouse RV but expression is not significantly different between males and 
females  ................................................................................ 159 
5.2.7 Investigation of the effect of estrogen on the migration of pulmonary 
artery smooth muscle cells .......................................................... 162 
5.2.7.1 The expression of ER-a and ER-b in male and female rat PASMCs. 
  ........................................................................... 162 
5.2.7.2 The effect of varying serum conditions on the migration of rat 
PASMCs.  ........................................................................... 164 
5.2.7.3 The effect of 17b-estradiol and 16a-OHE1 on the migration of 
PASMCs  ........................................................................... 167 
5.3 Discussion ......................................................................... 170 
6 GENERAL DISCUSSION ............................................................. 175 
6.1 General Discussion .............................................................. 176 
6.2 Future perspective ............................................................. 181 
7 APPENDICES ......................................................................... 183 
7.1 Development of a protocol to isolate cardiomyocytes from the adult rat 
right ventricle ............................................................................ 183 
7.2 Development of the pulmonary artery banding rat model ............. 188 
BIBLIOGRAPHY ........................................................................... 192 
 
  
xi 
 
List of Figures 
Figure 1.1 - Pulmonary artery remodelling. ........................................... 12 
Figure 1.2 - Right Ventricle Adaptation in Pulmonary Arterial Hypertension. .... 15 
Figure 1.3 - Canonical BMPR2 signalling pathway. .................................... 17 
Figure 1.4 - Proposed mechanism of action for the activation of BMPR2 signalling 
by FK506. .................................................................................... 25 
Figure 1.5 – Estrogen metabolism. ...................................................... 30 
Figure 2.1 - Schematic diagram showing FK506 study protocol and dosing 
regimen. ..................................................................................... 46 
Figure 2.2 - Schematic diagram showing Anastrozole study protocol and dosing 
regimen. ..................................................................................... 48 
Figure 2.3 - Right ventricular pressure traces ......................................... 51 
Figure 2.4 - Left ventricular pressure traces .......................................... 53 
Figure 2.5 - Right ventricular remodelling in PH. ..................................... 56 
Figure 2.6 – Pulmonary artery remodelling. ........................................... 60 
Figure 3.1- Schematic diagram showing FK506 study protocol and dosing 
regimen. ..................................................................................... 85 
Figure 3.2. The body weight (g) of male rats throughout the duration of the 
study protocol. ............................................................................. 87 
Figure 3.3. The weight (g) of female rats throughout the duration of the study 
protocol. ..................................................................................... 89 
Figure 3.4. Right Ventricular Systolic Pressure (RVSP) in male rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day). ..... 91 
Figure 3.5. Right Ventricular Systolic Pressure (RVSP) in female rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day). ..... 93 
Figure 3.6. The effect of hypoxia and FK506 treatment on pulmonary artery 
remodelling. ................................................................................ 95 
Figure 3.7. The effect of hypoxia and FK506 treatment on pulmonary artery 
remodelling. ................................................................................ 97 
Figure 3.8. The effect of hypoxia and treatment with FK506 (0.05mg/kg/day) on 
systemic pressure in male rats. .......................................................... 99 
Figure 3.9. The effect of hypoxia and treatment with FK506 (0.05mg/kg/day) on 
systemic pressure in female rats. ..................................................... 101 
xii 
 
Figure 3.10. Left Ventricular Systolic Pressure (LVSP) in male rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day). ... 103 
Figure 3.11. Left Ventricular Systolic Pressure (LVSP) in female rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day). ... 105 
Figure 4.1 - Schematic diagram showing FK506 study protocol and dosing 
regimen. ................................................................................... 113 
Figure 4.2. The effect of hypoxia and treatment with FK506 on right and left 
ventricular mass in male rats. ......................................................... 115 
Figure 4.3. The effect of hypoxia and treatment with FK506 on right and left 
ventricular mass in female rats. ....................................................... 117 
Figure 4.4 . Identification of the most appropriate housekeeping gene for qRT-
PCR analysis of RV tissue. ............................................................... 120 
Figure 4.5. The effect of hypoxia on the gene expression of Tgfβ pathway and 
Bmpr2 pathway in the male RV. ....................................................... 122 
Figure 4.6. The effect of hypoxia on the expression of gene involved in cardiac 
hypertrophy and cardiac fibrosis in the male RV. ................................... 124 
Figure 4.7. The effect of hypoxia on the gene expression of Tgfβ pathway and 
Bmpr2 pathway in the female RV. ..................................................... 126 
Figure 4.8. The effect of hypoxia on the expression of gene involved in cardiac 
hypertrophy and cardiac fibrosis in the female RV. ................................ 128 
Figure 4.9. FK506 treatment significantly reduces expression of Tgfβ1 in the 
male hypoxic RV. ......................................................................... 130 
Figure 4.10 FK506 treatment has no significant effect on the expression of genes 
involved in cardiac remodelling. ...................................................... 132 
Figure 4.11. Differential gene expression between the male and female normoxic 
RV. .......................................................................................... 134 
Figure 4.12. Differential gene expression between the male and female hypoxic 
RV. .......................................................................................... 136 
Figure 4.13 The effect of estrogen on Tgf-β1 gene expression in Ang II stimulated 
NRCFs. ..................................................................................... 139 
Figure 5.1- Schematic diagram showing Anastrozole study protocol and dosing 
regimen. ................................................................................... 149 
Figure 5.2. RVSP and lung BMPR2 expression in the female chronic hypoxia mouse 
model. ..................................................................................... 151 
xiii 
 
Figure 5.3. The effect of hypoxic and treatment with Anastrozole (3mg/kg/day) 
on RV and LV+S mass in female C56Bl/6 mice. ...................................... 153 
Figure 5.4. The effect of hypoxic and treatment with Anastrozole (3mg/kg/day) 
on RV and LV+S mass in male C56Bl/6 mice. ........................................ 155 
Figure 5.5. Differential gene expression between the male and female normoxic 
mouse RV. ................................................................................. 157 
Figure 5.6 Protein expression of BMPR2, ID1 and ID3 in the normoxic male and 
female mouse RV. ........................................................................ 158 
Figure 5.7. Cyp1b1 gene expression in the male and female normoxic mouse RV.
 .............................................................................................. 160 
Figure 5.8 Protein expression in the male and female mouse normoxic RV. ... 161 
Figure 5.9. Expression of ER-a and ER-b in male and female rat PASMCs. ...... 163 
Figure 5.10. The effect of serum and DMEM on the migration of male rat PASMCs.
 .............................................................................................. 165 
Figure 5.11. The effect of serum and DMEM on the migration of male rat PASMCs.
 .............................................................................................. 166 
Figure 5.12. The effect of 17β-estradiol and 16α-OHE1 on the migration of male 
and female rat pulmonary artery smooth muscle cells in charcoal stripped 
serum. ..................................................................................... 168 
Figure 5.13. The effect of 17β-estradiol and 16α-OHE1 on the migration of male 
and female rat pulmonary artery smooth muscle cells in charcoal stripped serum 
and FBS. ................................................................................... 169 
Figure 7.1 Representative image showing the rod shaped and ball shaped cells 
following adult rat RV cardiomyocyte isolation protocol. ......................... 185 
  
xiv 
 
List of Tables 
Table 1 – Updated clinical classification of PH. ........................................ 6 
Table 2 - Functional classification of pulmonary hypertension in adults. .......... 7 
Table 3 - Tissue Processing Schedule for embedding rat lung tissue and rat heart 
tissue in paraffin wax. ..................................................................... 58 
Table 4 - Krebs-Henseleit Solution contents ........................................... 62 
Table 5 - ADS buffer contents ............................................................ 65 
Table 6 - Neonatal heart digestion protocol ........................................... 65 
Table 7 - Plating media contents ........................................................ 65 
Table 8 – TaqMan Reverse Transcription Reagents. ................................... 72 
Table 9 - Mouse TaqMan Primers (Thermo Scientific, UK). .......................... 74 
Table 10 - Rat TaqMan Primers (Thermo Scientific, UK). ............................ 75 
Table 11 - Western Blotting protocols. ................................................. 79 
Table 12. Development of adult rat RV cardiomyocyte isolation in Wistar Hans 
male rats. ................................................................................. 186 
Table 13. Development of adult rat RV cardiomyocyte isolation in Wistar Hans 
female rat. ................................................................................ 187 
Table 14. Development of the pulmonary artery banding rat model protocol. 189 
Table 15. Summary of the phenotype and haemodynamic measurements of 
Pulmonary Artery Banding Sham surgery model. .................................... 191 
  
xv 
 
List of Publications, Presentations and Awards 
Publication 
Docherty C.K., Harvey K.Y., Mair K.M., Griffin S., Denver N., MacLean M.R. 
(2018) The Role of Sex in the Pathophysiology of Pulmonary Hypertension. In: 
Kerkhof P., Miller V. (eds) Sex-Specific Analysis of Cardiovascular Function. 
Advances in Experimental Medicine and Biology 1065:511-528. Springer, Cham 
Poster Presentation 
Griffin S., Docherty C.K., Nilsen M., Loughrey C.M. and Nicklin S.A. Sex 
differences in right ventricular remodelling in experimental pulmonary 
hypertension and the effect of FK506 (tacrolimus) treatment. British Heart 
Foundation Student Conference, Edinburgh, UK.  
Awards 
Graham Wilson Travelling Scholarship, May 2017.  
  
xvi 
 
Definitions/Abbreviations 
(v/v)   volume/volume 
(w/v)   weight/volume 
16α-OHE1  16α-hydroxyestrone 
ANG II   Angiotensin II 
ANOVA  Analysis of variance 
ANP   Atrial natriuretic peptide 
B2M    β2-microglobulin 
BMP    Bone morphogenetic protein 
BMPR2  Bone morphogenetic protein receptor 2 
BNP   Brain natriuretic peptide 
BSA    Bovine serum albumin 
BW   Body weight 
cDNA   Complementary deoxyribonucleic acid 
CI   Cardiac index 
CMC   Carboxymethyl cellulose 
CO   Cardiac output 
COL1A1  Collagen type 1 alpha 1 chain 
COL3A1  Collagen type 3 alpha 1 chain 
CRF   Central Research Facility 
CSS   Charcoal Stripped Serum 
CT   Cycle Threshold 
CTGF   Connective tissue growth factor 
CVRU   CardioVascular Research Unit 
CYP   Cytochrome P450 
CYP1a1  Cytochrome P450 1A1 
CYP1B1   Cytochrome P450 1B1 
DMEM   Dulbecco’s Modified Eagle’s Medium  
DMSO   Dimethyl Sulfoxide  
DNA   Deoxyribonucleic acid 
E1   Estrone 
E2   17β-Estradiol 
E3   Estriol 
ECL   Enhanced chemiluminescence 
xvii 
 
EDTA   Ethylenediaminetetraacetic acid 
EndMT  Endothelial-to-mesenchymal transition 
ER-α   Estrogen receptor-α 
ER-β   Estrogen receptor-β 
ERE   Estrogen response element 
ET-1   Endothelin 1 
EtOH   Ethanol 
FBS   Fetal Bovine Serum 
GAPDH  Glyceraldehyde phosphate dehydrogenase 
GPER   G protein-coupled estrogen receptor 1 
HD   High detergent 
HIF1α   Hypoxia-inducible factor 1-alpha 
hPASMCs   Human pulmonary artery smooth muscle cells 
Hr   Hour 
HRP   Horseradish peroxidise 
Id1    Inhibitor of DNA binding protein 1 
Id3    Inhibitor of DNA binding protein 3 
IL-1b   Interleukin-1b 
IP   Intra-peritoneal 
Klf15   Krüppel-like factor 15 
Krebs   Krebs-Henseleit solution 
LM   Lauryl Maltoside  
LV    Left ventricle 
LV+S   Left ventricle + septum 
LVP   Left ventricular pressure 
LVSP   Left ventricular systolic pressure 
MDD   Matrix driven delivery 
mins   Minutes 
mmHg   Millimetres of mercury 
MPVS   Millar Pressure Volume System 
Myh7   Myosin heavy chain 7 
NBF   Neutral buffered formalin 
NIH   National Institute of Health 
Nppa   Natriuretic Peptide A 
Nppb   Natriuretic Peptide B 
xviii 
 
OHE   Hydroxyestradiol 
PAB   Pulmonary artery banding 
PAH    Pulmonary arterial hypertension  
PAP    Pulmonary arterial pressure 
PASMCs  Pulmonary artery smooth muscle cells 
PBS    Phosphate buffered saline 
PenStrep  Penicillin + Streptomycin 
PH    Pulmonary hypertension 
Ppib   Peptidyl-prolyl cis-trans isomerase B 
pSmad  Phospho-Smad 
PV   Pressure-Volume 
PVDF   Polyvinylidene fluoride 
PVR   Pulmonary vascular resistance 
qPCR   Quantitative polymerase chain reaction 
RNA   Ribonucleic acid 
RPM   Rotations per minute 
RQ    Relative quantification 
RT   Reverse Transcription 
RV   Right Ventricle 
RVEF   Right ventricular ejection fraction 
RVH    Right ventricular hypertrophy 
RVP   Right ventricular pressure 
RVSP   Right ventricular systolic pressure 
SAP   Systemic arterial pressure 
SD   Sprague Dawley 
SDS    Sodium dodecyl sulphate 
SDS PAGE  SDS-polyacrylamide gel electrophoresis  
SEM   Standard error of the mean 
SMC    Smooth muscle cell 
SNP   Single nucleotide polymorphism 
SuHx    Sugen 5416/Hypoxia 
TBS   Tris-Buffered Saline 
TBST   Tris-buffered saline + 0.1% (v/v) Tween20 
TGF-β1   Transforming Growth Factor Beta 1 
TGFβR1  Transforming Growth Factor Beta Receptor 1 
xix 
 
TNF-a   Tumour necrosis factor a 
UK   United Kingdom 
USA   United States of America 
VEGF-a  Vascular Endothelial Growth Factor a 
WGA   Wheat Germ Agglutinin 
WKY   Wistar Kyoto 
WMB   West Medical Building 
xx 
 
Summary 
Pulmonary arterial hypertension (PAH) is a rare disease characterised by 
pathological remodelling of the pulmonary vasculature resulting in increased 
pulmonary vasculature resistance and pulmonary artery pressure. This eventually 
results in maladaptive changes within the right ventricle (RV) leading to RV 
dysfunction and ultimately RV failure. Investigations of heritable PAH identified 
mutations in BMPR2 as a major risk factor for disease development. 
Approximately 75% of heritable cases and 20% of idiopathic cases are associated 
with heterozygous mutations in this gene. However, penetrance rates are low, 
suggesting the involvement of other endogenous and environmental factors in 
triggering the development of disease.    
 
PAH patient registries have highlighted an increased female to male ratio within 
the patient population, in some registries the ratio is as high as 4:1. This 
indicated the female sex was associated with increased risk of disease and 
encouraged investigation into the role of sex hormones in the development of 
disease. Estrogen (17b-estradiol) and estrogen metabolites have been a focus of 
recent research, however, studies have produced conflicting results on the 
protective or pathological effect of estrogen in the pulmonary vasculature. This 
research is further complicated by the finding that although fewer males 
develop PAH, male PAH patients tend to have poorer clinical outcomes. This is 
thought to be associated with more rapid decline in RV function. These 
contradictions are known within the field as the “estrogen paradox”.  
Currently, the therapies licenced for the treatment of PAH only target the 
vasoconstriction of the pulmonary vasculature, therefore, there is a need to 
identify new therapeutic targets. The role of sex in the development of disease 
highlights a need to investigate the sex specific effects of potential PAH 
therapies. The main aim of this thesis was to investigate the sex-specific effects 
of two potential therapies for PAH patients – FK506 (tacrolimus) and Anastrozole 
(aromatase inhibitor). An additional aim was to characterise the male and 
female RV and identify sex-specific differences that may contribute to disease 
progression.  
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Firstly, the effect of FK506 treatment (0.05 mg/kg/day) was investigated in the 
chronic hypoxia rat model. To our knowledge, this was the first time FK506 
treatment had been investigated in this model. Administration of FK506 in male 
and female chronic hypoxia rats had no significant effect on right ventricular 
systolic pressure (RVSP), pulmonary artery remodelling or RV/LV+S. However, 
further investigation of the RV indicated that RV mass and RV mass/body weight 
were significantly decreased in the hypoxic FK506 treated males. This led to a 
gene expression study to investigate the effect of hypoxia and FK506 treatment 
in the male and female RV, as well as a direct comparison between the male and 
female RV. The key finding from this study was that hypoxia increased 
expression of Tgfb1 in the male RV only and treatment with FK506 significantly 
reduced expression. Furthermore, Tgfb1 expression is significantly higher in the 
male RV in normoxia and hypoxia compared with the female RV. Expression of 
genes associated with cardiac remodelling – Col1a1, Ctgf, Nppa and Myh7 – were 
all differentially expressed between the hypoxic male and female RV, with males 
displaying increased expression. These results are preliminary but could indicate 
a differential response to hypoxia by the male and female RV, which could be 
associated with disease progression. A model to isolate adult rat RV 
cardiomyocytes is under development during this thesis in order to investigate 
these findings further in male and female cells.  
The next study involved investigation of treatment with Anastrozole in the 
chronic hypoxia mouse model. This study was focused on female mice as 
Anastrozole had previously been shown to reverse pulmonary hypertension (PH) 
in female mice. However, Anastrozole had no significant effect on RVSP or 
RV/LV+S in female mice and had no significant effect on RV/LV+S in male mice. 
As the first study in this thesis had highlighted key differences in the male and 
female RV in adult rats, the male and female mouse RV was compared to 
understand if these findings were due to differences across species. These 
investigations showed that Id1 and Id3 proteins, downstream components of the 
BMPR2 signalling pathway, were expressed at significantly lower levels in the 
female normoxic RV. This again highlighted differences in a key signalling 
pathway in PAH that could contribute to the differences in susceptibility and 
progression of disease between males and females.  
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Continuing to assess the role of estrogen in the development of PAH, final 
investigations carried out in rat pulmonary artery smooth muscle cells (PASMCs) 
investigated the effects of 17b-estradiol (E2) and 16a-hydroxyestrone (16a-
OHE1) on cell migration. These results highlighted that although the use of 
charcoal stripped serum is preferred for in vitro investigations involving steroid 
hormones, the stripping process may also remove factors that promote cell 
migration. E2 and 16a-OHE1 did not stimulate migration of male or female rat 
PASMCs.  
In summary, this thesis provides preliminary evidence that there are significant 
differences between the male and female RV which could contribute to disease 
development, progression and the success of treatment. In future, it would be 
important to confirm these findings and the downstream effects of differential 
gene and protein expression utilising appropriate cell models. It is important 
that the sex-specific effects of potential PAH therapeutics are investigated as 
well as the lung and RV specific effects. PAH patients may benefit from sex-
specific treatment protocols which could ultimately reduce disease burden and 
mortality rates.  
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Chapter 1 
1 Introduction  
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1.1 Pulmonary circulation 
The roles of the pulmonary circulation and systemic circulation differ 
significantly and therefore the structure and function of the two circulatory 
systems are also significantly different. The systemic circulation is a high 
pressure, high resistance system, with systolic pressures of approximately 120 
mmHg and a mean pressure of approximately 100 mmHg (Hlastala and Berger, 
2001). The function of the systemic circulation is to deliver oxygenated blood to 
all peripheral tissues. Despite high blood volumes, the pulmonary circulation is a 
low pressure, low resistance system (Yuan and Rubin, 2001). It carries 
deoxygenated blood from the right ventricle (RV) to the right and left lungs and 
allows for high volume gaseous exchange (Rizzo et al., 2015). The primary 
function of the pulmonary circulation is to allow for gaseous exchange to take 
place between inspired air within the lungs and the blood in the capillaries 
surrounding the terminal alveoli of the right and left lung.  Systolic pressures 
within the pulmonary circulation are approximately 25 mmHg and mean 
pressures approximately 15 mmHg, significantly lower than the systemic 
pressure (Hlastala and Berger, 2001). Venous blood is received into the right 
atrium, via the vena cava, where it then passes into the RV through the tricuspid 
valve. During contraction of the heart, blood from the RV is ejected into the 
main pulmonary artery, which subsequently branches to form the left pulmonary 
artery and right pulmonary artery distributing blood to the right and left lung. 
The left and right pulmonary arteries enter the left and right lung parenchyma, 
respectively, and continue to branch to cover the entirety of the terminal alveoli 
at the most distal areas of the lung. The right pulmonary artery branches into 3 
vessels in order to supply the 3 lobes of the right lung – inferior, middle and 
superior. The left pulmonary artery branches into 2 vessels supplying the 2 lobes 
of the left lung – superior and inferior.  
Huang et al. (1996) describes 15 orders of pulmonary artery from the main 
pulmonary artery down to the capillaries surrounding the terminal alveoli  
(Huang et al., 1996). Order 15 describes the main pulmonary artery which is 
approximately 15.1 mm in diameter whereas order 1 pre-capillary vessels are 
only 20 µm in diameter. The diameter of the pulmonary vessels decreases 
rapidly with the order. Only the most proximal vessels (order 15-12) are greater 
than 2 mm in diameter. The structure and compliance of the vessels adapts as 
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they branch from the main pulmonary artery to the capillaries. In general, the 
higher order vessels are compliant with a developed elastic lamina, medium 
order vessels have increased muscularisation and the low order vessels have 
relatively lower numbers of smooth muscle cells and an increased number of 
endothelial cells comparatively (Elliott and Reid, 1965; Rizzo et al., 2015).  
1.2 The right ventricle 
Primarily, the role of the RV is to receive the venous return from the vena cava 
via the right atrium. Then, during each contraction of the heart muscle, eject 
the blood allowing the pulmonary circulation to deliver it to the right and left 
lungs. The RV must do this without increasing the pressure experienced by the 
right atria (Pinsky, 2016). Venous return under steady state is equal to cardiac 
output. As cardiac output, and therefore venous return, is dependent on 
physiological conditions such as stress or exercise, the RV has the capacity to 
respond to significant changes in blood flow (Pinsky, 2016). The pressure within 
the thoracic cavity also changes instantaneously with the movement of the chest 
during each breath and therefore venous return is also influenced by this 
pressure gradient (Pinsky, 1984). When functioning normally, the pulmonary 
vasculature can cope with these transient and prolonged changes in blood flow 
from the RV without a significant increase in pulmonary arterial pressure.  
It was assumed that the RV functioned similarly to the left ventricle (LV) but on 
a smaller and weaker scale. However, more recent investigations into the 
structure and function of the RV have shown it to be significantly different. 
Studies have investigated the relationship between RV volumes and RV pressure 
(Tyberg et al., 1986) (Pinsky et al., 1992). It is hypothesised that under normal 
conditions the RV fills without an increase in RV pressure or wall stretch. This 
feature of the RV is thought to be associated with a change in RV shape (Pinsky, 
2016).  
The contraction of the muscle fibres also differs between the left and right 
ventricle due to the orientation of the 3D network of myocardial fibres that 
make up the myocardium. Primarily, fibres of the LV are in a circumferential 
orientation. Contraction of these circumferential fibres is the main cause of a 
decrease in LV diameter, whereas, the oblique fibres contribute by shortening 
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the overall length of the ventricle (Sheehan and Redington, 2008). Contraction 
of the LV can be described as a twisting action as the muscle fibres of both the 
oblique and longitudinal axis contract (Pinsky, 2016). On the surface of the RV 
there are also circumferential muscle fibres which are a continuation of the 
myofiber tracts shared with the LV. However, the fibres which are most 
significantly involved in the contraction of the RV are longitudinal (Sakuma et 
al., 2002). These are positioned deeper within the RV myocardium in the 
subendocardial region (Rich, 2012; Geva et al., 1998). The interventricular 
septum also contributes to RV contraction and the subsequent ejection of blood. 
This is also via shortening of longitudinally oriented fibres. RV contraction 
creates a wave like “peristaltic” motion moving between the RV inflow tract, 
mid wall and outflow tract (Dell'Italia, 1991). It takes approximately 25-50 
milliseconds (ms) for the contraction to travel between the inflow and outflow 
regions (Pinsky, 2016). It is also thought that the RV free wall moves inwards and 
protrusion of the septum into the RV during LV contraction all contribute to the 
pumping action of the RV (Kovacs et al., 2019). It is not only during the peak in 
systolic pressure within the RV that blood is ejected, it is estimated that almost 
60% of the blood is ejected following the peak in pressure. The compliant and 
low resistance pulmonary circulation allows for this. Furthermore, the 
pulmonary artery is dilated and prepared to receive the blood as a result of the 
peristaltic contraction of the RV (Redington et al., 1990). 
The LV is better adapted to changes in afterload as a result of its more muscular 
phenotype. However, it is less capable than the RV to cope with changes in pre-
load. As described, even under normal physiological conditions, drastic changes 
in pre-load will take place when exercise is commenced for example. During 
these changes the RV doesn’t stretch but maintains its shape and therefore can 
continue to function normally. The ability of the RV to cope with alterations in 
preload is exemplified by the fact that it can continue to function normally even 
under pathological conditions of prolonged preload (Rich, 2012). On the 
contrary, it is much less capable of coping with changes in afterload compared 
to the LV. In pathological conditions involving a sustained increase in afterload, 
such as in pulmonary hypertension (PH), the RV falls into a state of dysfunction 
and eventually failure.  
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1.3 Pulmonary Hypertension  
Pulmonary hypertension (PH) is used to describe a group of pathologies 
associated with the pulmonary vasculature. Often there is a combination of 
different pathological changes which occur in the pulmonary vasculature. These 
pathological changes lead to an increase in pulmonary artery pressure (PAP), an 
increase in pulmonary vascular resistance and vasoconstriction of the pulmonary 
arteries. All of these factors contribute to constriction of the vessel lumen and, 
in some cases, complete obliteration of the vessel. The vascular changes 
ultimately lead to an increase in afterload experienced by the RV which in turn 
results in right ventricular dysfunction and subsequently right ventricular failure. 
These pathogenic changes can have fatal consequences.  
1.3.1 WHO Classifications 
Pulmonary hypertension can result from a wide range of clinical conditions and is 
classified into 5 categories depending on the mechanism of disease (Table 1). An 
updated version of the World Health Organisation (WHO) clinical classifications 
were published by Simonneau et al. in 2019 (Simonneau et al., 2019).  Similar 
pathological changes occur to all 5 groups, however, classification aids with the 
diagnosis, prognosis and treatment of PH patients. Pulmonary Arterial 
Hypertension (PAH) is classified as Group 1. This grouping includes idiopathic 
PAH (iPAH), heritable PAH (hPAH), drug and toxin induced PAH and associated 
PAH (aPAH). aPAH incorporates PAH resulting from other systemic conditions and 
diseases. The WHO have also published guidelines for the functional 
classification of pulmonary hypertension in adult patients (Galie et al., 2009b). 
The classification is based on the New York Heart Association (NYHA) 
classification of heart failure. Patients are assigned to 1 of 4 groups dependent 
on their symptoms and their capability to perform any type of physical activity 
(Table 2). Class I describes PH patients with no limitation to physical activity. 
Class IV describes PH patients who experience symptoms even at rest and are 
incapable of carrying out any physical activity without experiencing symptoms. 
The classifications are very broad, for example, class III could describe many PH 
patients with variable capacities for physical activity. However, it is thought to 
be useful in developing treatment strategies and predicting patient survival.      
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Updated clinical classifications of PH 
Group 1 Pulmonary Arterial Hypertension 
 1.1 Idiopathic PAH 
 1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK1, ENG, SMAD9, CAV1, KCNK3  
1.2.3 Unknown 
 1.3 Drug- and Toxin-induced PAH 
 1.4 PAH associated with 
      1.4.1 Connective tissue disease 
      1.4.2 HIV infection 
      1.4.3 Portal hypertension 
      1.4.4 Congenital heart disease 
      1.4.5 Schistosomiasis 
 1.5 Persistent PH of the newborn 
 1.6 Pulmonary veno-occlusive disease and/or pulmonary capillary 
hemangiomatosis 
 1.7 PAH long-term responders to calcium channel blockers 
Group 2 Pulmonary hypertension due to left heart disease  
 2.1 Systolic dysfunction 
 2.2 Diastolic dysfunction 
 2.3 Valvular heart disease 
 2.4 Congenital/acquired left heart inflow/outflow tract 
obstruction and congenital cardiomyopathies 
Group 3 Pulmonary hypertension due to lung disease and or/hypoxia 
 3.1 Chronic obstructive pulmonary disease 
 3.2 Restrictive lung disease 
 3.3 Other pulmonary diseases with mixed restrictive and 
obstructive pattern 
 3.4 Hypoxia without lung disease 
 3.5 Developmental lung diseases 
Group 4 Pulmonary hypertension due to pulmonary artery obstructions 
 4.1 Chronic thromboembolic PH 
 4.2 Other pulmonary artery obstructions 
Group 5 Pulmonary hypertension with unclear multifactorial mechanisms 
 5.1 Haematological disorders: chronic haemolytic anaemia, 
myeloproliferative disorders, splenectomy  
 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
 5.3 Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders 
 5.4 Other: tumoral obstruction, fibrosing mediastinitis, chronic 
renal failure, segmental PH. 
 5.5 Complex congenital heart disease 
Table 1 – Updated clinical classification of PH.  
World Health Organisation (WHO) Classification of Pulmonary Hypertension 
(Simonneau et al., 2019).  
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Functional classification of pulmonary hypertension in adults 
Class I Patients with PH but without 
limitation of physical activity. 
Ordinary physical activity does not 
cause undue dyspnoea, fatigue chest 
pain or near syncope  
Class II Patients with PH resulting in slight 
limitation of physical activity. 
Comfortable at rest. Ordinary physical 
activity causes undue dyspnoea, 
fatigue, chest pain or near syncope 
Class III Patients with pulmonary hypertension 
resulting in marked limitation of 
physical activity. Comfortable at rest. 
Less than ordinary activity causes 
dyspnoea or fatigue, chest pain or 
near syncope 
Class IV Patients with pulmonary hypertension 
resulting in inability to carry out any 
physical activity without symptoms. 
These patients manifest symptoms of 
right heart failure. Dyspnoea and/or 
fatigue may be present even at rest. 
Discomfort is increased by any 
physical activity undertaken. Syncope 
or near syncope can occur. 
Table 2 - Functional classification of pulmonary hypertension in adults. 
WHO functional classification of pulmonary hypertension in adults (Galie et al., 
2009b). 
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1.3.2 Clinical definitions 
Clinically, PAH is defined as sustained elevation in pulmonary vascular resistance 
(PVR) and a mean pulmonary arterial pressure (PAP) > 25mmHg at rest and > 
30mmHg during exercise (Mair et al., 2014a). The clinical symptoms of PAH 
include: fatigue, breathlessness during exercise, dizziness and chest pain. As the 
symptoms are non-specific, diagnosis is often delayed and the disease is well 
established, with significant haemodynamic and functional impairment, when a 
patient presents at clinic (Ling et al., 2012).  
1.3.3 Epidemiology 
Understanding the clinical features and disease development of a rare and 
complex disease, such as PAH, is challenging and, therefore, information is 
based on the data collected in registries. The first PAH register was developed in 
the 1980s by the National Institute of Health (USA) (Rich et al., 1987). There are 
now many different PAH registries in countries including: USA, UK, Spain, China 
and France. However, it is suggested that in order to advance our understanding 
of this complex disease, more still needs to be done to create a world-wide, 
centralised approach to PAH registries (Awdish and Cajigas, 2016).  
The prevalence of PAH is relatively low, a study by Ling et al. (2012) which 
investigated the UK registry estimated the prevalence as 6.6 adults per million in 
the UK/Ireland in 2009 (Ling et al., 2012). An early study of PAH in Scottish 
centres described the prevalence as 25 adults per million (Peacock et al., 2007). 
Finally, the French National Registry described 15 cases per million adults in 
2003 (Humbert et al., 2006). All of these studies show a low prevalence of PAH 
across different populations. Ling et al. (2012) also highlighted changes in the 
patient cohort within recent years suggesting that patients were now diagnosed 
at an older age, with more obesity and with a greater number of co-morbidities. 
The mean age of diagnosis in the data collected from the 8 PAH centres across 
the UK and Ireland was 50 years of age (Ling et al., 2012). This is in keeping with 
other recent studies based on the French and REVEAL registries which showed 
the mean age of diagnosis to be 50 and 53 years of age, respectively (Humbert 
et al., 2006; Badesch et al., 2010). In comparison, the NIH register from the 
1980s showed the mean age of diagnosis to be 36 years of age (Rich et al., 
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1987). Ling et al. (2012) also suggested that 2 distinct patient cohorts were 
becoming apparent. A younger patient cohort that were described as having 
worse haemodynamic profiles but fewer co-morbidities and better survival in 
comparison to the older patient cohort. There was a similar proportion of male 
and females patients with the 2 age-dependent cohorts (Ling et al., 2012).  
The proportion of female patients within the PAH patient cohort has also been 
revised over the years as the data collected from registries has advanced. The 
first registry showed 62.5% of the patient cohort were female (Rich et al., 1987). 
More recent studies have shown 70% (UK and Ireland), 65% (French registry) and 
80% (REVEAL registry) to be female (Ling et al., 2012; Humbert et al., 2006; 
Badesch et al., 2010). The reason behind the increased prevalence of PAH in 
females is the focus of current research and is not yet fully understood. The 3 
year survival rate was only 58.2% in 2010 (Humbert et al., 2010) but a more 
recent study of patients in a German PAH centre found the 3 year survival rate 
to have improved to 72.3% (Gall et al., 2017).  
1.3.4 Pathophysiology 
1.3.4.1 Pulmonary artery remodelling 
In PAH there is disruption to the normally controlled proliferation and migration 
of the cells that make up the pulmonary vasculature (Rabinovitch, 2008). It is 
understood that the pathological remodelling associated with PAH first develops 
in the most distal pulmonary arteries. It has been shown in the context of both 
experimental and clinical studies, that pathogenic alterations in endothelial 
cells (ECs) occurs prior to the muscularisation of the vessel (Rabinovitch et al., 
1986; Rosenberg and Rabinovitch, 1988). The mechanisms which initiate these 
pathogenic changes are not fully understood, however, studies have shown that 
both the cellular environment and genetic factors contribute to the instability of 
the EC layer within the vessel. For example, both hypoxia (Block et al., 1989) 
and reactive oxygen species (Thies and Autor, 1991) have been shown to damage 
the membrane of ECs which could drive the instability of the endothelial layer. 
Also, genetic factors such as dysfunctional bone morphogenetic protein receptor 
2 (BMPR2) signalling within the ECs can lead to increased apoptosis, again 
compromising the EC layer (Teichert-Kuliszewska et al., 2006).  
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Furthermore, a process known as endothelial-to-mesenchymal transition (EndMT) 
can contribute to alterations in ECs. During EndMT, ECs gain mesenchymal 
properties and their gene expression profile becomes more similar to that of 
smooth muscle cells (SMCs), in particular, the induction of a-smooth muscle 
actin (a-SMA) expression (Hemnes and Humbert, 2017; Xiong, 2015). Co-
expression of EC and SMC markers, such as von Willebrand factor and a-SMA, has 
been identified in the pulmonary endothelium of both PH rodent models and PH 
patients indicating EndMT has taken place (Good et al., 2015). Transforming 
growth factor-b (TGF-b) in combination with inflammatory cytokines, tumour 
necrosis factor-a (TNF-a) and interleukin-1b (IL-1b), have been shown to 
activate this process using a pulmonary artery EC in vitro model (Good et al., 
2015). Mechanical stresses experienced by the pulmonary artery endothelium 
such as high pulsatile flow and sheer stress are also thought to activate EndMT as 
well as an acute inflammatory response (Elliott et al., 2015). A number of recent 
studies suggest this process is key in pulmonary artery remodelling in PH (Good 
et al., 2015; Ranchoux et al., 2015; Hopper et al., 2016).  
The proliferation and migrations of SMCs also plays a significant role in 
pulmonary artery remodelling. The release of fibroblast growth factor 2 (FGF2), 
serotonin and vasoconstrictor endothelin-1 (ET-1) from ECs are thought to be key 
stimulators of SMC proliferation (Thompson and Rabinovitch, 1996; Dewachter et 
al., 2006; Davie et al., 2002). At the site of the alveoli, pericytes within the 
pulmonary arteries have been shown to differentiate into SMCs (Meyrick and 
Reid, 1980). SMCs are thought to play a key role in the pathological cell 
proliferation and migration observed in PAH as many of the cells responsible for 
the thickening of pulmonary vessels stain positive for a-smooth muscle actin (a-
SMA) (Jones et al., 1997). It is well established that hypoxia can induce 
pulmonary artery SMCs (PASMCs) migration, however, there remains a lack of 
understanding of the different mechanisms by which migration and proliferation 
are induced (Shimoda and Laurie, 2013). In addition, endothelial nitric oxide 
synthase (eNOS) present within ECs, is responsible for the production of the 
vasodilatory factor nitric oxide (NO) which can act to prevent SMC proliferation. 
The ECs of PAH patients produce lower levels of NO which again contributes to 
the pathological phenotype (Xu et al., 2004). Furthermore, there is an increase 
in the ratio of vasoconstrictor to vasodilatory agents in the pulmonary 
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vasculature, for example with lower levels of prostacyclin compared to 
thromboxane (Christman et al., 1992). All of these combined factors drive 
pathological changes to take place within the pulmonary vasculature, 
particularly the distal pulmonary arteries early in the process. SMCs can migrate 
from the larger, muscularised vessels to the distal vessels and contribute to their 
muscularisation (Sheikh et al., 2014). The remodelling process leads to the 
formation of a double elastic lamina (Rabinovitch, 1998; Todorovich-Hunter et 
al., 1988) (Figure 1.1A). This is the phenotypic feature used to identify 
remodelled vessels in experimental models of PH. These processes all lead to 
the complete loss of small and medium sized distal pulmonary arteries, a process 
known as vascular pruning (Mair et al., 2014a). However, it is not only the distal 
arteries which undergo remodelling, stiffening of the large elastic vessels also 
occurs (Humbert et al., 2019). These pathological changes lead to the 
muscularisation of previously non-muscular arteries with thickening of the 
medial layer and intimal hyperplasia (Figure 1.1B). Subsequently, this leads to 
narrowing of the lumen and eventually the lumen can become completely 
occluded with the formation of complex or plexiform vascular lesions (Figure 
1.1C). Plexiform lesions are made up of proliferative endothelial cells forming 
complex vascular channels (St Croix and Steinhorn, 2016) and are often 
symptomatic of end stage disease (Cool et al., 1999). All of these pathological 
changes contribute to the high pressure, high resistance pulmonary vasculature 
system associated with PAH.  
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Figure 1.1 - Pulmonary artery remodelling.  
A) Distal pulmonary artery with single elastic lamina. Remodelling results in 
muscularised distal pulmonary artery with double elastic lamina. B) Pulmonary 
artery with open lumen. Pulmonary artery remodelling involves hypertrophy of 
the medial smooth muscle cell layer as a result of increased smooth muscle cell 
migration and proliferation. This causes a significant decrease in lumen 
diameter. C) Plexiform lesion with complete loss of the vessel lumen.  
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1.3.4.2 Right ventricular remodelling and failure 
Pulmonary vascular remodelling and the resultant high pressure, high resistance 
system causes an increase in the afterload experienced by the RV (Bogaard et 
al., 2009). RV afterload describes the RV wall stress during ejection which, in 
general, is proportional to the pressure in the RV (Tedford, 2014). It is well 
established that increased afterload is the initial trigger for RV adaptations. 
Increased afterload leading to increased RV wall stress negatively impacts 
myocardial perfusion and increases the oxygen demand of the myocardium 
(Bogaard et al., 2009). In order to compensate for increases in RV wall stress, 
the RV increases wall mass, a process known as hypertrophy. Initially this 
concentric RV hypertrophy (RVH), which is defined by an increased mass to 
volume ratio, is adaptive as it can help to maintain contractile function, cardiac 
output (CO) and RV ejection fraction (RVEF) by partially compensating for the 
increased PVR (Lahm et al., 2018; Fang et al., 2012). RV-PA coupling, which 
describes this adaptation of RV contractility to match RV afterload, means that 
with minimal energy expenditure, the RV can continue to function at a high level 
(Vonk Noordegraaf et al., 2017). However, it will reach a stage when the RV is 
no longer able to maintain optimal contractility with increasing afterload and at 
this stage adaptations to the RV become maladaptive (Bogaard et al., 2009). The 
heart rate can increase in an attempt to compensate for decreased stroke 
volume but unfortunately this leads to further increases in afterload. At this 
point RV-PA uncoupling occurs as is seen in late stage disease or under the 
physiological stresses of exercise in disease. The changes occurring at this stage 
in disease development are maladaptive and RV dilatation and RV fibrosis 
develop and right heart function becomes impaired (Vonk-Noordegraaf et al., 
2013). A decrease in cardiomyocyte function is thought to occur as a result of 
changes in extracellular matrix components, an increase in reactive oxygen 
species, differential energy metabolism and electrical remodelling (Bogaard et 
al., 2009; Piao et al., 2010). Prolongation of action potential duration (Lee et 
al., 1997) and downregulation of potassium repolarisation channels (Lee et al., 
1999) have been shown to occur in RVH, both affecting cardiac contractility. The 
pressure overload experienced by the RV can also influence the LV as septal 
flattening and bowing causes the formation of a “D-shaped” LV (Sanz et al., 
2012) (Figure 1.2). The RV is known to have a more rapid progression to failure 
than the LV due to a reduced capillary density, increased susceptibility to 
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oxidative stress and likeliness to activate cell death pathways (Reddy and 
Bernstein, 2015). In RV failure, the RV is no longer capable of maintaining 
perfusion of the pulmonary circulation at a level that is necessary to ensure LV 
filling while maintaining normal diastolic pressures (Ryan et al., 2015). It is the 
main cause of mortality in PAH patients and the extent of right heart 
impairment is used in determining a prognosis in PAH (Mair et al., 2014a).  
However, following lung transplantation in PAH patients, the RV is able to 
recover which suggests that RV failure may be reversible (Bogaard et al., 2009). 
Patients with advanced disease who had PAPs of more than 60 mmHg and had 
the associated cardiac remodelling including large right atrium and RV, septal 
flattening and RV dysfunction were investigated for their cardiac response to 
bilateral lung transplantation (Kasimir et al., 2004). The PAP in all patients had 
returned to normal within only 12 weeks post-transplant. RV dysfunction had 
reversed completely. The heart and tricuspid valve were able to function 
normally. One factor which is thought to contribute to the remarkable ability of 
the RV of PAH patients to recover so effectively post lung transplant is the 
pattern of fibrosis. Fibrosis within the RV differs significantly compared with the 
fibrosis pattern of an LV experiencing pressure overload. There is much less 
extensive fibrosis of the RV and the fibrosis tends only to appear at the RV-
septal insertion points (Vonk-Noordegraaf et al., 2013; Clapham et al., 2019).  
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Figure 1.2 - Right Ventricle Adaptation in Pulmonary Arterial Hypertension. 
A) Normal, thin walled RV. B) Adapted RV as a result of PAH. The RV free wall 
has undergone hypertrophy. The RV chamber has also increased in size 
(dilatation) and caused the formation of a D-shaped LV.  
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1.4 Genetic predisposition 
Family studies which took place in the 1950s suggested that PAH could be 
inherited and the idea of genetic predisposition to disease development lead to 
investigations in this area. However, the role of the BMPR2 gene in heritable PAH 
was not identified until the year 2000 (Deng et al., 2000). Since then 
investigations have also demonstrated that mutations in activin receptor-like 
kinase 1(ALK-1) and potassium channel subfamily K, member 3 (KCNK3) are also 
a risk factor for PAH. Studies have shown that patients with heritable PAH are 
more likely to present at a younger age and with more severe haemodynamic 
profiles than those who develop idiopathic PAH (Sztrymf et al., 2008). The 
female to male ratio is also increased within the heritable PAH patient 
population suggesting that sex also plays a role in the prevalence of the disease 
(Humbert et al., 2006; Rich et al., 1987; Loyd et al., 1995).  
1.4.1 Bone morphogenetic protein receptor signalling  
BMPR2 belongs to the transforming growth factor (TGF)-b family (Garcia de 
Vinuesa et al., 2016). It is described as a serine/threonine transmembrane type 
II receptor. BMP signalling via BMPR2 plays a role in early development right 
through to adulthood (Wang et al., 2014). Its plays a role in early processes such 
as embryogenesis and also late processes such as adult tissue homeostasis. The 
binding of the BMP ligands results in hetero-dimerisation between BMPR2 and a 
type I receptor (Machado et al., 2006). The formation of the hetero-dimer, and 
the resultant phosphorylation of the type I receptor, triggers a signalling 
cascade. The first step in the signalling cascade is the phosphorylation of the 
Smad 1/5/8 proteins. These proteins then act to upregulate the expression of 
inhibitors of DNA binding proteins 1 and 3 (Id1/Id3) (Yang et al., 2013) (Figure 
1.3). These proteins have transcription factor activity which acts to inhibit 
cellular proliferation. However, not only is cellular proliferation influenced by 
BMP signalling, migration and apoptosis of both ECs and SMCs are also affected 
(Garcia de Vinuesa et al., 2016).  
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Figure 1.3 - Canonical BMPR2 signalling pathway.  
Binding of BMP ligand to BMPR2 dimerized to Type 1 receptor (e.g. ALK1, 
BMPR1) results in phosphorylation of Type 1 Receptor activating signalling 
cascade which leads to phosphorylation of Smad1/5/8 complex known as a 
signal transducer protein. This complex binds Smad4 and is translocated to the 
nucleus where it binds to other transcription factors (TF) and transcriptional 
activators leading to transcription regulation including expression of ID1 and 
ID3. ID1 and ID3 are known to inhibit proliferation. BMP – bone morphogenetic 
protein, BMPR2 – bone morphogenetic protein receptor 2 P –phosphorylation. ID 
– inhibitors of DNA binding proteins. TF – transcription factors. 
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1.4.2 Bone morphogenetic protein receptor 2 mutations as a risk 
factor for PAH 
The most well-established risk factor for the development of PAH is harbouring 
mutations in BMPR2. Mutations in BMPR2 are involved in both familial and 
idiopathic PAH, however, the proportion of familial cases with a heterozygous 
BMPR2 mutation are much higher at ~75% in comparison to ~20% for idiopathic 
cases (Machado et al., 2009). Molecular analysis of PAH patients has identified 
over 300 different mutation sites within the BMPR2 gene affecting the ligand-
binding, kinase and cytoplasmic domains. Mutations can affect interaction with 
the cytoskeleton as well as result in aberrant receptor function and therefore 
dysregulated downstream signalling. Dysregulated signalling involves a decrease 
in the phosphorylation of the Smad 1/5 proteins and consequently reduced 
expression of anti-proliferative Id1 and Id3 (Yang et al., 2013). The phenotypic 
effect of decreased Id1/3 expression is better understood in the pulmonary 
vasculature than in the RV. Within the pulmonary vasculature, decreased Id1/3 
expression can lead to increased proliferation of the PASMCs and consequently 
pathological remodelling of the pulmonary vasculature (Morrell et al., 2009). 
The presence of a mutation in BMPR2 has a significant impact on the diagnosis 
and prognosis of a patients. BMPR2 mutant patients tend to be younger and have 
worse haemodynamic profiles when they present at diagnosis than those patients 
without a mutation (Evans et al., 2016a). The more severe presentation of the 
disease means that the patients are more likely to be in need of a lung 
transplant and their survival rates are poorer. With regard to the RV, recent 
studies have begun to elucidate the effect of dysfunctional BMPR2 signalling. A 
study of PAH patients comparing BMPR2 mutation carriers with non-carriers 
suggested that BMPR2 mutations were correlated with decreased RV 
functionality despite similar afterload measurements and cardiac remodelling 
between the two groups (van der Bruggen et al., 2016). Therefore, the potential 
involvement of BMPR2 signalling in RV dysfunction in PAH must be better 
understood.  
Although BMPR2 mutations are well-established as a risk factor for PAH, their 
presence is not sufficient for disease development. Mutations in BMPR2 are 
inherited in an autosomal dominant pattern but only 20% of BMPR2 mutation 
carriers develop PAH - the penetrance of these mutations are particularly low 
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(Newman et al., 2004). However, the importance of BMPR2 in the development 
of iPAH is emphasised by the finding that all patients have reduced expression of 
BMPR2 protein even in the absence of a BMPR2 mutation (Atkinson et al., 2002). 
The reduced penetrance of BMPR2 mutations indicates that there must be other 
genetic and environmental factors involved that also contribute to disease 
development. One of the factors affecting penetrance of the disease is thought 
to be the alternative splicing of BMPR2. There are two isoforms of BMPR2 – the 
full transcript and one lacking exon 12 – these result from alternative splicing of 
BMPR2 (Machado et al., 2006). The removal of exon 12 from the transcript is 
significant as it encodes a cytoplasmic domain and it is the largest of the exons 
within BMPR2. The transcript lacking exon 12 is known as isoform B and the full 
transcript is isoform A. Studies have shown that PAH patients have an increased 
isoform B: isoform A ratio when compared to those who carry a BMPR2 mutation 
but are unaffected. This suggests that alternative splicing could be involved in 
the penetrance of the disease (Cogan et al., 2012). As sex has been shown to 
play a significant role in the development of PAH, studies have also investigated 
the effect of estrogen metabolism in the penetrance of disease. Investigations 
involving individuals with BMPR2 mutations have shown that the penetrance of 
disease can also be influenced by genetic variation in the estrogen metabolizing 
enzyme cytochrome P450 1B1 (CYP1B1) and the metabolites it produces (Austin 
et al., 2009). 
1.5 PAH Therapeutics 
1.5.1 Current PAH therapeutics 
There are several different factors which contribute to the challenges associated 
with the development of PAH therapeutics. PAH is a complex, multifactorial 
disease and many of the molecular pathways which contribute to its 
development are not yet fully understood, making it difficult to identify 
potential therapeutic targets. Furthermore, as patients do not present at clinic 
until the onset of symptoms, the disease is well established when treatment 
begins. Therefore, the development of therapeutics has to be aimed at slowing 
the progression of the disease or reversing the pathological changes. The 
epidemiology of the disease has also changed significantly in recent years. PAH 
patients are more elderly and present with more co-morbidities making 
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treatment even more challenging.  Current pharmacological interventions are 
based on pathological mechanisms that were identified many years ago. The 
increase in 5 year survival rates, from 36% in the NIH registry in the 1980s (Rich 
et al., 1987) to 60% in the UK and Ireland registry in 2012 (Ling et al., 2012), 
suggests that the current therapies have played a role in prolonging the life of 
PAH patients. Current therapies primarily target the increased vasoconstriction 
of the pulmonary vasculature (Ryan et al., 2015) and they are unable to reverse 
the remodelling of the pulmonary vasculature or the right ventricle. Therefore, 
there is a real need to develop our understanding of this disease in order to 
identify new therapeutic targets and work towards further reducing the 
mortality rate.  
Current pharmacological interventions target 3 main pathways - prostacyclin, 
endothelin-1 (ET-1) and nitric oxide - that contribute to increased 
vasoconstriction and the pro-proliferative and anti-apoptotic phenotype of the 
pulmonary vascular in PAH (Lau et al., 2017). There are 5 classes of drug that 
are currently approved that target these pathways: prostacyclin IP receptor 
agonist, prostacyclin analogues, phosphodiesterase type 5 (PDE5) inhibitors, 
soluble guanylate cyclase stimulator and endothelin-1 receptor antagonists 
(ERAs) (Lau et al., 2017). Calcium channel blockers are also currently prescribed 
as therapy for patients with PAH (Medarov and Judson, 2015).  
Treatment with a combination of therapies from the point of diagnosis has been 
shown to have improved clinical outcomes in PAH patients (Sitbon et al., 2016; 
Galie et al., 2015; Galie et al., 2016). The clinical outcomes following duo-
combination therapy of ERA (ambrisentan) and PDE 5 inhibitor (tadalafil) were 
improved in comparison to mono-therapy (Galie et al., 2015). There is currently 
a clinical trial underway investigating the clinical outcomes associated with a 
triple combination therapy with an ERA, PDE 5 inhibitor and a prostacyclin IP 
receptor agonist (TRITON study, Clinical trial no. NCT02558231). The 2015 
ECS/ERS guidelines for the treatment of PAH advise that prior to selecting a 
treatment protocol, patients should be risk stratified. It is recommended that 
patients who fall into the high-risk category be treated with combination 
therapy from diagnosis and patients that fall into low- or medium-risk categories 
can be treated with dual or mono-therapy (Galie et al., 2015). However, 
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patients must be continually monitored and where low-risk status is not 
achieved, additional therapies should be added to their treatment protocol. In 
the past, patients were treated with different therapies on a sequential basis 
and only when the initial treatment was deemed to have unsatisfactory clinical 
outcomes would the therapy subsequently be changed to a different therapy 
(Sitbon et al., 2016; Galie et al., 2015; Galie et al., 2016).  
1.5.1.1 Calcium channel blockers 
The role of pulmonary artery vasoconstriction in the pathogenesis of PAH is well 
established. Therefore, the effect of vasodilators on disease progression has 
been investigated for many years. Vasoconstriction is dependent on the levels of 
intracellular calcium Ca2+ and influx of calcium to the vascular SMC (VSMC) via L-
type calcium channels (Godfraind, 2017; Medarov and Judson, 2015). The use of 
calcium channel blockers (CCBs) in the pulmonary vasculature can prevent 
vasoconstriction by blocking voltage gated calcium channels and stopping the 
influx of Ca2+ into the PASMC (McMurtry et al., 1976). This in turn prevents an 
increase in PVR. Studies conducted by Rich et al. in 1987 and 1992 suggested 
that treatment strategies involving high doses of calcium channel blockers 
(CCBs), such as diltiazem or nifedipine, could significantly reduce PAP and PVR 
in a subset of patients described as “responders” (Rich and Brundage, 1987; Rich 
et al., 1992). Since then CCBs have been used clinically as a therapeutic for 
PAH. More recent studies have since indicated those who respond positively to 
acute vasodilatory testing with CCBs tend to respond well to CCBs in the long 
term. However, long term responders to CCBs only make up <10% of the iPAH 
population (Sitbon et al., 2005). Therefore, the clinical impact of CCBs is limited 
and this type of therapy is only beneficial for a small proportion of the patient 
population.   
1.5.1.2 Prostacyclin Analogues 
Prostacyclin is produced in endothelial cells by the action of prostacyclin 
synthase on arachidonic acid (Olschewski et al., 2001). It has anti-proliferative 
and immunomodulatory effects and therefore prostacyclin analogues are very 
useful in the treatment of patients with PAH. Prostacyclin analogues, such as 
epoprostenol and treprostinil, target the prostacyclin receptor leading to 
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activation of downstream pathways involved in cAMP production and vasodilation 
(Coleman et al., 1994). Epoprostenol is the key therapy for patients with severe 
PAH. In these patients, epoprostenol has been shown to improve haemodynamic 
profiles and survival rates after only 3 months of administration (Barst et al., 
1996). Administration of this drug is challenging, primarily due to its extremely 
short half-life of 2-3 minutes (Lau et al., 2017), meaning it can only be 
administered intravenously as a continuous infusion. This type of drug 
administration can impact patient quality of life and also requires education of 
patients and highly skilled medical staff. There are more options available for 
the administration of trepostinil such as oral, subcutaneous and intravenous 
administration as well as via inhalation (Lau et al., 2017). However, these routes 
of administration also come with restrictions and challenges. Subcutaneous 
administration is associated with infusion site pain and oral and inhaled 
trepostinil is restricted to specific patient groups (Jing et al., 2013; McLaughlin 
et al., 2010).      
1.5.1.3 Prostacyclin IP receptor agonist 
Recently identified as a therapy for PAH is the prostacyclin IP receptor agonist 
selexipag (Asaki et al., 2015). Selexipag must be converted to its active form by 
hydrolysis in the liver (Lau et al., 2017).  It is thought the side effects of this 
drug are reduced in comparison to other prostacyclin analogues due to the 
receptor specificity, however, its safety had to be investigated following the 
death of five patients who had been administered this drug. Findings of the 
investigation conducted by the European Medicines Agency (EMA) in 2017 
concluded that mortality rates were not affected by the use of selexipag as 
death rates were similar across different treatment groups (EMA, 2017). 
However, patients administered this drug continue to be monitored.     
1.5.1.4 Endothelin Receptor Antagonists 
ET-1 was first identified as a potent vasoconstrictor in 1988 by Yanagisawa et al. 
(1988) (Yanagisawa et al., 1988). ET-1 is produced primarily in endothelial cells 
but it has also been identified in a number of other cell types including: SMCs 
and cardiac myocytes (Sakurai et al., 1991). There are 2 receptor subtypes 
within the endothelin pathway that ET-1 acts upon - endothelin A receptor (ETA) 
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and endothelin B receptor (ETB). ETA	is more highly expressed in VSMCs and ETB 
is expressed in both VSMCs and ECs (Seo et al., 1994).  In PAH patients, there is 
increased expression of ET-1 in both circulating levels and local expression in the 
lung (Bauer et al., 2002; Behr and Ryu, 2008; Giaid et al., 1993). ET-1, acting at 
both the ETA and ETB receptor, can lead to increased proliferation and the 
activation of vasoconstriction in isolated pulmonary artery smooth muscle cells 
(PASMCs) and pulmonary artery endothelial cells (PAECs) (MacLean et al., 1994; 
Davie et al., 2002).  
The three drugs designed to target the receptors of the endothelin pathway are: 
bosentan, macitentan and ambrisentan. Bosentan and macitentan target both 
receptors while ambrisentan targets ETA only (Lau et al., 2017). Liver 
dysfunction is a side effect associated with the use of bosentan in up to 10% of 
PAH patients (Humbert et al., 2007). However, these adverse side effects do not 
continue when drug use is stopped.   
1.5.1.5 Phosphodiesterase 5 Inhibitors 
Phosphodiesterase (PDE) enzymes regulate the breakdown of an intracellular 
second messenger known as cGMP. cGMP is involved in controlling SMC relaxation 
and therefore plays a role in vasoconstriction of the pulmonary vasculature in 
PAH patients. One of the PDE enzymes, known as PDE5, is highly expressed in 
the pulmonary vasculature and is involved in the hydrolysis of cGMP. PDE5 
inhibitors, such as sildenafil and tadalafil, have been developed which block the 
catalytic domain of PDE5 and therefore prevent hydrolysis of cGMP and control 
its endogenous levels (Rybalkin et al., 2003). Sildenafil and tadalafil are 
different structurally and in terms of their half-life. Sildenafil has a much 
shorter half-life meaning it requires 3 times daily dosing whereas tadalafil can 
be taken once a day (Galie et al., 2009a; Galie et al., 2005).  
1.5.2 Potential therapeutics  
1.5.2.1 FK506 
A recent high throughput study identified that the FDA approved 
immunosuppressive drug FK506 (tacrolimus) was able to increase expression of 
BMPR2 (Spiekerkoetter et al., 2013). This suggested that FK506 had the potential 
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to be used as a therapy for PAH as the reduced BMPR2 expression in PAH 
patients, even those without a loss of function mutation, is thought to be a key 
driver in the development of disease. FK506 induced BMPR2 signalling through its 
action as a calcineurin inhibitor and through its binding to FK-binding protein 12 
which is a repressor of bone morphogenetic protein (BMP) signalling. The 
mechanism of action proposed by Spiekerkoetter et al (2013) is shown below in 
Figure 1.4. Treatment with FK506 in the monocrotaline rat model and the Sugen 
hypoxia (SuHx) rat model showed improvements in all parameters of PH 
(Spiekerkoetter et al., 2013). FK506 significantly reduced RVSP, RVH (as 
measured by RV/LV + Septum) and pulmonary artery remodelling in all models 
investigated. However, this study was performed in male mice and rats only and 
therefore was lacking any investigation into the sex-dependent effects of this 
treatment.  
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Figure 1.4 - Proposed mechanism of action for the activation of BMPR2 
signalling by FK506.  
A-B) Ligand is bound to BMPR2 dimerized with Type 1 Receptor. A) A sub-
activating ligand binding does not lead to BMPR2 signalling. B) Activating BMP 
ligand binds leading to FKBP12 and Calcineurin dissociating from receptor and 
normal BMPR2 signalling. C-D) Ligand binds to mutant BMPR2 dimerized with 
Type 1 Receptor. C) Activating BMP ligand binds resulting in abberant BMPR2 
signalling. D) Sub-activating ligand binds in the presence of FK506. FK506 acts 
to inhibit calcineurin and binds FKBP12. This releases inhibitory effect on 
BMPR2 signalling even in the presence of BMPR2 mutation. BMP – bone 
morphogenetic protein. BMPR2 – bone morphogenetic protein receptor 2. 
FKBP12 – FK binding protein 12.  
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The same group also went on to trial compassionate use of low dose FK506 in 
patients with late stage, severe PAH for whom there are no other treatment 
options available (Spiekerkoetter et al., 2015). Three female patients aged 36, 
50 and 55 were treated with FK506 and monitored throughout the treatment 
regime. At 12 months, 2 of the 3 patients showed improved or stable RV function 
in relation to ejection fraction, stroke volume index and cardiac output index. 
Neither of the patients had a PAH related hospitalisation within the 12-month 
period. The third patient unfortunately had to discontinue FK506 treatment as a 
result of significant clinical worsening, however, once stabilised the patient 
voluntarily started on FK506 once again and at 12 months of round 2 of FK506 
also hadn’t had any PAH related hospitalisations. This study showed promise that 
FK506 could significantly improve the quality of life and survival rates of PAH 
patients.  
A Phase IIa clinical trial conducted by the same group in the USA was published 
in 2017 (Spiekerkoetter et al., 2017). This trial aimed to determine the safety 
and tolerability of low dose-FK506 in PAH patients. Although the study showed 
that FK506 was reasonably well tolerated in all patients with nausea/diarrhoea 
being reported as the most common side effect, expression of BMPR2 and 
parameters of PAH were not significantly improved across the patient cohort. 
There was a trend towards improvement in 6 min walk distance and in 
measurements associated with heart failure however only in some patients and 
the changes did not reach significance. It was suggested that a phase IIb efficacy 
trial would be appropriate but, currently, there is not a trial underway. 
1.5.2.2 Aromatase inhibitors 
Aromatase inhibitors act to prevent the production of endogenous estrogen from 
the androgens - androstenedione and testosterone (Kelly and Buzdar, 2010; 
Grodin et al., 1973). As studies have indicated a pathogenic effect of estrogen in 
the pulmonary vasculature, aromatase inhibitor – Anastrozole – is being 
considered as a therapeutic for the treatment of PAH. Anastrozole is currently 
licenced for the treatment of hormone receptor positive breast cancer (Geisler 
et al., 1996; Baum et al., 2002). It reversibly binds to the haem group of 
aromatase inhibiting its catalytic activity (Kelly and Buzdar, 2010). The half-life 
of the drug is approximately 50 hours and within 7- 10 days a steady level within 
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the plasma can be achieved (Kelly and Buzdar, 2010). As this therapy is already 
licenced for the treatment of breast cancer and its efficacy is well studied and it 
is already known to have limited side effects this makes it an attractive 
therapeutic for PAH patients.  
Initial pre-clinical studies showed that treatment with Anastrozole at 3 
mg/kg/day significantly reversed PH disease phenotype in female chronic 
hypoxia mice and female Sugen hypoxia rats (Mair et al., 2014b). This finding 
was not replicated in male mice. Anastrozole treatment in female BMPR2 mutant 
mice showed its ability to improve parameters of metabolic dysfunction (Chen et 
al., 2017). The demographics of PAH patients has changed in recent years with 
more patients presenting with other co-morbidities such as obesity. These 
patients will have significantly more adipose tissue which is a well-established 
site of estrogen production. Treatment with anastrozole significantly improved 
RVSP in ob/ob male and female mice that spontaneously develop PH (Mair et al., 
2019). Almost a third of PAH patients are clinically obese when they present at 
diagnosis, therefore these findings are relevant to the treatment of the current 
PAH population (Farber et al., 2015).  
These findings in pre-clinical models led to a small Phase II trial in male and 
female PAH patients to assess the safety and tolerability (Kawut et al., 2017). 
Anastrozole successfully reduced circulating 17β-estradiol levels by 
approximately 40% after 3 months of treatment. The study indicated that 
Anastrozole was well tolerated by PAH patients and was capable of improving 6 
min walk distance in these patients. The effect of Anastrozole on other disease 
parameters assessed such as functional class or adverse events was not as clear. 
One potential limitation of the use of Anastrozole to treat PAH patients is that 
estrogen has been shown to be cardioprotective (Iorga et al., 2017) and although 
treatment may improve lung pathology it may have a detrimental effect on the 
RV function, the main determinant in PAH patient survival. This small Phase II 
did not highlight any adverse effects of Anastrozole treatment on RV function 
predominantly assessed by tricuspid annular plane systolic excursion (TAPSE) 
measurements. This study indicated a larger scale clinical trial was appropriate. 
The PHANTOM Phase II clinical trial is currently recruiting patients 
(NCT03229499). This clinical trial will investigate the effect of Anastrozole 
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versus placebo treatment on 6 min walk distance and other clinical parameters 
of PAH during a 6-month period. The safety and tolerability of the drug will also 
be investigated over a 12-month dosing period.  
1.6 Estrogen 
Estrogens are a group of sex hormones made up of estrone (E1), 17b-estradiol 
(E2) and estriol (E3). E2 has been described as the most potent and predominant 
of the estrogen subtypes, E1 is most significant post-menopause and E3 is 
important during pregnancy when it plays a role in maintaining a healthy uterine 
lining (Khosla et al., 1997; Stricker et al., 2006). The estrogens are the primary 
female sex hormones produced predominantly in the ovaries in females and at 
lower levels in the testes of males, specifically in the Leydig cells and the 
seminiferous epithelium (Cooke et al., 2017). Estrogens are required for female 
reproductive system development and maintenance and in postmenopausal 
women, the E2 concentration within the serum drops significantly (Becker, 
2008). Recently, there has been a greater understanding of the role estrogens 
play in other systems within the body, including the cardiovascular system. 
Younger women have been shown to be protected from cardiovascular disease 
and this is thought to be associated with the role of estrogen in the 
cardiovascular system as when women reach postmenopausal age this cardio 
protection is lost (Blenck et al., 2016). 
1.6.1 Estrogen biosynthesis and metabolism 
Estrogen metabolism is a large enzymatic pathway involving many of the 
cytochrome P450 (CYP) enzymes. CYP enzymes are a large family of heme-
containing mono-oxygenases that are responsible for catalysing the metabolism 
of endogenous and exogenous substances such as steroids and hormones as well 
as any drugs or chemicals consumed by the body (Nelson et al, 1996). Estrogens 
and the other sex hormones are biosynthesised from cholesterol (Tofovic and 
Jackson, 2020). The full metabolism pathway involved in the production of 
estrogen metabolites from cholesterol is shown in Figure 1.5. Briefly, cholesterol 
is converted to pregnenolone by the action of the CYP enzyme CYP11A1. The 
metabolism of pregnenolone to progesterone is by 3-hydroxysteroid 
dehydrogenase (HSD). CYP17A1 then catalyses the conversion of pregnenolone to 
  29 
 
androstenedione. At this point, androstenedione can be metabolised straight to 
estrone (E1) by the action of CYP19A1, also known as aromatase, or converted to 
the androgen, testosterone, by 17b-hydroxysteroid dehydrogenase (HSD) (Tofovic 
and Jackson, 2020). 17b-HSD can catalyse both the forward and reverse reaction 
between androstenedione and testosterone. Estradiol (E2) is produced by the 
action of aromatase on testosterone or the action of 17b-HSD on estrone 
(Tofovic and Jackson, 2020). Aromatisation of both androstenedione and 
testosterone results in the production of estrone and estradiol, respectively 
(Grodin et al., 1973). E1 and E2 are interconverted by the action of 17b-HSD 
enzymes. E1 is further metabolised to an intermediate 16a-hydroxyestrone 
(16aOHE) before the synthesis of E3 estriol (Tofovic and Jackson, 2020). 
Although, 16aOHE is an intermediate between estrone and estriol, this 
metabolite has also been shown to exert its own effects as is the case with many 
of the metabolites of estrogen. Estrogens can be excreted from the body in urine 
and faeces, they are converted to inactive metabolites prior to excretion. These 
are mainly sulphated and glucuronidated derivatives (Liu et al., 2009; Thomas 
and Potter, 2013).  
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Figure 1.5 – Estrogen metabolism.  
Both androgens are estrogens are metabolised from cholesterol. Cholesterol is 
converted to the androgen androstenedione by the action of CYP11A1, 3β-HSD 
and CYP17A1. Androstenesione can then either be converted to testosterone by 
17β-HSD or estrone by aromatase also known as CYP19A1. Testosterone is the 
main pre-cursor for all the estrogen metabolites. Again aromatase is 
responsible for the convertion of testosterone to 17β estradiol. From there 
various CYP enzymes including CYP1B1 can metabolise 17β estradiol to 16α-, 4- 
and 2- OHEestradiol. These metabolites can then be further metabolised by 
COMT to 4- or 2- methoxyestradiol. CYP – cytochrome P450, HSD – 
hydroxysteroid dehydrogenase, OHEstradiol – hydroxyestradiol and COMT – 
catechol-O-methyltransferase.  
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As stated previously, the primary site for estrogen production in pre-menopausal 
women is the ovaries. However, there are other key sites of estrogen production 
such as the adrenal glands, brain, skin, adipose tissue and the liver (Cui et al., 
2013; Barakat et al., 2016). The expression of aromatase in many different 
tissues throughout the body has suggested that estrogen can be synthesised from 
androgens locally. The synthesis of estrogen has been shown to take place in the 
SMCs of the vasculature (Harada et al., 1999), including the pulmonary 
vasculature (Mair et al., 2014b). Estrogen production within the vasculature is 
thought to be associated with its role in maintaining vascular homeostasis and 
arterial vasodilation (Novella et al., 2019). It is also known that estrogen can be 
stored in tissues as estrone-sulfate. It is synthesised from E1 estrone by the 
enzyme estrogen sulfotransferase, when required the conversion of estrone-
sulfate to estrone is controlled by steroid sulfatase (Thomas and Potter, 2013).  
1.6.2 Estrogen signalling 
The classic estrogen signalling pathway involves the binding of estrogen to either 
estrogen receptor-a (ER-a) or estrogen receptor-b (ER-b). The genes ESR1 and 
ESR2 encode for ER-a and ER-b respectively. ER-a and ER-b are not located on 
the cell membrane but are located within the cytoplasm or nucleus. As estrogens 
are lipophilic, they can easily cross the cell membrane in order to exert their 
effects on the receptors. The activation of ERs results in both genomic and non-
genomic signalling (Vrtačnik et al., 2014). Both ERs are expressed in vascular 
SMCs and ECs (Lindner et al., 1998; Andersson et al., 2001; Mendelsohn and 
Karas, 1999). ER-a has been shown to have 3 different isoforms, a full-length 
isoform at 68 kDa and two truncated versions that are only 46 kDa and 36 kDa 
(Heldring et al., 2007). It is thought that the different isoforms could play a role 
in the different types of signalling that ER-a is capable of. Another estrogen 
receptor known as G protein-coupled estrogen receptor (GPER1) has more 
recently been identified. Expression of GPER1 has also been identified in both 
vascular SMCs and ECs (Lindsey et al., 2011) as well as many other tissue types 
including heart and lung (Otto et al., 2008). 
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1.6.2.1 Nuclear signalling 
Following ligand binding, there is the formation of hetero- or homo-dimers and 
activation of the receptors. The receptor dimer then translocates to the nucleus 
where it can act to influence gene expression via the estrogen response 
elements present in the promoter region of many different genes (Vrtačnik et 
al., 2014). The recruitment of additional transcription factors as well as 
activators and repressors can influence the action of the ER. The estrogen 
response element itself can also either act to enhance or repress transcription of 
the target gene (Hall et al., 2001). However, ERs have also been shown to bind 
to other transcription factors and modulate the transcription of genes which do 
not contain the estrogen response element (Vrtačnik et al., 2014). Examples of 
other transcription factors that facilitate estrogen signalling include: nuclear 
factor kB (NF-kB), GATA binding protein 1 (GATA1) and signal transducer and 
activator of transcription 5 (STAT5) (Bjornstrom and Sjoberg, 2005). 
1.6.2.2 Non-genomic estrogen signalling 
Estrogen receptor signalling has also been shown to exert rapid signalling 
effects, faster than those that could be achieved via normal genomic signalling 
and therefore must also initiate non-genomic effects. It occurs via the activation 
of cytosolic signalling pathways and involves second messengers. GPER1, a G-
protein coupled receptor (GPCR) with seven transmembrane domains, has been 
identified which binds to 17-b estradiol and results in estrogen dependent 
signalling. Its binding affinity for 17b-estradiol is lower than that of the two 
nuclear ERs (Thomas et al., 2005). Signalling via GPER1 can activate ERK 
signalling (Gonzalez de Valdivia et al., 2017), however, this finding is not 
replicated across all cell types (Evans et al., 2016b). The G proteins, Gs and Gi, 
are coupled to GPER1 and signalling is mediated through these proteins. Gs and 
Gi proteins modulate the intracellular cAMP levels through positive and negative 
regulation of adenylyl cyclase (Filardo et al., 2000; Filardo et al., 2002). 
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1.7 Sex differences in the cardiovascular system 
1.7.1 Downstream effects of estrogen in the cardiovascular 
system 
The protective effects of estrogen in the cardiovascular system are reinforced by 
the lower rates of cardiovascular disease in premenopausal women compared to 
age-matched men (Mendelsohn and Karas, 1999; Stampfer and Grodstein, 1994). 
There has been evidence to suggest that estrogen exerts many different 
protective effects on the cardiovascular system including preventing vascular 
inflammation (Nathan et al., 1999), and stimulating vasodilation via the release 
of NO (Chen et al., 1999) as well as protecting against the uncontrolled 
proliferation of vascular SMCs (Pare et al., 2002). Signalling via ER-a has been 
shown to be responsible for many of these protective effects as well as playing a 
key role in the response to vascular injury such as stimulating vascular re-
endothelialisation (Pare et al., 2002; Brouchet et al., 2001).  
1.7.2 Sex differences in pulmonary hypertension 
The REVEAL registry identified a 4:1 ratio of females to males within the PAH 
population, suggesting increased female susceptibility (Badesch et al., 2010). 
Several other registries have also identified a female predominance however not 
all to the same extent as the REVEAL registry (Rich et al., 1987; Humbert et al., 
2006; Ling et al., 2012). Despite the increased female to male ratio, there are 
currently no approved therapies that are targeted specifically towards males or 
females. The REVEAL registry highlighted other sex-specific differences in the 
manifestation of PAH. For example, it showed that females often present with a 
lower mean PAP than males and have a better 5 year survival rate at 62% 
compared to only 52% for males (Shapiro et al., 2012). Male sex has been 
identified as an independent predictor of worse survival and this is thought to be 
associated with increased and accelerated RV dysfunction (Jacobs et al., 2014; 
Kawut et al., 2009). This conflict between susceptibility and survival rate is 
known as the “estrogen paradox”(Lahm et al., 2014). The estrogen paradox has 
been a focus for many different research groups for many years. Investigations 
have attempted to identify the role of sex and estrogen in the initiation and 
development of PAH.  
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1.7.3 Estrogen in Pulmonary Hypertension 
1.7.3.1 Estrogen in the pulmonary vasculature 
Experimentally, there is conflicting evidence as to whether estrogen is 
pathogenic or protective in the pulmonary vasculature. The protective effects of 
17-b estradiol have been shown in the male chronic hypoxia rat model (Xu et al., 
2010; Lahm et al., 2012) and the inflammatory monocrotaline model (Farhat et 
al., 1993). However, inhibiting endogenous estrogen production with an 
aromatase inhibitor (Anastrozole) was shown to attenuate the pulmonary 
hypertension (PH) phenotype in female chronic hypoxic mice and female Sugen 
5416/Hypoxia (SuHx) rats (Mair et al., 2014b). This suggests that estrogen plays 
a pathogenic role in the development of PH in females. Estrogen can be 
metabolised by the cytochrome P450 family of enzymes - CYP1A1, CYP1A2 and 
CYP1B1. E2 can be hydroxylated to 2-hydroxyestradiol (OHE), 4-OHE and 16α-
hydroxyestradiol (16α-OHE2) (Samavat and Kurzer, 2015). These metabolites 
have been shown to have opposing effects in the pulmonary vasculature with 2-
OHE having a protective effect (Tofovic et al., 2008) and 16α-OHE1 inducing 
proliferation of human PASMCs (White et al., 2012). The dissociation between 
clinical and experimental findings adds to the complexity of deciphering the 
interaction between sex hormones and the development of PAH.  
1.7.3.2 Estrogen in the right ventricle 
It is important to gain an understanding of the effect of sex on the healthy RV 
and also the effect of sex on the diseased RV. Understanding factors which 
effect RV function is vitally important for PAH as RV failure is ultimately the 
cause of death in PAH patients. Although more females develop PAH, the male 
sex has been identified as an independent predictor of worse survival. This is 
thought to be associated with increased and accelerated RV dysfunction (Kawut 
et al., 2009; Jacobs et al., 2014). This observation highlights that there are sex-
specific differences in RV function. Research into the effects of estrogen on RV 
function is still very much in its infancy. Initial clinical and experimental studies 
have suggested a protective effect of estrogen on RV function. In control groups, 
higher estradiol levels are associated with increased RVEF in postmenopausal 
women using hormone replacement therapy (Ventetuolo et al., 2011). A recent 
study identified single nucleotide polymorphisms (SNPs) in the CYP1B1 gene that 
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are associated with RVEF and showed higher urinary estradiol metabolite levels 
were associated with significantly increased RVEF in white subjects (Ventetuolo 
et al., 2016b). Experimentally, female SuHx rats have been shown to have 
increased cardiac index (CI) in comparison to the male SuHx rats and male rats 
treated with 17-β estradiol showed improvements in RV function and structure. 
This study also suggested an inverse correlation between estrogen receptor-α 
(ER-α) RV expression and right ventricular systolic pressure (RVSP) and RVH 
(Frump et al., 2015). Additionally, in a SuHx mouse model, estrogen was shown 
to improve RVEF and CI through increasing RV contractility, suggesting an 
inotropic effect of estrogen on the RV myocardium (Liu et al., 2014). These 
studies are very much preliminary studies, however, they underline the 
importance of the role of estrogen in RV function and therefore survival in PAH.  
The potentially pathogenic effect of estrogen in the pulmonary vasculature 
versus its protective effect in the RV could make targeting estrogen as a 
therapeutic for PAH particularly challenging as therapies would have to be 
targeted to the RV. Additionally, using experimental models of PH it may be 
difficult to identify if the effect of estrogen on RV function is secondary to the 
effect on the pulmonary vasculature or if it is a result of direct action on the 
myocardium. Further work is required in order to understand the mechanism by 
which estrogen influences RV function and structure and how this can be 
exploited.  
1.7.4 Sex differences in BMPR2 in pulmonary hypertension 
A greater number of females develop PAH, in some registries the female to male 
ratio is as high as 4:1 (Badesch et al., 2010). There are sex-specific differences 
in the expression and activity of BMPR2, even under basal conditions, which 
could contribute to the greater number of females within the PAH patient 
population (Mair et al., 2015). Female human pulmonary artery smooth muscle 
cells (hPASMCs) obtained from non-PAH controls have been shown to have 
reduced expression of BMPR2 at both a gene and protein level when compared to 
male hPASMCs obtained from non-PAH controls (Mair et al., 2015). Furthermore, 
the downstream factors in the BMPR2 signalling pathway, Smad 1 and Id1/3, 
were also down regulated in female hPASMCs. This suggests that females could 
be pre-disposed to PAH because they have basally lower levels of BMPR2. 
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Interestingly, when male non-PAH control hPASMCs were stimulated with 
estrogen there was no change in the expression of BMPR2 and Smad 1 but there 
was a reduction in mRNA and protein levels of the Id genes (Mair et al., 2015). 
These findings suggest that estrogen could be responsible for driving the 
suppression of the BMPR2 pathway and the predisposition of females to PAH. 
Sex-specific differences in BMPR2 expression have also been highlighted in PAH 
patients. For example, BMPR2 gene expression in lymphocytes was 
approximately 20% lower in female patients than in male patients (Austin et al., 
2012). These observations are also apparent in experimental models. For 
example, when comparing whole lung BMPR2 expression in male and female 
mice, BMPR2 gene expression was lower in the female mouse compared to male 
mouse (Austin et al., 2012). This same study also highlighted an estrogen 
response element (ERE) in the BMPR2 promotor. This ERE was found to be a 
highly conserved functional binding site for estrogen receptor alpha (ER-α). 
Based on these findings, it was suggested that estrogen is able to reduce 
expression of BMPR2 through the direct binding of ER-α to the BMPR2 promoter. 
This strengthens the hypothesis that estrogen can cause sex-specific differences 
in BMPR2 expression, which ultimately results in the predisposition of females to 
PAH.   
At the moment, there is very little known about sex-specific differences in 
BMPR2 expression in the RV and the potential effects this might have on RV 
function in PAH.  
1.8 Animal models of pulmonary hypertension + right 
ventricular dysfunction 
Despite the number of rodent models that have been developed for the study of 
PAH, no one model completely recapitulates all of the severe disease 
phenotypes and disease progression that is seen in humans. The different animal 
models can represent aspects of the disease phenotype. However, this also 
highlights the disparate nature of the different PH subtypes and that the 
initiating pathophysiology is likely to influence the development of the disease.  
Mouse models have the benefit of being genetically modifiable, however, it is 
understood that rat models display a more robust PH phenotype than mouse 
models.  
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1.8.1 Chronic hypoxia model 
Rodents can be exposed to chronic hypoxia via either normobaric hypoxia or 
hypobaric hypoxia. Muscularisation of the distal pulmonary arteries, associated 
with an increase in smooth muscle actin (Stenmark et al., 2009), and infiltration 
with inflammatory cells (Burke et al., 2009) are key features of this model. The 
extent to which chronic hypoxia induces the PH phenotype is variable, 
muscularisation of pulmonary arteries ranges from mild to moderate across 
different mouse strains (Gomez-Arroyo et al., 2012). Increases in RV mass and 
RVSP are modest in chronic hypoxia mice (Gomez-Arroyo et al., 2012). Some 
studies investigating the C57Bl6 chronic hypoxia mouse model report an increase 
of 5 mmHg in RVSP with no corresponding increase in RV mass (Vanderpool et 
al., 2011). However, numerous studies have shown an increase in RVSP, RV mass 
and pulmonary artery remodelling (Mair et al., 2014b; Mair et al., 2015). The use 
of a mouse model does allow for genetic manipulation and the effect of hypoxia 
on the transgenic mice to be investigated. Induction of chronic hypoxia is 
relatively easy and although there are some variations in the exact phenotype, 
relatively speaking the overall phenotype is reproducible meaning this is a 
popular model in research.     
The rat model of chronic hypoxia has been shown to be more robust than the 
mouse model (Colvin and Yeager, 2014). Exposure of rats to chronic hypoxia 
results in remodelling of the pulmonary vasculature, particularly hypertrophy of 
the medial layer, and an increase in PAP (Hislop and Reid, 1976; Rabinovitch et 
al., 1979; Stenmark et al., 2006). RV hypertrophy will develop in this model, 
however, there is no evidence of RV failure (Stenmark et al., 2009) and 
therefore pathobiology obviously differs between this model and human disease 
development. However, there are also strain dependent phenotypes that exist 
within rat chronic hypoxia models. It is well characterised that the fawn hooded 
strain of rat will develop a more severe phenotype than other strains (Sato et 
al., 1992).  
1.8.2 Sugen Hypoxia model 
Another agent which is used in the development of PH rodent models is Sugen 
5416, a vascular endothelial growth factor receptor (VEGFR) 1/2 antagonist 
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(Taraseviciene-Stewart et al., 2001; Nicolls et al., 2012). Rats which have been 
administered Sugen 5416 by subcutaneous injection and exposed to chronic 
hypoxia for a period of 3 weeks, followed by a further period of 10-11 weeks of 
normoxia develop a severe PH phenotype. The disease phenotype continues to 
progress even after the animals have been returned to normoxia (Nicolls et al., 
2012; Taraseviciene-Stewart et al., 2001). This model is thought to best 
represent the pathological changes that occur in human pulmonary vasculature 
as there is development of angio-obliterative lesions similar to the plexiform 
lesions of iPAH (Abe et al., 2010). These lesions develop during the period of 
normoxia that follows the 3-week hypoxic period. Delivery of a pan-caspase 
inhibitor to SuHx rats was able to prevent the development of these lesions and 
therefore it is thought that apoptosis plays an essential role in lesion 
development (Taraseviciene-Stewart et al., 2001). Histopathological analysis of 
the lesions in SuHx rats shows similarities to the plexiform lesions in the human 
disease (Abe et al., 2010). This progressive PH phenotype is specific to the 
Sugen-Hypoxia (Su-Hx) model, other models such as the chronic hypoxia model 
will eventually show reversal of the pathological changes after being returned to 
normoxia.   
1.8.3 Monocrotaline model 
Monocrotaline (MCT) is an alkaloid agent with overall lung toxicity which is 
delivered to rats as a model of the pathophysiological changes that occur in the 
lung during the development of PH (Kay et al., 1967). The effects are 
characterised by an increase in cell proliferation within the pulmonary 
vasculature (Meyrick and Reid, 1982). The exact mechanism by which MCT 
induces a pathological response is unknown but there has been evidence to 
suggest it is due to endothelial damage (Jasmin et al., 2001) and inflammation 
(Wilson et al., 1989). Due to the toxic nature of MCT and how this influences the 
development of the disease-like phenotype, it is likely that MCT will have other 
toxic effects which are unrelated to the PH phenotype. Studies have described 
pathological effects in the liver and the heart with the presence of occlusive 
lesions within veins of the liver (Roth et al., 1981) and RV and LV myocarditis 
(Miyauchi et al., 1993).  Furthermore, the development of the pathological 
changes in pulmonary vasculature will not be representative of disease 
development in humans and therefore provides a limited understanding of the 
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pathways involved in disease development and the potential effects of 
therapies. Monocrotaline treated rats develop RV failure (Hessel et al., 2006) 
and therefore for animal welfare reasons these animals must be monitored 
carefully.  
1.8.4 Pulmonary artery banding model  
The pulmonary artery banding model has been developed as both a rat and 
mouse model applicable for the study of RV hypertrophy, dysfunction and failure 
(Rockman et al., 1994; Dias et al., 2002; Bogaard et al., 2011). The right 
ventricle is subjected to a continued increase in afterload as a result of banding 
the main pulmonary artery either through the use of suture or a clip. The 
outcomes of this model very much depend on the extent of the constriction. Mild 
constrictions will result in a RV dysfunction phenotype with increased RVSP and 
RVH (Faber et al., 2006). A more severe constriction will result in features more 
similar to RV failure and there are normally high mortality rates within these 
groups (Borgdorff et al., 2015b). This model has been described as a model that 
recapitulates the continual pressure overload of the RV and eventual RV failure 
(Borgdorff et al., 2015a). The surgical procedure has recently been described in 
both mice and rats (Tarnavski et al., 2004; Mendes-Ferreira et al., 2016). 
However, the surgical methodology varies across the different studies both in 
how the pulmonary artery is accessed and how it is banded. Tarnavski et al. 
(2004) suggests a left thoracotomy and the use of a suture and a blunted needle 
as a guide to constrict the artery in a PAB mouse model. The use of a surgical 
clip to constrict the pulmonary artery in a rat model was recently described 
(Hirata et al., 2015). This method was associated with lower intra-surgical 
mortality rates and increased RV dysfunction and RV fibrosis. Tarnavski et al., 
2004 describes the challenges associated with the surgical procedure as a result 
of the physiology of the RV and pulmonary artery (Tarnavski et al., 2004). The 
RV is less capable of withstanding the stress associated with the manipulation of 
the thin walled pulmonary artery by the operator. The position of the atria over 
the pulmonary artery presents further technical complexities as the atria are in 
constant motion and are also unable to withstand any pressure as a result of 
manipulation. In addition, any manipulation of the artery can lead to momentary 
disruption of the blood flow from the RV to the lungs. This can lead to 
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respiratory and cardiac distress which in turn reduces the intra-operative 
survival rates of animals involved in a study.  
1.9 Hypothesis and Aims 
PAH is a devastating disease which has a serious detrimental effect on the 
patient’s quality of life and has poor survival rates. The vague symptoms of PAH 
mean that the disease is often already established when a patient presents at 
clinic. Development of PAH involves irreversible, pathogenic remodelling of the 
pulmonary vasculature which leads to the development of a high pressure, high 
resistance pulmonary system. The increased afterload experienced by the RV 
leads to RV dysfunction and eventually failure. RV failure is the main cause of 
death in PAH patients. There are currently no curative therapies available for 
PAH and none of the current therapies target the pathological changes which 
take place in the RV despite this being the main cause of death in patients. 
Limited research has been conducted into the factors influencing the RV and 
how these might be targeted as therapeutics.  
Furthermore, the gender disparity that is evident within the PAH population is 
not yet fully understood. The increased number of female patients is evident 
across all registries (Humbert et al., 2006; Rich et al., 1987; Ling et al., 2012) 
and is as high as 4:1 in the REVEAL registry (Badesch et al., 2010) suggesting that 
the female sex plays a role in susceptibility of disease. There is strong evidence 
to suggest that estrogen can have a pathogenic effect in the pulmonary 
vasculature (Mair et al., 2014b; White et al., 2012; Wright et al., 2015). There is 
a further estrogen paradox that exists within PAH in that although there are 
more females within the patient population, males tend to have poorer 
haemodynamic profiles, increased RV dysfunction and poorer survival rates. The 
role of estrogen in the RV and how this contributes to the presentation of 
disease in male and female patients is not well understood. Furthermore, PAH 
patients are currently not stratified for treatment based on sex and the sex-
dependent effects of current therapeutics are not fully understood. Therefore, 
there is a real need to develop our understanding of the role of sex and estrogen 
in the development and progression of PAH and how to treat it.  
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The hypothesis of this thesis was that sex and, in particular, estrogen influence 
the development of PAH and independently also influence the RV which could be 
related to the sex-dependent presentation of disease within the PAH population. 
Furthermore, it was also hypothesised that potential therapies for PAH would 
have sex-dependent effects which should be considered during the development 
of new therapeutics.  
The central aim of this thesis was to develop our understanding of the effect of 
sex and estrogen in the RV, on the development of PAH and on the response to 
potential PAH therapies. There were several research aims identified in order to 
investigate this:  
• The characterisation of right ventricular gene expression in male and 
female rodents.  
• The characterisation of the right ventricle in response to chronic hypoxia 
in male and female rats.  
• The characterisation of the sex dependent effects of FK506 (tacrolimus) 
treatment on parameters of experimental PH.  
• The development of a surgical model of right ventricular dysfunction in 
rats.  
By developing our understanding of these areas, we hope to better understand 
the sex differences in the development and progression of PAH in order to 
identify new therapeutic targets and develop new therapies for this devastating 
disease. 
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Chapter 2 
2 Materials and methods 
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2.1 Chemicals and Reagents 
All chemicals and reagents were supplied by Sigma-Aldrich (Dorset, United 
Kingdom (UK)) or ThermoFisher Scientific (Paisley, UK) unless otherwise stated. 
Materials and reagents required for ribonucleic acid (RNA) analysis were supplied 
by Qiagen (Manchester, UK). Cell culture plastics were supplied by Corning 
(Flintshire, UK). Anastrozole used for in vivo experiments was supplied by Tocris 
(Bristol, UK) and FK506 used for in vivo experiments was supplied by Cayman 
Chemical via Cambridge BioScience (Cambridge, UK). 
2.2 Ethical Approval 
All animal procedures performed were approved by the Home Office according 
to regulations regarding experiments with animals in the UK (United Kingdom 
Animal Procedures Act 1986). All animal experimentation also adhered to the 
“Guide for the Care and Use of Laboratory Animals” produced by the United 
States National Institutes of Health (NIH). Experiments were performed at the 
University of Glasgow under the personal licence I85F0A9AF and the project 
licence 60/4404 or the project licence of Dr. C.M. Loughrey (60/4503 and 
PO5FE1F82). 
2.3 Animals 
2.3.1 Animal welfare 
Animals were housed across three different licensed facilities within the 
University of Glasgow: Central Research Facility (CRF), West Medical Building 
(WMB) or Cardiovascular Research Unit (CVRU). All animals received a normal 
diet (Rat and mouse No.1 maintenance diet, Special Diet Services) and had 
access to food and water ad libitum. Animals were housed in a controlled 
environment - controlled lighting (7am to 7pm) and temperature maintained at 
21±3°C. Animals were randomly selected from the cage and allocated to a study 
group. Age and sex matched controls were utilised where appropriate. 
Experimental groups were blinded to the investigator during the acquisition and 
analysis of haemodynamic data. 
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2.3.2 Sprague Dawley Rats 
Male and female Sprague Dawley rats (CD IGS Crl:CD(SD)) were obtained from 
Charles River (UK). Rats were initially housed in either the CRF or the CVRU 
(University of Glasgow) and monitored during a 7-day acclimatisation period 
before use in any experimental procedures.  During experimental procedures, 
rats were housed in either the WMB or the CVRU.  
2.3.3 Wistar Rats 
Male and female Wistar Hans rats were obtained from Envigo (Oxon, UK). Rats 
were housed in either the CRF or the CVRU, University of Glasgow, and 
monitored during a 7-day acclimatisation period before use in any experimental 
procedures.    
2.3.4 C57Bl/6 mice 
C57Bl/6 mice were obtained from Envigo (Oxon, UK). All mice were initially 
housed in the CRF and monitored during a 7-day acclimatisation period before 
use in any experimental procedures. During experimental procedures mice were 
housed either in the WMB or the CRF.     
2.4 Animal Models of Pulmonary Hypertension 
2.4.1 Hypobaric Hypoxic Chamber 
Hypobaric hypoxic chambers were used to create a chronic hypoxia environment. 
On day 1, pressure within the chamber was slowly reduced from atmospheric 
pressure (1013mbar) to 750mbar and left overnight to allow for a period of 
acclimatisation. On Day 2, the pressure within the chamber was slowly reduced 
to 550mbar, approximately half of atmospheric pressure (1013mbar). This low 
oxygen environment results in vasoconstriction and the development of a 
pulmonary hypertension phenotype (Mair et al., 2014b). Chambers were brought 
back to atmospheric pressure slowly when required. Food and water were 
replenished as needed and bedding was changed every 7 days. The temperature 
and humidity within the chamber were monitored each day to ensure they 
remained within appropriate limits. Male and female rats were housed in 
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different hypoxic chambers. Male and female mice were also housed in different 
hypoxic chambers. Rat and mouse studies did not overlap to ensure that mice 
and rats were not housed in the same area at the same time.  
2.4.2 Chronic Hypoxia Rat Model 
Male and female Sprague Dawley rats were placed in the hypobaric hypoxic 
chambers at approximately 100g and 175g total body mass, respectively. This 
was in an attempt to ensure rats weighed approximately 220g after 2 weeks of 
chronic hypoxia. Rats were acclimatised at 750mbar for 24 hrs. The hypobaric 
chambers were then maintained at 550mbar for the remainder of the 35 days. 
This study was extended to 35 days, instead of the standard 28-day model, in 
order to be in alignment with a previous study conducted by Spiekerkoetter et 
al, 2015. As described, chambers were brought back to atmospheric pressure 
slowly when required. 
2.4.3 Chronic Hypoxia Mouse Model 
Male and female C57Bl/6 mice were recruited to the study at 6-8 weeks old. 
Mice were placed in the hypobaric hypoxic chambers and acclimatised at 
750mbar for 24 hrs. The hypobaric chambers were then maintained at 550mbar 
for the remainder of the 28 days. The standard hypoxic mouse model within the 
field is 28 days. As described, chambers were brought back to atmospheric 
pressure slowly when required. 
2.5 Preparation of drugs 
2.5.1 FK506 
Preparation of FK506 (Cayman Chemical via Cambridge BioScience, 
CAY10007965) in pellet form was completed by Innovative Research of America 
(Florida, USA). Innovative Research of America prepared FK506 in a pellet 
containing a matrix of the carrier binder consisting of cholesterol, lactose, 
celluloses, phosphates and stearates. The pellet was designed to release FK506 
at a dose of 0.05 mg/kg/day for 21 days. The dose was based on an animal body 
weight of 220g therefore each FK506 pellet contained 231µg of FK506. Placebo 
pellets consisted of the matrix only. 
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2.5.2 Anastrozole  
Carboxymethyl cellulose (CMC) (sodium salt, low viscosity – Sigma-Aldrich, C-
5678) was dissolved in distilled water to create a 1% CMC (w/v) solution. 
Anastrozole (Tocris Bioscience, 3388) was then suspended in the appropriate 
volume of 1% CMC to create a solution at 0.3 mg/mL. Even distribution was 
achieved by sonication. 1% CMC and Anastrozole solutions were frozen at -20°C 
and defrosted as required. The 0.3 mg/mL Anastrozole solution allowed 100µL 
per 10 g of body weight to be distributed to each mouse achieving a final dose of 
3 mg/kg/day (Mair et al., 2014b).  
2.6 Administration of Drugs 
2.6.1 FK506 administration  
  
Figure 2.1 - Schematic diagram showing FK506 study protocol and dosing 
regimen. 
Male and female Sprague Dawley rats were kept in normoxic or hypoxic 
conditions for a period of 35 days. On day 14, FK506 pellets (0.05mg/kg/day) or 
placebo pellets were administered, and the rats returned to normoxia or 
hypoxia. On day 35 haemodynamic measurements were collected and the 
animals humanely killed prior to tissue harvesting.   
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This study aimed to investigate the effect of FK506 on an established hypoxic 
phenotype, this is known as a reversal study. Therefore, rats were housed in 
hypoxia for 14 days prior to subcutaneous pellet insertion. Subcutaneous pellet 
insertion took place on day 14 of the study with the aim of dosing all rats, both 
male and female, at approximately 220g body weight. However, on day 14 the 
body weight of rats ranged between 180-250g. Body weight (g) was recorded at 
the time of pellet insertion. Rats were anaesthetised in an anaesthetic box with 
4% (v/v) isoflurane (Abbot Laboratories, Berkshire, UK) in oxygen. Rats were 
then transferred to a face mask and maintained on 3% (v/v) isoflurane in oxygen 
at a rate of 1L/min. Rats were placed in the prone position and the fur at the 
dorsal neck behind the ears was removed. A small incision was made using 
sterile scissors and a subcutaneous pocket created. The pellet was placed on a 
sterile MP-182 10 Gauge Precision Trochar (Innovative Research of America) and 
inserted into the small subcutaneous pocket. When the trochar was removed the 
wound was closed using wound glue (3M, Bracknell, UK). Animals were allowed 
to fully recover from anaesthesia before being returned into hypoxic conditions. 
The matrix driven delivery (MDD) allowed FK506 to be released continuously at a 
rate of 0.05 mg/kg/day for 21 days. Placebo control pellets were inserted in the 
same manner. Age and sex matched controls were kept under normoxic 
conditions and dosed using the same dosing regimen (Figure 2.1). Haemodynamic 
assessment, followed by tissue harvest, was performed on day 35 of the study. 
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2.6.2 Anastrozole administration  
 
Figure 2.2 - Schematic diagram showing Anastrozole study protocol and 
dosing regimen. 
Male and Female C57Bl/6 mice were kept in normoxia or hypoxia for a period of 
28 days. On day 14 daily intra-peritoneal (i.p.) injections of Anastrozole 
(3mg/kg/day) or vehicle (1% CMC) began in normoxic and hypoxic mice for the 
remainder of the 28 days. On day 28 tissue was harvested from the normoxic 
group and the male hypoxic group. Haemodynamic assessment and tissue 
harvest were completed for the female hypoxic group.  
This study aimed to investigate the effect of Anastrozole on an established 
hypoxic phenotype, this is known as a reversal study. Therefore, mice were 
housed in hypoxia for 14 days prior to intraperitoneal (i.p.) dosing. Dosing began 
on Day 14 of the study. Mice were dosed via i.p. injection with 3mg/kg/day of 
Anastrozole or the equivalent volume of vehicle (1% CMC) every day – a total of 
14 doses. Age and sex matched controls were kept under normoxic conditions 
and dosed using the same dosing regimen (Figure 2.2). 
2.7 Assessment of Pulmonary Hypertension Phenotype 
2.7.1 Anaesthesia  
Rats were anaesthetised in an induction chamber using 4% (v/v) isoflurane 
(Abbot Laboratories, Berkshire, United Kingdom) in oxygen at a flow rate of 
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1L/min. Mice were anaesthetised in an induction chamber using 3% (v/v) 
isoflurane in oxygen at a flow rate of 0.5L/min. Body weight (g) was recorded 
immediately after the induction of anaesthesia, prior to haemodynamic 
measurements. Animals were then placed in the supine position on the 
procedure table and anaesthesia maintained via a face mask. Rats were supplied 
with 3% (v/v) isoflurane and mice were supplied with 1.5% (v/v) isoflurane in 
oxygen at a flow rate of 1L/min and 0.5L/min, respectively, in order to maintain 
anaesthesia. Rats were placed on a heat mat while under anaesthesia and a 
rectal temperature probe (RS components, Corby, UK) was used to monitor body 
temperature. Hind limb reflex was assessed to confirm sufficient level of 
anaesthesia before beginning any experimental procedure. Hind limb reflex, 
breathing rate, the depth of each breath and heart rate were continually 
monitored throughout the procedure.  
2.7.2 Haemodynamic Measurements 
Right ventricular pressure (RVP), left ventricular pressure (LVP) and systemic 
arterial pressure (SAP) were measured using a Millar Ultra Pressure Volume Loop 
System (MPVS) and the appropriate pressure volume (PV) catheter. Different 
models of the Mikro-Tip® ultra-miniature PV loop catheters (Millar, Texas, USA) 
were utilised for different studies. The SPR 869 PV catheter was utilised for rat 
studies, the PVR 1030 PV catheter was used for mouse right ventricle (RV) 
measurements and the PVR 1045 PV catheter was used for mouse left ventricle 
(LV) measurements. The PVR 1030 PV catheter and the PVR 1045 PV catheter 
differ in the electrode spacing, 3mm on the 1030 and 4.5mm on the 1045. It was 
recommended that due to the smaller size of the RV the 1030 PV catheter with 
the smaller spacing was used. Data was collected using Powerlab 8/35 data 
acquisition system (AD instruments, Oxford, UK) and interpreted using LabChart 
7 software (AD instruments, Oxford, UK). 
2.7.2.1 Right Ventricular Pressure  
Once appropriate anaesthesia was established, a small area of skin and fur was 
removed from the ventral side of the neck, exposing the muscular layer beneath 
the skin. The muscle and connective tissue were bluntly dissected ensuring 
minimal damage to the tissue. The right jugular vein was exposed and the vein 
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carefully isolated from the surrounding tissue. Surgical nonsterile suture 
(Harvard Apparatus, Massachusetts, USA, size 3-0 for rats and size 5-0 for mice) 
was placed under the vein and the suture tied off at the superior end to prevent 
blood flow through the vein. The suture was taped down to create tension along 
the length of the vein and a small incision was made in the vein using a 25G 
needle (Harvard Apparatus, 72-2251). The appropriate catheter was then fed 
into the right jugular vein, in some cases a second suture was passed under the 
vein and was used to tie the catheter in place. The catheter was then advanced 
towards the RV. Correct placement of the catheter within the RV was confirmed 
with a characteristic right ventricular pressure trace (Figure 2.3). When satisfied 
with the placement of the catheter, right ventricular pressure was recorded. 
The closed chest approach allowed the most physiologically relevant 
measurements to be obtained, however, it was more challenging to ensure the 
correct placement within the ventricle. Correct placement within the chamber is 
required to ensure a clean pressure trace therefore, it was not always possible 
to achieve the high-quality exemplar pressure traces. The pressure trace was 
recorded for as long as was necessary to achieve a stable pressure trace 
recording, on average between 2 and 10 mins. 
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Figure 2.3 - Right ventricular pressure traces 
Representative right ventricular pressure traces. A) Diagram to represent the 
placement of the catheter within the RV. B) Normal right ventricular pressure 
(RVP) trace obtained from a rat housed in normoxia (time on x-axis plotted 
again mmHg on the y axis). C) Pulmonary hypertensive right ventricular 
pressure (RVP) trace obtained from a rat housed in hypoxia (time on x-axis 
plotted again mmHg on the y axis).  
2.7.2.2 Systemic Arterial Pressure and Left Ventricular Pressure 
Following the recording of RV pressure, the catheter was removed from the 
jugular vein and the vein remained tied off. Further blunt dissection allowed 
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identification of the right carotid artery. The artery was isolated from the 
surrounding connective tissue and the vagus nerve was carefully separated from 
the artery. A tie was placed on the superior end of exposed artery using surgical 
nonsterile suture (Harvard Apparatus, Massachusetts, USA, size 3-0 for rats and 
size 5-0 for mice). This allowed the artery to be manipulated in order to expose 
the required length. A surgical micro-clip (Fine Science Tools, Heidelberg, 
Germany, FST#18055-04) was then placed at the most inferior end to prevent 
blood flow through the artery. Using surgical spring scissors, a small incision was 
made in the artery and the catheter was fed into the artery. Another suture was 
placed around the catheter in the artery to hold in place. The clip was released, 
the catheter quickly advanced and the suture tightened to hold the catheter in 
the artery and prevent blood loss. Systemic pressure was recorded in the carotid 
artery. Following a period of pressure recording within the artery, the catheter 
was advanced slowly until it reached the LV. Correct placement of the catheter 
within the LV was confirmed by a characteristic left ventricular pressure trace 
(Figure 2.4). When satisfied with the placement of the catheter, left ventricular 
pressure was recorded. The pressure trace was recorded for as long as was 
necessary to achieve a stable pressure trace recording, on average between 2 
and 10 mins. 
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Figure 2.4 - Left ventricular pressure traces 
A) Diagram to represent the placement of the catheter within the LV. B) Normal 
left ventricular pressure (LVP) trace obtained from a rat housed in normoxia 
(time on x-axis plotted again mmHg on the y axis). C) Pulmonary hypertensive 
left ventricular pressure (LVP) trace obtained from a rat housed in hypoxia 
(time on x-axis plotted again mmHg on the y axis).  
2.7.2.3 Volume calibration 
Post-surgery a cuvette calibration was performed using the volume calibration 
cuvette (AD instruments, Oxford, UK) in order to calibrate the volume 
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measurements collected by the Millar PV loop system. Blood was collected from 
the animal after removal of the catheter from the carotid artery using a 1 mL 
syringe. The collected blood was used to fill wells of known volumes in the 
cuvette. The catheter was then inserted into each well and the conductivity 
recorded. This was performed quickly in order to ensure minimal clotting of the 
blood, however, this was a challenge associated with performing the technique 
in this manner. The LabChart software then generated a standard curve from the 
conductivity of the blood within a known volume. The standard curve was then 
extrapolated in order to determine blood volume within the ventricle and 
subsequently cardiac output. 
2.7.2.4 Analysis of haemodynamic measurements  
At the end of the study, all pressure traces were collected for analysis. The most 
stable section of the pressure trace was selected for analysis. The analysis for 
the rat study consisted of a 20 second section of the most stable RV pressure 
trace and systemic pressure trace and a 1 min section of stable trace was 
analysed for the left ventricular pressure. The analysis for the mouse study 
consisted of a 1 min section of stable pressure trace from the RV, LV and the 
systemic circulation. Where it was not possible to obtain 20 seconds or 1 minute 
of steady trace, the longest possible steady trace was selected. The mean 
maximum pressure was calculated from the maximum pressure reached in each 
systole during the length of the recording. Mean maximum pressure was 
displayed describing the right ventricular systolic pressure (RVSP) and the left 
ventricular systolic pressure (LVSP). The mean maximum and minimum pressure 
of the systemic arterial pressure (SAP) trace was displayed showing systolic and 
diastolic systemic blood pressure. In addition, developed pressure (systolic-
diastolic pressure) and mean SAP were also calculated.  
2.7.3 Tissue collection 
2.7.3.1 FK506 rat study 
On removing the catheter from the carotid artery, blood was collected. Blood 
was used to perform the cuvette calibration associated with the Millar PV loop 
system as described above. The remainder of the blood was collected in 
ethylenediaminetetraacetic acid (EDTA) tubes and stored on ice before 
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centrifugation at 1700 g for 10mins at 4˚C. The plasma supernatant was then 
collected and snap frozen in liquid nitrogen. Post-mortem, the right lung lobes 
were tied off at the right bronchus using surgical nonsterile suture (Harvard 
Apparatus, Massachusetts, USA, size 3-0). The right bronchus had to be tied off 
as the left lung lobe was inflated at a later stage and an open right bronchus 
would have resulted in leakage of the liquid and failure to inflate the left lobe. 
The three right lobes were then removed and snap frozen in liquid nitrogen. A 
lobe of the liver, the right kidney and the spleen were also collected and snap 
frozen in liquid nitrogen for future analyses. Hearts were removed from the 
cadaver and collected for right ventricular hypertrophy measurements. In an 
attempt to better visualise the morphological features of the lungs using 
histological techniques, the left lung lobe was inflated using 10% (v/v) neutral 
buffered formalin (NBF) until the whole lobe appeared maximised in size and 
then removed from the cadaver ensuring not to deflate the lung. The lung lobe 
was then submerged in 10% (v/v) NBF and stored at room temperature until 
required for processing. Where possible, urine was also collected and snap 
frozen in liquid nitrogen. All tissues snap frozen in liquid nitrogen were then 
stored at -80°C until required. This tissue was used for protein and RNA analysis.    
2.7.3.2 Anastrozole mouse study 
Mice were sacrificed on Day 28 of the study. Post-mortem, heart and lungs were 
removed, and the 3 right lung lobes snap frozen in liquid nitrogen. The heart was 
used to measure right ventricular hypertrophy and the RV and left ventricle + 
septum (LV+S) were then snap frozen in liquid nitrogen for protein/RNA analysis. 
A lobe of the liver was also collected and snap frozen in liquid nitrogen. Tissue 
was stored at -80°C until required.  
2.7.4 Right ventricular hypertrophy 
Right ventricular hypertrophy (as shown in Figure 2.5) was investigated in all 
hearts from the rat FK506 study and the mouse Anastrozole study. In order to 
collect the right ventricular hypertrophy measurement, blood vessels and 
connective tissue were removed from the heart, followed by the right and left 
atria. The wall of the RV was finely dissected from the LV+S with the use of a 
microscope when required. Both the RV and LV+S were then blotted dry and 
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weighed separately. The ratio of the RV free wall mass to the LV+S mass is one 
of the standard measures for right ventricular hypertrophy and is known as the 
Fulton’s Index (Fulton et al., 1952). The Fulton’s index (RV mass/LV+S mass) is 
displayed, however, further analysis was included for the FK506 study in order to 
accurately determine cardiac hypertrophy including: RV mass, LV+S mass, RV 
mass/body weight and LV+S mass/body weight. Following RVH analysis, hearts 
were then collected for either protein/RNA analysis or histological analysis. 
From each group of the FK506 study n=4 RV and LV+S were snap frozen and n=2 
RV and LV+S were submerged and stored in 10% NBF for histological analysis. All 
RV and LV+S tissue from the mouse Anastrozole study was snap frozen in liquid 
nitrogen.  
 
Figure 2.5 - Right ventricular remodelling in PH.  
Schematic diagram showing a transverse section of the heart. A) Normal heart 
with thin walled RV. B) Adapted RV as a result of PAH. The RV free wall has 
undergone hypertrophy. The RV chamber has also increased in size (dilatation) 
causing septal flattening and the formation of a D-shaped LV. 
2.7.5 In vivo studies acknowledgements 
Assistance in the administration of drugs, haemodynamic assessment and tissue 
harvest was provided in the Anastrozole mouse study by Margaret Nilsen and the 
FK506 rat study by Margaret Nilsen and Dr. Craig Docherty. 
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57 
 
2.8 Histology 
2.8.1 Tissue Processing  
As stated, the left lung lobes and hearts were stored in 10% NBF at room 
temperature until required. The lung lobes were cut into 4-5 sections and placed 
into biopsy cassettes. RV and LV+S tissue was cut along the transverse axis into 
2-3 sections. Lung and heart tissue were washed under running water to remove 
excess 10% NBF before being dehydrated through an ethanol gradient then 
immersed in histoclear and finally paraffin wax using the Citadel 1000 Tissue 
processor (Thermo Fisher, UK). Rat heart and lung tissues underwent the same 
processing protocol (Table 3). Following processing, the lung sections and heart 
sections were embedded in paraffin blocks, using a Shandon Histocenter 3 
(ThermoFisher Scientific, Leicestershire, UK). Lung and LV tissue were wax 
embedded in an orientation that would allow for transverse lung sections. RV 
tissue was embedded in 2 different orientations that would allow for transverse 
and longitudinal sections. Paraffin embedded tissues were stored at room 
temperature however immediately prior to sectioning, wax blocks were placed 
at -20°C to improve the quality of sections. Tissues were cut at 5 µm sections 
using a Leica RM2125 microtome (Leica Microsystems, Milton Keynes, United 
Kingdom) and mounted on to poly-l-lysine (Sigma-Aldrich, P4707) coated glass 
microscope slides. Sections of the RV were created from at least two distinct 
areas to provide a better analysis across the heart. Slides with lung sections 
were stored at room temperature. 
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Solution Incubation 
period 
70% Ethanol 1.5 hrs 
80% Ethanol 1.5 hrs 
95% Ethanol 2 hrs 
95% Ethanol 2.5 hrs 
100% Ethanol 2 hrs 
100% Ethanol 2 hrs 
100% Ethanol 2 hrs 
HistoClear 1.5 hrs 
HistoClear 1.5 hrs 
Paraffin wax 1 hr 
Paraffin wax 1 hr 
 
Table 3 - Tissue Processing Schedule for embedding rat lung tissue and rat 
heart tissue in paraffin wax. 
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2.8.2 Elastin picrosirius red staining  
A modified Miller’s Elastin staining protocol was utilised to assess pulmonary 
artery remodelling (Miller, 1971). The sections were deparaffinised in HistoClear 
(Fisher Scientific Ltd, Leicestershire, UK) and rehydrated through an ethanol 
gradient 100% ethanol, 90% ethanol and 70% ethanol for 5 minutes at each 
gradient, before being washed in distilled water. Oxidation of the sections was 
achieved using 0.5% (w/v) potassium permanganate solution for 5 minutes. 
Sections were washed in running tap water for 5 minutes and then immersed in a 
1% (w/v) oxalic acid solution for 2-3 minutes to decolourise the sections before 
another wash in running tap water and 95% ethanol. Sections were then 
immersed in Miller’s elastin stain (Thermo Scientific, UK), which stains elastin 
fibres black, for 2 hrs. Following staining, sections were once again rinsed in 95% 
ethanol and running tap water. Sections were briefly counterstained using picro-
sirius red (solution of Sirius red in picric acid) (Sigma-Aldrich, Dorset, UK) before 
rinsing with running tap water once again. Finally, sections were immediately 
dehydrated in an ethanol gradient 1 minute in 70% ethanol, 1 minute in 90% 
ethanol and 2 x 5 minutes in 100% ethanol before 2 x 5 minutes in HistoClear. 
Slides were then mounted using DPX mounting medium (Sigma-Aldrich, Dorset, 
UK) and covered with cover slips.    
2.8.3 Pulmonary artery remodelling 
Lung sections were microscopically assessed for remodelled and non-remodelled 
pulmonary arteries approximately <80 µM in diameter using a light microscope. 
Remodelled pulmonary arteries were identified as those with a double elastic 
lamina (Figure 2.6). The percentage of remodelled pulmonary arteries was then 
calculated as the number of remodelled arteries/the total number of pulmonary 
arteries within the section.  
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Figure 2.6 – Pulmonary artery remodelling.  
Representative images of a normal, unremodelled (single elastic lamina) 
pulmonary artery and a remodelled (double elastic lamina) pulmonary artery. 
Scale bar = 25 µM, magnification x40. 
2.9 Cell Culture 
All cell culture was performed under sterile conditions within a class II laminar 
flow cabinet. Cells were maintained in Corning flasks and plates (Flintshire, UK) 
in a humidified incubator at 37°C and 5% (v/v) carbon dioxide. 
2.9.1 Primary cell isolations  
2.9.1.1 Adult rat cardiomyocyte isolation 
Prior to beginning the cell isolation, Krebs-Henseleit (Krebs) solution was made 
up as described in Table 4. The pH of the Krebs solution was increased to pH 
7.68 at room temperature using sodium hydroxide. The solution was then stored 
in the fridge until required. On the day of use, 11.1 mM glucose was added to 
the solution immediately prior to use. 
Adult rat cardiomyocytes were isolated from male and female Wistar Hans rats 
(Envigo, Oxon, UK). A Langendorff perfusion with collagenase digestion was 
utilised. Rats were killed by cervical dislocation and the hearts rapidly excised 
and placed into chilled Krebs solution. The cull and heart excision were 
performed by staff in the Cardiovascular Research Unit (CVRU). Any lung tissue 
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or connective tissue was removed and the aorta isolated. The heart was quickly 
cannulated via the aorta on the Langendorff perfusion set up. Perfusion with 
Krebs solution warmed to 37°C at a flow rate of 7 mL/minute was performed for 
several minutes until the perfusate ran clear. At this point, 0.025g of 
Collagenase Type I (Worthington Biochemical via Lorne Laboratories, UK, 
260units/mg Cat No: LS004196 Lot:47K17730B) and 0.002g of protease type XIV 
(P5147 - Sigma-Aldrich, UK) was added to 30 mL of Krebs solution to be perfused 
through the heart, resulting in a final concentration of 0.7 mg/mL collagenase 
and 0.06 mg/mL protease. The hearts were perfused with the digestion mix for 
varying time periods before perfusion with a 0.5% BSA in Krebs solution for 
varying time periods. Development of this protocol is described in Appendix 7.1. 
Perfusion with BSA aided the termination of enzymatic activity. At the end of 
the perfusion steps, the heart was cut down from the cannula and the vessels 
and atria removed. The RV was then carefully dissected from the LV and the RV 
and LV was then placed into separate weight boats with 0.5% BSA in Krebs 
solution. From this point onwards the RV and LV were treated separately. The 
RV and LV were cut into small pieces and then transferred to 15 mL tubes 
(Corning, Flintshire, UK) containing approximately 6 mL and 10 mL of 0.5% BSA 
Krebs solution, respectively. Using a flame blunted plastic Pasteur pipette the 
pieces of tissue were agitated in order to gently release the cells from the 
tissues. When the solution appeared straw coloured, indicating a release of 
cells, the tissue was allowed to settle to the bottom of the 15 mL tube and half 
the volume of BSA/Krebs solution was transferred to a new 15mL tube. Fresh 
BSA/Krebs solution was added to the original tube to increase the volume to the 
starting volume and the process began again. The process was repeated 4-5 
times until the tissue had been successfully broken up and the majority of cells 
released. The cell suspension from each 15 mL tube containing RV and LV cells 
was then examined under a microscope to inspect the quality of the digestion 
indicated by the number of viable rod-shaped cardiomyocytes. The 15 mL tubes 
with the greatest number of viable rod-shaped cardiomyocytes as visible by eye 
were selected for the remainder of the experiment and the 15 mL tubes 
combined. The calcium concentration of the cell suspension was then increased 
to 1mM in gradual increments by adding 1µL of 100mM calcium chloride (CaCl2) 
per 1 mL of cell suspension every 5mins. This incremental addition of CaCl2 
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reduces hypercontraction of the cardiomyocytes as a result of rapid calcium 
influx.  
Salt Supplier and 
Catalogue Number 
Final 
Concentration 
required 
(mM) 
In 1L 
distilled 
water (g) 
NaCl Fisher Chemical 
S/3161/53 
120 7.0128 
HEPES  Sigma-Aldrich H3375 
250g 
20 4.7656 
KCl VWR 26764.260 500G 5.4 0.4026 
NaH2PO4 Fisher Scientific 
13472-35-0 
0.52 0.0624 
MgCl26H20 VWR 
25108.260 500G 
3.5 0.7114 
Taurine Sigma-Aldrich 
T0625-100G 
20 2.5020 
Creatine Sigma-Aldrich C0780-
100G 
10 1.4912 
***Glucose 
(anhyd) 
 
Fisher Chemical 
G/0500/53 
11.1 2 
Table 4 - Krebs-Henseleit Solution contents 
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2.9.1.2 Neonatal rat cardiac cell isolation  
Wistar Kyoto (WKY) rat breeding cages were set up in the Cardiovascular 
Research Unit (CVRU) to provide neonatal pups. WKY rats were obtained through 
the internal breeding programme at the University of Glasgow. Both neonatal rat 
cardiac fibroblasts and neonatal rat cardiomyocytes were isolated from neonatal 
hearts through a process involving enzymatic digestion and differential plating. 
Male and female neonatal rats were culled by decapitation on day 3-5. All the 
hearts from the litter were collected together. Hearts were quickly excised from 
the chest cavity and placed into chilled ADS buffer on ice. ADS buffer contents 
are as described (Table 5). The contents were added to 1 L of distilled water and 
the pH increased to 7.35 using sodium hydroxide. The buffer was then filtered 
and stored at 4°C. Hearts in ADS buffer were then moved into a sterile laminar 
flow hood and the remainder of the protocol was completed under sterile 
conditions. The atria and connective tissue were removed and the hearts washed 
in clean ADS buffer. The ventricles were then cut into small pieces and 
transferred to a 100 mL Duran bottle by Pasteur pipette. Any remaining ADS 
buffer was carefully removed and the enzyme mix was added. The enzyme mix 
was made up of 0.03 g collagenase type II (ThermoFisher Scientific, 17101-015) 
and 0.03 g pancreatin from porcine pancreas (Sigma-Aldrich, P3292-25G) in 
approximately 50 mL ADS buffer. The enzyme solution was filter sterilised 
before use. The appropriate volume of enzyme mix was added to the neonatal 
heart pieces and the Duran bottle placed in a shaking water bath at 37°C with a 
specific stroke speed and duration (Table 6). The digestion step was repeated 
several times as detailed (Table 6). Following the first digestion, the 
supernatant was removed and discarded. After each of the subsequent digestions 
(digestions 2-6), the supernatant was collected and transferred to a sterile 50 
mL tube (Corning, Flintshire, UK) containing 2 mL FBS. The 50 mL tube was then 
centrifuged at 900xg for 5 mins. The supernatant was discarded and the pellet 
containing the fibroblasts and myocytes was gently re-suspended in 4 mL of FBS. 
This cell suspension was then pooled in 50 mL tube was then stored in the cell 
culture incubator with the lid slightly loosened. The resuspended pellet was then 
added to the same tube after each digestion. Therefore, all cells from each 
digestion were collected in a 50 mL tube which was then centrifuged at 900xg 
for 6 minutes. Following the final centrifugation, the cell pellet was re-
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suspended in plating media (Table 7) and plated onto poly-l-lysine (Sigma-
Aldrich, P4707) coated 10 cm cell culture dishes (Corning, 430167). The plates 
were placed in the incubator for at least 1 hr to allow the neonatal cardiac 
fibroblasts to adhere to the plate. The plates were then washed gently using the 
plating media within the plate, and the plating media removed. This media 
contained the neonatal cardiac myocytes that did not adhere to the poly-l-lysine 
coated plates. Plating media was replaced on the neonatal cardiac fibroblasts 
and the cells stored in the cell culture incubator. After 24 hrs, the plating media 
was changed to DMEM (Thermo Fisher Scientific, 41966-029) supplemented with 
20% (v/v) FBS, 100 U/mL penicillin and 100 µg/mL streptomycin (ThermoFisher 
Scientific, 15140-122).   
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Salt Catalogue number 
(Sigma-Aldrich) 
Final 
concentration 
required 
(mM) 
In 1L of 
distilled 
water 
(g) 
NaCl S9888 116 6.8 
HEPES H4034 20 4.76 
NaH2PO4 S3139 1 0.12 
Glucose G7528 5.5 1.0 
KCl P3911 5 0.4 
MgSO4 M2643 0.8 0.1 
Table 5 - ADS buffer contents 
Digest Volume of the enzyme mix 
(mL) 
Time 
(minutes) 
Speed 
(strokes/min)  
1 10 5 160 
2 10 20 150 
3 8 25 150 
4 8 25 150 
5 6 25 150 
6 6 25 150 
Table 6 - Neonatal heart digestion protocol 
 Supplier mL/500mL Final concentration 
DMEM ThermoFisher 
Scientific 
340 68% (v/v) 
M199 ThermoFisher 
Scientific 
85 17% (v/v) 
Horse Serum ThermoFisher 
Scientific 
50 10% (v/v) 
FBS ThermoFisher 
Scientific 
25 5% (v/v) 
Penicillin + 
Streptomycin 
ThermoFisher 
Scientific 
5 1% (v/v) 
100 U/mL Penicillin 
100 µg/mL 
Table 7 - Plating media contents 
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2.9.1.3 Adult rat pulmonary artery smooth muscle cell isolation 
The digestion mixture was made up of a ratio of 1:3:17:17 of Elastase (Sigma-
Aldrich, Dorset, UK): Soyabean trypsin inhibitor (Sigma-Aldrich, Dorset UK): 
Collagenase type 1 (Lorne Laboratories, Reading, UK): BSA (Sigma-Aldrich, 
Dorset, UK). The digestion mix was stored at 4˚C until required. Post mortem, 
the left lung lobe was collected from male and female Wistar rats (Envigo, Oxon, 
UK). Lungs were collected in DMEM supplemented with 10% (v/v) FBS and 1% 
(v/v) antibiotic antimycotic solution (10,000units penicillin, 10,000 µg 
streptomycin and 25 µg amphotericin B., Sigma-Aldrich, UK). The main 
pulmonary artery in the left lung lobe was carefully dissected and placed into a 
glass bottle containing the digestion mix with 25 mL of Nutrient Mixture F-12 
Ham (Sigma-Aldrich, UK, 6658) and a magnetic stirrer bar. The bottle was then 
placed on a heated stirrer plate. Temperature was monitored to ensure the 
mixture was kept at approximately 37˚C. Pulmonary arteries were digested until 
they appeared “hairy”. Following this, the digestion mix containing cells was 
filtered through 100 µm sterile filter. The mixture was centrifuged at 220 g for 1 
minute at room temperature. The cell pellet was resuspended in complete DMEM 
and plated in T25 flasks. Media was changed after 24-48 hrs to remove dead 
cells. 
2.9.2 Passaging and plating cells 
Once the rat PASMCs or the neonatal cardiac fibroblast cells had reached the 
appropriate confluency (the coverage of the cell monolayer on the surface of the 
flask) the media was removed from the flask. Cells were washed with sterile 1 x 
PBS warmed to 37°C to ensure all serum was removed from the cells. Following 
the PBS wash, 2-3 mL of Trypsin-EDTA (0.5%) solution (ThermoFisher Scientific, 
15400-054), warmed to 37°C, was then added to the cells for approximately 5 
minutes and the flask placed in the incubator during this time. Trypsin is a 
proteolytic enzyme which acts to detach the cells from the flask. EDTA within 
the solution acts as a chelator for calcium ions which further aids the process of 
cell detachment. Cell detachment from the flask was confirmed by assessing the 
cells under a microscope and DMEM containing FBS was then added to neutralise 
the action of trypsin-EDTA solution. The cell suspension was then transferred to 
a sterile tube and the cell suspension centrifuged at 210 g for 5 mins at room 
67 
 
temperature. The supernatant containing the Trypsin-EDTA solution was then 
removed and the cell pellet resuspended in the appropriate volume of DMEM. 
Cells were then plated into fresh flasks. When passaging neonatal rat cardiac 
fibroblasts, the cells were passaged at a ratio of 1:2 or 1:3. For example, the 
cells from 1 flask were split into 2 flasks (1:2).  
When experimental set up required a specific number of cells to be seeded in 6, 
12, 24 or 96 well plates, the cells within the cell suspension were counted. Once 
the pellet had been resuspended the cell suspension was mixed well and 10 µL of 
the cell suspension was added to a haemocytometer. The number of cells within 
each of the 4 quadrants, made up of 16 large squares, were counted. The mean 
cell count across the 4 quadrants was calculated. The haemocytometer is 
designed such that the number of cells in 1 quadrant is equivalent to the number 
of cells x	10!	per mL. Each quadrant has an area of 1 mm2 and the depth 
between the grid and the coverslip is 0.1 mm therefore the volume of cell 
suspension in this area is 0.1 µL. Therefore, the mean number of cells in a 
quadrant is equal to the same number x 104 cells/mL. 
The volume of cell suspension required was calculated as: 
$ℎ&	'&((	)&*+,-.	/&01,/&)	('&((+/4()$ℎ&	*146&/	78	'&((+/4(	78	'&((	+1+9&*+,7* 
The cell suspension was then mixed well before plating the appropriate volume 
into the wells.  
When required cells were cryopreserved for short- and long-term storage. Cells 
were trypsinised and subjected to centrifugation as described above. The 
supernatant was removed and the cell pellet remained. Normally, the cell pellet 
from 1 x T75 cm2 flask was resuspended in 1 mL of 10% (v/v) dimethyl sulfoxide 
(DMSO, Fisher Scientific) in FBS. The cell suspension was then quickly transferred 
to a cryopreservation vial and then vial either wrapped in bubble wrap and 
placed into -80°C or placed into a freezing container with 100% isopropanol and 
then into -80°C. Both methods help to slow the freezing process to help prevent 
cell rupture which can result from rapid freezing. The freezing container allows 
cooling at a rate of approximately 1°C per minute. For short term storage, cells 
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were stored in -80°C and for longer term storage cells were transferred to liquid 
nitrogen storage tanks.  
2.9.2.1 Charcoal stripped serum  
Charcoal stripped serum (CSS) was kindly gifted by Dr. Craig Docherty, University 
of Glasgow. FBS was stripped of endogenous estrogens with the use of dextran-
activated charcoal (Johansen, 2014). The charcoal stripping process allows non-
polar components, such as hormones, to be selectively removed from the serum. 
Dextran-activated charcoal was added to FBS at 0.1 g/10 mL. It was then gently 
shaken overnight at 4˚C before being subjected to centrifugation at 1811 g for 
30 mins at 4˚C. The serum was then filtered using a 0.22 µM filter and the 
process repeated. After this step the serum was aliquoted and frozen at -20˚C 
until required.  
2.9.3 Estrogen Stimulations of Neonatal Cardiac Fibroblasts 
Neonatal cardiac fibroblasts were plated into 6 well plates at a density of 2x105 
cells per well. Cells were maintained in DMEM supplemented with 20% (v/v) FBS 
and 100 U/mL penicillin and 100 µg/mL streptomycin (ThermoFisher Scientific, 
15140-122) for 24 or 48 hrs until cells reached 70-80% confluency. Once 
confluent, cells were serum starved for 24 hrs in serum free, phenol red free 
DMEM (ThermoFisher Scientific, UK, 21063029) supplemented with 100 U/mL 
penicillin and 100 µg/mL streptomycin (ThermoFisher Scientific, 15140-122) and 
1 nM sodium pyruvate (ThermoFisher Scientific, UK, S8636). This process of 
quiescence allowed for growth arrest and synchronisation of the cell cycle. Any 
experiment which involved stimulation with estrogen or an estrogen metabolite 
utilised phenol red free media from the quiescence stage onwards. Phenol red is 
a weak estrogenic mimic which could have influenced the action of exogenous 
estrogen added to stimulate the cells. Cells were stimulated for 24 hrs, unless 
otherwise indicated, with Angiotensin II (Ang II) (Sigma-Aldrich, Dorset, UK) at 
100 nM and Β-estradiol (Sigma-Aldrich, UK, E2758-250MG) at 1 nM or 10 nM in 
phenol red free DMEM described above. β-estradiol was resuspended in 100% 
ethanol to create a 10 mM stock solution. At the end of the stimulation, DMEM 
was removed and the cells washed twice with PBS.  
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2.9.4 Migration Assay  
Rat PASMCs (Passage 2) were plated onto 24 well plates at high confluence. Cells 
were initially cultured with DMEM (ThermoFisher Scientific, 41966-029) 
supplemented with 10% FBS. When the cells appeared 90-100% confluent they 
were quiesced using Phenol Red Free media (Life technologies, 21063-029) 
containing either no serum or 0.5% FBS/0.5% CSS for 24 hrs in order to achieve 
growth arrest and synchronisation of the cell cycle. From this point onwards, 
cells were cultured in phenol red free media as phenol red is a weak estrogenic 
mimic (Welshons et al., 1988) which could have influenced the results. After 24 
hrs in low serum media scratches were made in the cell monolayer down the 
centre of the well using a P10 pipette tip inserted over a P200 pipette tip. The 
pipette tip was placed against a ruler in an attempt to increase reproducibility 
of the scratches. Media was then removed, the plates inverted, and lines drawn 
horizontally across the bottom of the plates in the middle of the wells. These 
lines were used as guides for the position at which to measure migration. Phenol 
red free media with the appropriate serum concentration was added to the 
wells. 17β-Estradiol (E2) (Steraloids, New England, USA, E0950-000) was 
dissolved in 100% ethanol (EtOH) to create a 1 mM stock solution and stored at -
20˚C. 16α-hydroxyestrone (16α-OHE1) (Steraloids, New England, USA, E1250-
000) was also dissolved in 100% EtOH to create a 1 mM stock solution and stored 
at -20˚C. E2 and 16α-OHE1 were diluted in media to create a final concentration 
in the well of 10 nM (1x10-8 M) and 1 nM (1x10-9 M). Each condition was repeated 
in duplicate. An unstimulated control was included with the same percentage 
serum containing media. As positive controls, 10% serum (FBS/CSS) were 
included and EtOH vehicle negative controls were also included and were 
repeated in either duplicate or triplicate, depending on the wells available. 
Photographs were taken using a Moticam ST 5.0MP camera and Motic Images Plus 
2.0 software. 0 hr photographs were then taken at the point indicated by the 
line/s drawn on the bottom of the wells. During initial experiments only 1 
photograph was taken per well, whereas for later experiments 2 photographs 
were taken at different points in each well. Cells were incubated with the 
appropriate treatment for 24 hr and images were captured in the same manner 
at approximately the same position as the 0 hr image. Using Image J software, 
the area of a small section of the scratch indicated by the line was calculated in 
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both 0 hr and 24 hr photographs. The percentage wound closure was then 
calculated by the equation (0 hr area – 24 hr area/ 0 hr area) *100 = percentage 
of wound closure. The area was therefore always relevant to the initial area 
measured in the 0 hr photograph.   
2.10 Analysis of RNA 
2.10.1 RNA extraction 
Total RNA was extracted from RV tissue, LV tissue or cells harvested at the end 
of the study. Approximately half of the RV tissue and one quarter of the LV 
tissue was selected for RNA analysis. For tissue RNA extraction, a 5 mm stainless 
steel bead (Qiagen, UK, 69989) and 700 µL of QIAzol lysis reagent (Qiagen, UK, 
79306) was added to each sample. Samples were then homogenised in the Tissue 
Lyser II (Qiagen, UK, 85300). RNA extraction from cells was performed by cells 
first being washed with PBS and then 700 µL of QIAzol lysis reagent was added to 
each well. The bottom of the wells was then scraped to remove the cells from 
the surface of the well and the cells in the QIAzol suspension were then 
transferred to RNase free microcentrifuge tubes. Samples from both tissue and 
cells were incubated at room temperature for 5 mins after which 140 µL of 
chloroform was added and the microcentrifuge tubes shaken vigorously. 
Microcentrifuge tubes were subjected to centrifugation at 12,000 g for 15 mins 
at 4°C. Further extraction and purification were performed using the miRNeasy 
extraction kit (Qiagen, UK, 217004) as per the manufacturer’s instructions. A 
DNase digestion step was performed to prevent contamination of the RNA 
sample with deoxyribonucleic acid (DNA). Next, 10 µL of the DNase digestion 
enzyme and 70 µL of the RDD buffer (Qiagen, UK, 79254) were mixed and added 
to the mini spin column and incubated for between 20 – 40 mins. Finally, RNA 
was eluted in 33 µL of RNase free water (Qiagen, UK) and passed through the 
column twice to maximise RNA yield. RNA samples were then immediately 
placed on ice or stored at -80°C.  
2.10.2 Quantification of RNA     
RNA was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, UK). Each sample was assessed for RNA concentration (ng/mL) and 
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the quality indicated by the 260/280 ratio. A 260/280 ratio of 2.0 indicates high 
quality RNA and the ratio of the majority of samples fell within the range of 
1.95-2.05. However, a few samples outwith this range were included in final 
analysis due to the small number of samples. Each sample was analysed twice 
and a mean concentration calculated. 
2.10.3 Complementary DNA preparation 
Reverse transcription (RT) of RNA to produce complementary DNA (cDNA) was 
carried out using the TaqMan Reverse Transcription Reagents kit (Applied 
Biosystems, USA, N808-0234) with 40 µL reactions performed for each sample. 
500 ng, 1 µg or 1.5 µg of RNA was added to the reaction. The different 
concentrations were due to differences in RNA concentration between cells, RV 
tissue and LV tissue and low volumes of RNA towards the end of the study. No 
comparisons were made across different cDNA plates. Reaction mixtures (Table 
8) and RNA were added to 96 well plates. Plates were sealed with an adhesive 
sheet before brief centrifugation which ensured all components were mixed at 
the bottom of the well. RT was performed using the Veriti 96 well fast Thermal 
Cycler (Applied Biosystems, UK) or the Peltier Thermal Cycler PTC-225 (MJ 
Research). The following cycling conditions were selected: 10 mins at 25°C, 30 
mins at 48°C and 5 mins at 95°C. 96 well plates containing cDNA were then 
stored at -20°C.  
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Solution Volume (µL) Final 
Concentration  
10 x RT Buffer 4 1 x RT buffer 
25 mM MgCl2 8.8 5.5 mM 
dNTPs 8 2 mM 
Random hexamers 2 2.5 µM 
RNase Inhibitor 0.8 0.4 U/µL 
Multiscribe enzyme 1 1.25 U/µL 
RNA + RNase free 
water 
15.4  
 
Table 8 – TaqMan Reverse Transcription Reagents.  
Reverse Transcription reagents, the volume used in each 40 µL reaction and the 
final concentration of reagents. 
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2.10.4 Quantitative Polymerase Chain Reaction (qPCR) 
TaqMan reaction mixtures with 10 µL volumes were produced with TaqMan 
Universal master mix II, no UNG (Applied Biosystems, USA, 4440040), the 
appropriate primer (Life Technologies, UK) (Table 9, Table 10), RNase free 
water (Qiagen, UK) and cDNA sample. Samples were repeated in triplicate on the 
same 384 well plate in order to account for technical errors. Non-template 
controls containing RNase free water instead of cDNA sample were also included 
for each primer to ensure there was no contamination of the master mix. After 
the addition of all the components, plates were sealed with an optical adhesive 
sheet and briefly centrifuged to remove all air bubbles and mix the components 
at the bottom of the well. The ViiA7 Real Time PCR system was used to perform 
quantitative real-time PCR (qRT-PCR). The cycling conditions were as follows: 
50°C for 2 mins, 95°C for 10 mins and then 40 cycles of 95°C for 15 secs, 60°C 
for 1 min. Beta-2-microglobulin (B2M) was used as the housekeeper gene. The   
2-ΔCT method (Schmittgen and Livak, 2008) was used to calculate and display 
levels of gene expression. 
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Gene Gene name Species Code 
B2M B2m Mouse Mm00437762_m1 
BMPR2 bmpr2 Mouse Mm00432134_m1 
Col1a1 Col1a1 Mouse Mm00801666_g1 
Col3a1 Col3a1 Mouse Mm01254476_m1 
CTGF Ctgf Mouse Mm01192933_g1 
Cyp1b1 Cyp1b1 Mouse Mm00487229_m1 
Id1 Id1 Mouse Mm00775963_g1 
Id3 Id3 Mouse Mm01188138_g1 
Mm00492575_m1 
Smad 1 Smad1 Mouse Mm00484723_m1 
TGFb1 Tgfb1 Mouse Mm01178820_m1 
TGFbR1 TgfbR1 Mouse Mm00436964_m1 
Table 9 - Mouse TaqMan Primers (Thermo Scientific, UK).  
The mRNA target, gene name and catalogue number for each primer.  
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Gene Gene name Species Code 
b-Actin Actb Rat Rn00667869_m1 
ANP Nppa Rat Rn00664637_g1 
B2M B2M Rat Rn00560865_m1 
BMPR2 Bmpr2 Rat Rn01437214_m1 
β-myosin heavy chain Myh7 Rat Rn01488777_g1 
BNP Nppb Rat Rn00676450_g1 
Col1a1 Col1a1 Rat Rn01463848_m1 
Col3a1 Col3a1 Rat Rn01437681_m1 
CTGF CTGF Rat Rn01537279_g1  
Id1 Id1 Rat Rn00562985_s1 
Id3 Id3 Rat Rn04219390_g1 
Ppib Ppib Rat Rn00574762_m1 
Smad 1 Smad1 Rat Rn00565555_m1 
TBFb1 TBFb1 Rat Rn00572010_m1 
TGFbR1 TGFbR1 Rat Rn00688966_m1 
Table 10 - Rat TaqMan Primers (Thermo Scientific, UK).  
The mRNA target, gene name and catalogue number for each primer.  
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2.11 Western Blotting  
2.11.1 Protein Extraction 
Protein was extracted from RV tissue, LV tissue and lung tissue harvested on Day 
28 of the mouse Anastrozole study. A small section of each tissue was used for 
protein extraction, normally, half of the mouse RV, one quarter of the mouse LV 
and one of the right lung lobes. The tissue was moved into a fresh, cold 2 mL 
microcentrifuge tube and placed on ice. A 5 mm stainless steel bead (Qiagen, 
UK), 300 µL of 1% lauryl maltoside/PBS (LM buffer) (Abcam, UK) and Halt™ 
Protease Inhibitor Cocktail (ThermoFisher Scientific, 78429) was added to each 
sample. Samples were homogenised in the Tissue Lyser II (Qiagen, UK) at 25 Hz 
for 4 x 30 secs with 30 secs rest in between each homogenisation, this helped to 
prevent heating of the sample. The homogenised samples were then left on ice 
for 30 mins. Samples were then subjected to centrifugation at 10,600 g for 
10mins at 4°C. Following centrifugation, the supernatant was then transferred 
to a new pre-cooled microcentrifuge tube and moved immediately onto ice or 
stored at -80°C.  
2.11.2 Quantification of protein     
Protein was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, UK). The Protein A280 setting was selected and each sample was 
assessed for the protein concentration (mg/mL). Each sample was analysed 
twice and a mean concentration calculated. 
2.11.3 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS PAGE) allows 
the separation of proteins across a gel due to their molecular weight. Protein 
samples were prepared for western blotting with NuPAGE reducing agent (Life 
technologies, UK) and NuPAGE sample loading buffer (Life technologies, UK) at a 
ratio of 5:1:2, respectively. Samples were then heated to 70°C for 10 mins to 
disrupt the tertiary protein structure and denature the proteins. This was 
followed by centrifugation at 10,600 g for 1 min. Samples were then stored at -
20°C until required. On the day of the western blotting experiment, samples 
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were loaded into NuPAGE Novex 4-12% Bis-Tris Mini gels (Life Technologies, UK) 
and SeeBlue Plus2 (Invitrogen, UK) was used as a molecular weight ladder. 
Approximately 20 µg of protein was loaded into each well of the gel. When 
appropriate, 20 µg of positive control tissue, prepared in the same way, was also 
loaded on to the gel. The gel tanks were filled with 5% (v/v) NuPAGE MOPS 
buffer (Life technologies, UK) in distilled water. A voltage of 150 V was applied 
to the gel tanks for approximately 1.5 hrs or until adequate separation of the 
molecular weight ladder was visualised. The sample loading buffer and the 
molecular weight ladder allowed the progress of the proteins through the gel to 
be monitored.   
2.11.4 Protein transfer and visualisation 
Following gel electrophoresis, proteins were transferred onto a polyvinylidene 
fluoride (PVDF) microporous membrane (Millipore, USA). PVDF membranes were 
activated with 100% methanol prior to use. The transfer buffer was as follows: 
5% (v/v) NuPAGE transfer buffer (Life technologies, UK), 20% (v/v) Methanol and 
(v/v) 75% distilled water. Sponges used in the transfer tanks were soaked in 
transfer buffer prior to use and a roller was used to exclude all air bubbles from 
the sponges which could affect the successful transfer of proteins. The transfer 
tanks were set up using sponges, paper, PVDF membrane and the gel containing 
the proteins. The transfer was run at 35 V for approximately 2 hrs and 15 mins, 
during this time the proteins migrated from the gel onto the PVDF membrane. 
After termination of the transfer, membranes were stained with 0.1% (w/v) 
Ponceau S in 5% (v/v) acetic acid solution to ensure the presence of proteins on 
the membrane. The PVDF membranes were then washed using tris-buffered 
saline with 0.1% (v/v) Tween20 (TBST) (ThermoFisher Scientific, UK) 3 times for 
10 mins. This ensured all Ponceau S had been removed from the membrane. 
Membranes were then blocked to prevent non-specific antibody binding, using a 
non-fat milk solution made up of 5% Milk powder (w/v) in TBST. 
2.11.5 Immunoblotting 
The identification of proteins on the membrane was achieved by exposing the 
membrane to a protein-specific antibody. Membranes were washed for 3 x 10 
minutes in TBST before primary antibodies were added (Table 11). All primary 
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antibodies were made up in 5% (w/v) (BSA)/TBST, with the exception of α-
tubulin which was made up in 5% (w/v) milk powder (Milk powder)/TBST. 
Membranes were incubated with primary antibodies overnight at 4°C on a 
shaker. Membranes were washed 3 times in TBST to remove all excess primary 
antibody that had not bound to its specific protein prior to the addition of an 
appropriate secondary antibody (Table 11). Secondary antibodies were 
conjugated with horse radish peroxidase (HRP) to allow detection of the 
antibody using an enhanced chemiluminescence (ECL) method. Secondary 
antibodies were made up in 5% milk powder or high detergent (HD) 5% milk 
powder (per 5 mL: 3.7 mL water, 0.5 mL 5% Milk powder, 0.5 mL 10x PBS 0.25 
mL 20% Triton-x-100 and 0.05 mL 10% sodium dodecyl sulphate (SDS)). 
Membranes were incubated with secondary antibodies for approximately 1 hr at 
room temperature on a shaker. Protein bands were visualised using ECL solutions 
with either Immobilon western chemiluminescence horseradish peroxidise (HRP) 
substrate (Merck Millipore, USA) or Pierce ECL (ThermoFisher Scientific, UK). 
This allowed visualisation of the protein bands following exposure of the 
membrane to x-ray film. Following this, membranes were washed for 3 x 10 
minutes in TBST before membranes were stripped using Restore Western Blot 
Stripping buffer (Thermo Scientific, UK) for 15 mins at room temperature on a 
shaker. The same protocol was then followed for the loading control which was 
either glyceraldehyde phosphate dehydrogenase (GAPDH), α-tubulin or α-actin. 
Protein bands on the x-ray film were quantified by densitometry analysis using 
Image Studio Lite Version 5.2 software (Licor, UK). The ratio of the protein of 
interest to loading control was calculated.
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Primary Antibody Dilution Secondary Antibody Dilution  ECL 
BMPR2 (BD Biosciences, 
612292) 
1:500 in 5% BSA Anti-mouse (Sigma-Aldrich, 
A9044/ Calbiochem, 401215) 
1:10,000 in 5% Milk 
powder/TBST 
Millipore 
Id1 (CalBioreagents, M085) 1:1000 in 5% BSA Anti-rabbit (Calbiochem, 401315) 1:10,000 in 5% Milk 
powder/TBST 
Millipore 
Id3 (CalBioreagents, M100) 1:1000 in 5% BSA Anti-rabbit (Calbiochem, 401315) 1:10,000 in 5% Milk 
powder/TBST 
Millipore 
ER-α (Abcam, 32063) 1:1000 in 5% BSA Anti-rabbit (Calbiochem, 401315) 1:20,000 in HD 5% Milk 
powder/TBST 
Millipore 
CYP1B1 (Abcam, 78044) 1:1000 Anti-rabbit (Calbiochem, 401315) 1:10,000 in 5% Milk 
powder/TBST 
Millipore/ 
ThermoFisher 
Aromatase (Abbexa) 1:500 in 5% BSA Anti-rabbit (Calbiochem, 401315) 1:20,000 in 5% Milk 
powder/TBST 
Millipore 
α-tubulin (Abcam, ab7291) 1:10,000 in 5% Milk 
powder 
Anti-mouse (Sigma-Aldrich, 
A9044) 
1:10,000/1:20,000 in 5% 
Milk powder/TBST 
ThermoFisher 
α-Actin Sigma-Aldrich, 
A9357) 
1:10,000 in 5% BSA Anti-mouse (Sigma-Aldrich, 
A9044) 
1:10,000 in 5% Milk 
powder/TBST 
ThermoFisher 
 Table 11 - Western Blotting protocols.   
Primary and secondary antibodies with dilutions and the appropriate ECL.
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2.12 Development of the Pulmonary Artery Banding 
Surgical Model 
Work was completed to develop a pulmonary artery banding (PAB) model at the 
University of Glasgow. The team developing this model included myself, 
Margaret Nilsen and Michael Dunne. The Named Veterinary Surgeon also provided 
advice regarding the surgical procedure and intra-operative/post-operative 
analgesics. The staff in the CVRU also provided assistance with animal welfare 
following surgery. The sham surgery was also undergoing development to act as 
a control. The full development of the surgical procedure is described in 
Appendix 7.2. Briefly, the surgery was being developed to include the following 
main steps: a lateral thoracotomy to expose the pulmonary artery, the 
positioning of a suture under the pulmonary artery using a ligation aid, 
constriction of the pulmonary artery with the suture and the use of a blunted 
needle to guide the diameter of the tie and finally closure of the wound. 1 male 
Wistar rat (Envigo, Oxon, UK) and 1 male Sprague Dawley rat (Charles River, UK) 
successfully recovered from sham surgery and were haemodynamically assessed 
at 6 weeks and 4 weeks post-surgery, respectively.  
 
2.13 Statistical Analysis 
All data is displayed as mean ± standard error of the mean (S.E.M.). Protein 
results are displayed as the ratio of the densitometry measurements for the 
protein of interest to the loading control. Gene expression data is displayed as  
2-ΔCT relative to the housekeeping gene B2M. Data was analysed using unpaired t-
test (two-tailed) or one-way analysis of variance (ANOVA) with Bonferroni post-
hoc test, with the mean of pre-selected groups compared, as indicated. 
Statistical analysis was performed using GraphPad Prism Software version 7 and 
8 (GraphPad Software Inc., California, USA). P values of < 0.05 were considered 
statistically significant. The significant differences between the pre-selected 
groups have been shown. Significant differences are displayed * p<0.05, ** 
p<0.01, *** p<0.001 and **** p<0.0001.
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Chapter 3 
3 The effect of FK506 treatment on parameters of 
experimental pulmonary hypertension.  
82 
 
3.1 Introduction 
An understanding of the genetic factors contributing to the development of 
disease allows potential drug targets to be identified. Mutations in BMPR2 are 
the most well understood risk factor in the development of PAH. Over 400 
different mutations across the ligand binding domain, kinase domain and 
cytoplasmic domain have been identified in the BMPR2 gene (Austin and Loyd, 
2014). The majority of mutations identified in PAH patients are nonsense and 
frameshift mutations that render the protein non-functional. Therefore, it is 
thought that haploinsufficiency of BMPR2 contributes to the pathogenesis of the 
disease (Southgate et al., 2020).  
Despite the role of BMPR2 being well established in PAH, there are no therapies 
which currently target it. A recent study identified FDA approved compounds 
which increased the expression of BMPR2 (Spiekerkoetter et al., 2013) an 
approach which might be useful to investigate for PAH. Repurposing drugs which 
are FDA approved for other conditions is a particularly useful approach for rare, 
orphan diseases such as PAH as often the appropriate funding is not available 
within the pharmaceutical industry to identify new therapeutic targets. The 
compound FK506 (tacrolimus) is currently used as an immunosuppressive drug 
and is often used to treat patients who are undergoing an organ transplant (Fung 
and Starzl, 1995). The Spiekerkoetter et al. (2013) study highlighted that 
treatment with low dose FK506 (tacrolimus) was able to increase BMPR2 
expression in an in vitro setting and reverse the PH phenotype in several 
different animal models (Spiekerkoetter et al., 2013). FK506 was able to 
mediate these effects via interaction with its pharmacological target FKBP12 
which in turn prevented FKBP12 binding to the BMP receptors. It was also shown 
to activate BMPR2 mediated signalling even in the absence of BMP ligands. The 
encouraging results in the pre-clinical setting meant that investigations into 
FK506 as a potential therapy to treat PAH have progressed to clinical 
investigations. The first study involved compassionate use of low dose FK506 in 3 
female patients with late stage disease (Spiekerkoetter et al., 2015). Two out of 
the three patients appeared to respond to treatment with improved or stable RV 
function and neither patient had a PAH related hospitalisation during the 12 
months of treatment. This then led to a Phase IIa clinical trial investigating 
safety and tolerability (Spiekerkoetter et al., 2017). Although within the patient 
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cohort FK506 was generally well tolerated and there was no concern over the 
safety or toxicity of the compound, neither an improvement in PAH parameters 
nor an increase in BMPR2 expression were observed. Although one of the 
outcomes of the study was that a phase IIb clinical trial was appropriate, 
recruitment for a phase IIb trial has not yet begun.  
Another well-established risk factor in the development of PAH is the female 
sex. PAH registries show a female to male ratio of up to 4:1 (Badesch et al., 
2010). Therefore, the role of sex in the pathological processes of PAH must be 
considered. This finding must also be considered during the development of new 
therapies as it possible that the therapy related clinical outcomes may differ 
between men and women. Studies have shown sex-specific differences in the 
expression of BMPR2 and BMPR2 mediated signalling within PAH (Austin et al., 
2012; Mair et al., 2015). Furthermore, sex-specific differences in the penetrance 
of BMPR2 mutations has also been highlighted. Females have shown 
approximately 42% penetrance and males only 14% penetrance (Larkin et al., 
2012). Therefore, understanding the sex-specific effects of a potential PAH 
therapeutic is key to understanding its potential effect on the clinical outcomes 
of the PAH patient population. The study by Spiekerkoetter et al. (2013) in 
which treatment with FK506 was investigated in multiple animal models was only 
conducted using male animals (Spiekerkoetter et al., 2013). Therefore, there is 
a need to fully investigate the effects of treatment with FK506 in female animals 
as the majority of the PAH patient population who will be treated with this 
potential therapy are female.  
Here, the effect of FK506 (0.05mg/kg/day) on parameters of experimental 
pulmonary hypertension was investigated in a rat model of chronic hypoxia.  
The aims of this investigation were: 
To characterise the chronic hypoxia model in both male and female rats. The 
effect on haemodynamic parameters along with the associated pathological 
changes in the pulmonary vasculature were assessed.  
To assess the effects of FK506 treatment (0.05mg/kg/day) on these parameters.   
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To assess the effects of FK506 treatment (0.05mg/kg/day) on systemic and left 
ventricular pressure in order to identify any potential off target, systemic 
effects.  
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3.2 Results 
Sprague Dawley rats were placed in a hypobaric hypoxic chamber for 35 days. On 
day 14 of the study drug releasing pellets were inserted subcutaneously in the 
neck. The pellets either released FK506 at a dose of 0.05 mg/kg/day or a 
placebo. The placebo consisted of cholesterol, lactose, celluloses, phosphates 
and stearates which made the matrix of the carrier binder in the FK506 pellets.  
Rats were returned to the hypoxic chamber for the remainder of the study. Age 
and sex matched controls were kept under normoxic conditions and followed the 
same dosing regimen. On day 35 of the study rats were haemodynamically 
assessed using the Millar PV loop system, humanely killed and tissues were then 
collected (Figure 3.1).  
 
Figure 3.1- Schematic diagram showing FK506 study protocol and dosing 
regimen.  
Male and female Sprague Dawley rats were kept in normoxic or hypoxic 
conditions for a period of 35 days. On day 14, FK506 pellets (0.05mg/kg/day) or 
placebo pellets were administered, and the rats returned to normoxia or 
hypoxia. On day 35 haemodynamic measurements were collected and the 
animals humanely killed prior to tissue harvesting. 
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3.2.1 Hypoxia but not treatment with FK506 significantly affects 
the body weight gain of male rats  
As standard, body weight is monitored for the duration of the study in order to 
monitor animal welfare and also ensure dosing regimens are appropriate for the 
weight of the animals. The pellets were designed to slowly release FK506 at a 
dose of 0.05 mg/kg/day. The concentration of FK506 released was based on an 
average body weight of 220 g. Therefore, the aim was to insert the pellets 
subcutaneously when the rats weighed approximately 220 g. Rats were weighed 
prior to beginning the administration of FK506 (Figure 3.2A) and at the end of 
the 3 week dosing period (Figure 3.2B). The average weight gain for each of the 
animals was then calculated (Figure 3.2C). No significant difference in the 
weight gain of male rats dosed with FK506 (0.05 mg/kg/day) or placebo was 
observed. However, hypoxia significantly reduced the weight gain in both 
treatment groups (normoxic placebo group 135± 9.0g vs hypoxic placebo group 
103.5± 4.5g,  *p<0.05, normoxic FK506 group 138.5± 5.3g vs hypoxic FK506 group 
94.3± 6.6g, **p<0.01, n=6).  
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Figure 3.2. The body weight (g) of male rats throughout the duration of the 
study protocol. 
A) Body weight (g) of male rats at the time of pelleting. B) Body weight (g) of 
male rats at the end of the study. C) Body weight gain (g) in male rats 
throughout the duration of the dosing period. n=6, *p<0.05, **p<0.01.  
Statistical analysis was performed using one-way ANOVA followed by Bonferroni 
post-hoc test. Data is displayed with the bar representing the mean ± S.E.M. 
The measurement from each individual animal is also represented.  
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3.2.2 Hypoxia or treatment with FK506 does not significantly 
affect the body weight gain of female rats  
The weight of female rats was also monitored and the weights at the start 
(Figure 3.3A) and end of the treatment regime (Figure 3.3B) recorded. The rats 
within the hypoxic FK506 treatment group had a significantly lower body weight 
prior to starting the dosing regimen compared to the placebo treatment group 
(221.5± 3.8g vs 200.3± 2.2g *p<0.05, n=6). However, by the end of the dosing 
period there was no significant difference between the groups. The weight gain 
across the 3 week dosing period was then calculated. Treatment with FK506 had 
no significant effect on the weight gain under either normoxic or hypoxic 
conditions (Figure 3.3C). The weight gain of female rats housed in normoxia vs 
hypoxia was not significantly different.  
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Figure 3.3. The weight (g) of female rats throughout the duration of the 
study protocol.  
A) Weight (g) of female rats at the time of pelleting. B) Weight (g) of female 
rats at the end of the study. C) Weight gain (g) in female rats throughout the 
duration of the dosing period. n=6, *p<0.05. Statistical analysis was performed 
using one-way ANOVA followed by Bonferroni post-hoc test. Data is displayed 
with the bar representing the mean ± S.E.M. The measurement from each 
individual animal is also represented. 
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3.2.3 Treatment with FK506 had no significant effect on RVSP in 
male rats 
Haemodynamic measurements were recorded using the Millar PV loop system. 
RVSP (mmHg) was assessed as a parameter of experimental PH and to confirm 
the hypoxia regime induced a PH phenotype. The effect of treatment with FK506 
on RVSP was also assessed. In the placebo treated male rat group, hypoxia 
significantly increased RVSP (27.9± 1.7 mmHg vs 45.3± 3.9 mmHg, *p<0.05, n=6)  
as expected indicating that a PH phenotype had been induced in these animals 
(Figure 3.4). However, there was no significant difference in the RVSP between 
the placebo and FK506 hypoxic groups, indicating treatment with FK506 
(0.05mg/kg/day) was not sufficient to reverse the increase in RVSP induced by 
hypoxia in these animals. Heart rate (HR) was also assessed during the period of 
the RVSP recording (Figure 3.4C). There was no significant difference in heart 
rate across the 4 groups of male rats. Previous studies have shown heart rate in 
male Sprague Dawley rats under 3% isoflurane to be approximately 360bpm (Kato 
et al., 2016), therefore the HR across all groups was as expected.  This indicates 
that hypoxia and FK506 did not influence the heart rate. This finding also 
confirms that any change in RVSP is not associated with increased HR or a 
change in cardiac output as a result of increased heart rate.     
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Figure 3.4. Right Ventricular Systolic Pressure (RVSP) in male rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day).  
A) Representative images showing the right ventricular systolic pressure traces 
collected by Millar PV loop system and AD Instruments software. B) RVSP 
(mmHg) in male rats housed in normoxia or hypoxia treated with placebo or 
FK506 (0.05mg/kg/day). C) Heart rate (beats per minute, bpm) during the RVSP 
recording. n=6, *p<0.05. Statistical analysis was performed using one-way 
ANOVA followed by Bonferroni post-hoc test. Data is displayed with the bar 
representing the mean ± S.E.M. The measurement from each individual animal 
is also represented. 
92 
 
3.2.4 Treatment with FK506 had no significant effect on RVSP in 
female rats 
RVSP (mmHg) was assessed in placebo and FK506 treated female rats exposed to 
normoxic or hypoxic conditions. Hypoxia significantly increased RVSP in female 
rats (placebo group 28.0± 0.9 mmHg vs 54.9± 4.5 mmHg, ****p<0.0001, FK506 
group 25.9± 1.1 mmHg vs 44.3± 3.1 mmHg, **p<0.01, n=5-6) (Figure 3.5). Again, 
FK506 treatment had no significant effect on RVSP in female rats suggesting that 
treatment with FK506 at 0.05 mg/kg/day does not reverse the increase in RVSP 
associated with exposure to hypoxia. There were no significant differences in HR 
across the 4 groups (Figure 3.5C). Again, this suggests that increased RVSP is 
associated with pathological changes related to exposure to hypoxia and not as a 
result of increased heart rate.  
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Figure 3.5. Right Ventricular Systolic Pressure (RVSP) in female rats housed 
in normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day).  
A) Representative images showing the right ventricular systolic pressure traces 
collected by Millar PV loop system and AD Instruments software. B) RVSP 
(mmHg) in female rats housed in normoxia or hypoxia treated with placebo or 
FK506 (0.05mg/kg/day). C) Heart rate (beats per minute, bpm) during the RVSP 
recording. n=5-6, **p<0.01****p<0.0001.  Statistical analysis was performed using 
one-way ANOVA followed by Bonferroni post-hoc test. Data is displayed with the 
bar representing the mean ± S.E.M. The measurement from each individual 
animal is also represented. 
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3.2.5 FK506 did not reverse pulmonary artery remodelling in 
hypoxic male rats 
Remodelled pulmonary arteries were defined as pulmonary arteries exhibiting a 
double elastic lamina, visualised by staining with Miller’s elastin stain. 
Pulmonary artery remodelling was assessed by the number of remodelled 
pulmonary arteries as a percentage of the total number of pulmonary arteries in 
a lung section. Hypoxia significantly increased the percentage of remodelled 
pulmonary arteries in male rats (placebo group 3.4± 0.2% vs 38.8± 1.7%, 
****p<0.0001, FK506 group 4.3± 1.2% vs 37.0± 2.2%, ****p<0.0001, n=4). However, 
FK506 treatment (0.05mg/kg/day) had no significant effect on the percentage of 
remodelled pulmonary arteries (Figure 3.6).  
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Figure 3.6. The effect of hypoxia and FK506 treatment on pulmonary artery 
remodelling.  
Male rats housed under normoxia or hypoxia and treated with placebo or FK506 
(0.05mg/kg/day). A) Representative images of pulmonary arteries under each 
condition. B) Quantification of the percentage of pulmonary arteries that 
appear remodelled with a double elastic lamina. n=4, ****p<0.0001.   Statistical 
analysis was performed using one-way ANOVA followed by Bonferroni post-hoc 
test. Data is displayed with the bar representing the mean ± S.E.M. The 
measurement from each individual animal is also represented. Scale bar = 
25µM, magnification = x40. 
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3.2.6 FK506 did not reverse pulmonary artery remodelling in 
hypoxic female rats 
Pulmonary artery remodelling was calculated in the same way for female rats. 
Again, hypoxia significantly increased the percentage of remodelled pulmonary 
arteries in female rats (placebo group 3.4± 0.9% vs 37.8± 5.8%, ***p<0.001, FK506 
group 3.7± 1.2% vs 34.1± 1.3%, ***p<0.0001, n=3-4). However, FK506 treatment 
(0.05mg/kg/day) had no significant effect on the percentage of remodelled 
pulmonary arteries (Figure 3.7). 
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Figure 3.7. The effect of hypoxia and FK506 treatment on pulmonary artery 
remodelling.  
Female rats housed under normoxia or hypoxia and treated with placebo or 
FK506 (0.05mg/kg/day). A) Representative images of pulmonary arteries under 
each condition. B) Quantification of the percentage of pulmonary arteries that 
appear remodelled with a double elastic lamina. n=3-4, ***p<0.001.   Statistical 
analysis was performed using one-way ANOVA followed by Bonferroni post-hoc 
test. Data is displayed with the bar representing the mean ± S.E.M. The 
measurement from each individual animal is also represented. Scale bar = 
25µM, magnification = x40.  
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3.2.7 Systemic blood pressure in male rats is not influenced by 
treatment with FK506 
It was important to assess the effect of FK506 treatment on the systemic 
circulation. Assessment of systemic blood pressures would ensure that any 
effects of FK506 were specific for the pulmonary circulatory system and were 
not the result of FK506 influencing the systemic circulation. Mean systemic 
arterial pressure (normoxia placebo 69.1± 4.2 mmHg, normoxia FK506 74.3± 4.7 
mmHg, hypoxia placebo 87.2± 2.9 mmHg, hypoxia FK506 78.8± 9.8 mmHg, n=4-6) 
(Figure 3.8A), pulse pressure (normoxia placebo 33.4± 2.4 mmHg, normoxia 
FK506 32.9 ± 1.8 mmHg, hypoxia placebo 26.3± 1.6 mmHg, hypoxia FK506 30.5± 
3.1 mmHg, n=4-6) (Figure 3.8B), systolic pressure (normoxia placebo 88.5± 3.4 
mmHg, normoxia FK506 93.0 ± 3.5 mmHg, hypoxia placebo 101.3± 2.2 mmHg, 
hypoxia FK506 95.2± 8.0 mmHg, n=4-6) (Figure 3.8C) and diastolic pressure 
(normoxia placebo 55.1± 4.1 mmHg, normoxia FK506 60.1± 4.6 mmHg, hypoxia 
placebo =75.1± 2.9 mmHg, hypoxia FK506 64.7± 10.2 mmHg, n=4-6) (Figure 3.8D) 
(mmHg) are all displayed. These measurements were within the expected ranges 
for the concentration of isoflurane used to anaesthetise the animals (Yang, 
2014). There were no differences in any parameter between hypoxia or 
normoxia in animals on placebo. Furthermore, treatment with FK506 had no 
significant effect on any of these parameters under normoxic or hypoxic 
conditions. Therefore, any effect of FK506 on the pulmonary phenotype could be 
assumed to be pulmonary specific and there are no off target or non-specific 
effects of this treatment on the systemic circulation.   
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Figure 3.8. The effect of hypoxia and treatment with FK506 (0.05mg/kg/day) 
on systemic pressure in male rats.  
Male rats were housed under normoxia or hypoxia and treated with placebo or 
FK506 (0.05mg/kg/day). A) Mean systemic arterial pressure (mmHg) B) Pulse 
pressure (mmHg). C) Systemic systolic pressure (mmHg).  D) Systemic diastolic 
pressure (mmHg). n=4-6.  Statistical analysis was performed using one-way 
ANOVA followed by Bonferroni post-hoc test. Data is displayed with the bar 
representing the mean ± S.E.M. The measurement from each individual animal 
is also represented. 
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3.2.8 Systemic blood pressure in female rats is not affected by 
treatment with FK506 but hypoxia significantly influenced 
the systemic circulation 
The effect of FK506 on the systemic circulation was also assessed in the female 
animals. FK506 had no significant effect on the parameters of systemic blood 
pressure that were assessed, mean systemic arterial pressure (Figure 3.9A), 
pulse pressure (Figure 3.9B), systolic pressure (Figure 3.9C) and diastolic 
pressure (Figure 3.9D) (mmHg), under normoxic or hypoxic conditions. However, 
unlike the male rats, each of the parameters of systemic pressures was 
significantly affected by hypoxia in female rats. Hypoxia significantly increased 
mean systemic pressure (placebo group 67.2± 5.6 mmHg vs 96.8± 2.3 mmHg, 
**p<0.01, FK506 group 72.4± 4.2 mmHg vs 103.8± 2.4 mmHg, ***p<0.0001, n=5-6), 
systolic pressure (placebo group 85.1± 4.2 mmHg vs 108.7± 2.2 mmHg, **p<0.01, 
FK506 group 86.5± 3.6 mmHg vs 115.5± 2.7 mmHg, ***p<0.0001, n=5-6) and 
diastolic pressure (placebo group 52.6± 5.4 mmHg vs 84.2± 2.3 mmHg, 
***p<0.001, FK506 group 58.9± 3.9 mmHg vs 91.2± 2.3 mmHg, ***p<0.0001, n=5-
6). Correspondingly, pulse pressure was significantly decreased by hypoxia with 
the placebo treated group (placebo group 32.5± 1.7 mmHg vs 24.5± 0.8 mmHg, 
*p<0.05, n=5-6). 
  
101 
 
 
Figure 3.9. The effect of hypoxia and treatment with FK506 (0.05mg/kg/day) 
on systemic pressure in female rats.  
Female rats were housed under normoxia or hypoxia and treated with placebo 
or FK506 (0.05mg/kg/day). A) Mean systemic arterial pressure (mmHg) B) Pulse 
pressure (mmHg). C) Systemic systolic (mmHg). D) Systemic diastolic pressure 
(mmHg). n=5-6, *p<0.05, **p<0.01, ***p<0.001.  Statistical analysis was 
performed using one-way ANOVA followed by Bonferroni post-hoc test. Data is 
displayed with the bar representing the mean ± S.E.M. The measurement from 
each individual animal is also represented. 
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3.2.9 Treatment with FK506 had no effect on LVSP in male rats 
housed in normoxic or hypoxic conditions 
Left ventricular systolic pressure (LVSP) was another parameter assessed in order 
to confirm that any effects of FK506 were RV-specific and not a result of an 
overall cardiac effect. There was no significant difference in LVSP across the 4 
groups of male rats (normoxia placebo 97.1± 3.1 mmHg, normoxia FK506 102.5 ± 
3.6 mmHg, hypoxia placebo 106.4± 3.1 mmHg, hypoxia FK506 98.9± 4.8 mmHg, 
n=4-6) (Figure 3.10). This suggests that FK506 does not affect LVSP in male rats. 
Furthermore, hypoxia did not influence LVSP.   
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Figure 3.10. Left Ventricular Systolic Pressure (LVSP) in male rats housed in 
normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day).  
A) Representative images showing the left ventricular systolic pressure traces 
collected by Millar PV loop system and AD Instruments software. B) LVSP 
(mmHg) in male rats housed in normoxia or hypoxia treated with placebo or 
FK506 (0.05mg/kg/day). n=4-6.  Statistical analysis was performed using one-
way ANOVA followed by Bonferroni post-hoc test. Data is displayed with the bar 
representing the mean ± S.E.M. The measurement from each individual animal 
is also represented. 
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3.2.10 Treatment with FK506 had no effect on LVSP in female 
rats housed in normoxic or hypoxic conditions 
In female rats, treatment with FK506 did not influence LVSP. Consequently, it 
could be confirmed that any effect on RVSP would be the result of pulmonary or 
RV specific action of FK506 and not the result of an overall cardiac effect. There 
was a significant difference in LVSP between the normoxic and hypoxic female 
rats within the FK506 group (92.9± 1.6 mmHg vs 113.6± 2.1 mmHg, **p<0.01, 
n=4-6) (Figure 3.11). The difference in LVSP between the 2 groups appears to be 
a result of a reduced mean LVSP in the normoxic group in comparison to normal 
physiological levels of 120mmHg. This, therefore, suggests that these findings 
are not the result of hypoxia increasing LVSP in female rats.  
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Figure 3.11. Left Ventricular Systolic Pressure (LVSP) in female rats housed 
in normoxia or hypoxia and treated with placebo or FK506 (0.05mg/kg/day).  
A) Representative images showing the left ventricular systolic pressure traces 
collected by Millar PV loop system and AD Instruments software. B) LVSP 
(mmHg) in female rats housed in normoxia or hypoxia treated with placebo or 
FK506 (0.05mg/kg/day). n=4-6, **p<0.01.  Statistical analysis was performed 
using one-way ANOVA followed by Bonferroni post-hoc test. Data is displayed 
with the bar representing the mean ± S.E.M. The measurement from each 
individual animal is also represented.  
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3.3 Discussion 
The aim of this chapter was to characterise the chronic hypoxia model in male 
and female rats by assessing haemodynamics and the pathological changes in the 
pulmonary vasculature. This was necessary as this model of 5 week chronic 
hypoxia differed from the 4 week chronic hypoxia the lab had used previously 
(Docherty et al., 2019). However, it was felt to be important to replicate the 
successful 3 week dosing regimen of the published study by Spiekerkoetter et al. 
(2013) and therefore the rats had to remain in hypoxia for a total of 5 weeks. All 
parameters investigated indicated that the 5 week hypoxia regime had 
successfully induced a PH phenotype similar to that which the group had 
previously observed (Docherty et al., 2019). Hypoxia significantly increased RVSP 
along with the percentage of remodelled pulmonary arteries within the lung in 
both male and female rats. The effects of hypoxia on cardiac remodelling was 
also assessed however, cardiac-specific effects are discussed in Chapter 4. The 
effect of hypoxia on the systemic system as well as on the LV were also 
assessed. Hypoxia had no significant effect on LVSP in male rats. Within the 
FK506 treated group of female rats, there was a significant difference in LVSP 
between the normoxic and hypoxic groups. Systemic blood pressures were also 
significantly different between the normoxic and hypoxic groups. However, this 
is thought to be associated with a reduced LVSP in the normoxic group as the 
LVSP falls below the physiological level of 120 mmHg (Ross et al., 2010). 
Additionally, the systolic blood pressure and the diastolic blood pressure all fell 
below the expected physiological values of 120 mmHg and 80 mmHg (Ross et al., 
2010). This could be associated with the concentration of anaesthetic or the 
duration of the procedure both of which have been shown to influence LVSP and 
systemic blood pressures (Redfors et al., 2014). It is well understood that 
increases in isoflurane concentration result in decreased systemic blood 
pressures (Conzen et al., 1992; Yang, 2014).  The concentration and duration of 
isoflurane were dependent on each individual animal and therefore were very 
difficult to control for during the experiment. Previous experience within the lab 
has shown that obtaining appropriate haemodynamic pressure traces in the 
hypoxic animals can be technically more challenging and therefore the 
procedure can take longer and the animals are under anaesthetic for a longer 
period of time. This would ultimately affect systemic and LVSP pressures. A 
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closed chest approach was performed as the pressures obtained are more 
physiologically relevant than an open chested approach. However, there are 
challenges associated with this method. Positioning of the catheter in the 
correct position in the RV is more challenging and the conformational changes 
and increased pressure in the RV of hypoxic animals makes this increasingly 
challenging. This could be the result of many different factors including, cardiac 
remodelling, the animal’s tolerance to anaesthetic or the investigator’s skill on 
the day of the procedure. Systemic blood pressure could be measured by another 
method such as tail cuff or telemetry prior to terminal haemodynamic 
measurements. However, these methods come with their own caveats as they 
often induce stress in the animal which in turn can influence blood pressure.  
The next aim of this study was to investigate the effect of FK506 (0.05 
mg/kg/day) on the parameters of experimental PH in male and female rats. The 
aim was to insert the pellets when male and female rats weighed approximately 
220 g as pellets were manufactured to release a dose of 0.05 mg/kg/day based 
on a body weight of 220 g. This weight was selected in order to keep in line with 
the previous study in which animals were started on the dosing regimen between 
180-220g (Spiekerkoetter et al., 2013). Male and female rats gained weight 
throughout the study and there were significant differences in weight gain 
between normoxic and hypoxic groups. Therefore, the dose of FK506 would not 
have been consistently 0.05 mg/kg/day in all groups across the 3 weeks. This 
finding should be considered when assessing the effect of FK506 on the 
parameters of experimental PH. This dosing regimen was selected as it did not 
require daily dosing allowing the rats to be maintained in hypoxia for longer 
periods of time. Other studies performed by the group have utilised the slow-
release pellets as a drug delivery method for 2-methoxyestradiol and this was 
shown to be successful in male and female rats regardless of weight gain 
(Docherty et al., 2019). In future, it would be important to collect blood samples 
from the rats and monitor the plasma concentration of FK506 to confirm the 
dosing method was appropriate.  
Treatment with FK506 (0.05 mg/kg/day) in both male and female chronic 
hypoxia rats had no significant effect on parameters of experimental PH. 
Hypoxia significantly increased RVSP in both male and female rats, however, 
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FK506 did not significantly reverse this increase in RVSP. Although FK506 did not 
significantly reduce hypoxic RVSP, when comparing the male FK506 treated 
groups, there was no significant difference between normoxic and hypoxic RVSP 
whereas a significant difference was present between the equivalent female 
groups. Hypoxia significantly increased pulmonary artery remodelling in both 
male and female rats and FK506 did not significantly reverse this phenotype. The 
previous study in male rats utilising the monocrotaline and Sugen Hypoxia rat 
model showed that FK506 significantly reversed the PH phenotype 
(Spiekerkoetter et al., 2013). Additionally, the compassionate use of low dose 
FK506 in female PAH patients also suggested treatment had a positive effect on 
the clinical outcomes of the female patients (Spiekerkoetter et al., 2015). 
Therefore, it was expected that FK506 would significantly affect RVSP and 
pulmonary artery remodelling in both male and female chronic hypoxia rats in 
the current study and the aim was to investigate potential sex-specific effects of 
FK506. The dose and the dosing period were replicated from the Spiekerkoetter 
et al. (2013) study however, the delivery of FK506 and the rat model differed. 
The previous study had used an osmotic mini-pump for delivery of FK506 in each 
of the animal models (Sugen hypoxia and the monocrotaline rat model) 
(Spiekerkoetter et al., 2013) which differed from the use of slow-releasing 
pellets for FK506 delivery in the chronic hypoxia rat model used in this study. 
The design of osmotic mini-pumps would mean that a constant dose of FK506 
would have delivered across the 3 weeks dosing period also.  
Each group within the study had n= 6 based on availability of the hypobaric 
chambers and the limited space within the chambers. These n numbers were 
similar to related published studies, e.g. the Spiekerkoetter et al. (2013) 
study had n= 6-8 in the monocrotaline rat model groups and n=8 in 
the Sugen Hypoxia rat model groups (Spiekerkoetter et al., 2013). However, 
power calculations performed using the data generated in the study in this thesis 
suggested n=10 would allow an experimental power of 78% to detect 15 mmHg 
change in pressure assuming 5% significance level (InVivoStat 
software). Therefore, in order to fully determine the effect of FK506 on 
parameters of PAH it would be necessary to increase the n numbers of this 
study in the future.  
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The final aim of this part of the study was to assess the effects of FK506 
treatment (0.05mg/kg/day) on systemic and left ventricular pressure in order to 
identify any potential off target, systemic effects. FK506 (0.05mg/kg/day) had 
no significant effect on LVSP or systemic blood pressures in male or female rats. 
We investigated these parameters in order to confirm that any effects of FK506 
on RVSP were specific to the pulmonary circulation and not the result of an 
overall systemic effect.  
In summary, investigation of the 5 week chronic hypoxia rat model showed that 
this model was able to induce an experimental PH phenotype, specifically 
increased RVSP and pulmonary artery remodelling. This confirmed that this 
model could be used as a rodent model for PH phenotype in future studies and 
also allowed the investigation of the effect of FK506 on PH phenotype. FK506 at 
0.05 mg/kg/day did not significantly reverse the increased RVSP or pulmonary 
artery remodelling in this model. In addition, FK506 did not affect any of the 
measurements associated with systemic blood pressure or LVSP. In future, it 
would be important to continue with this investigation and confirm if the lack of 
response to FK506 was associated with the rodent model selected and the dosing 
regimen. As previous studies have shown FK506 to be successful in improving the 
PH phenotype (Spiekerkoetter et al., 2013; Spiekerkoetter et al., 2015) this data 
perhaps highlight that the correct protocol is critical in the success of this 
therapy. These data suggest that further investigation of FK506 as a potential 
therapeutic for the treatment of PAH must be conducted. Furthermore, the 
potential sex-specific effects of FK506 still need to be fully elucidated.  
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Chapter 4 
 
4 Sex differences in right ventricle in experimental 
pulmonary hypertension and the effect of FK506 
treatment.  
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4.1 Introduction 
In pulmonary hypertension, remodelling of the RV is initiated by increased 
afterload. Increased afterload results from the pathological changes that take 
place in the pulmonary vasculature creating a high pressure, high resistance 
system. Initially, the RV remodels in an attempt to maintain cardiac output and 
right ventricular ejection fraction (RVEF) by increasing the RV wall mass to 
compensating for increased wall stress, a process known as hypertrophy (Lahm 
et al., 2018; Fang et al., 2012). In the early stages of disease these adaptations 
are sufficient to maintain cardiac function. In later stage disease, increases in 
RV wall mass are no longer able to maintain RV function. At this point, 
maladaptive remodelling occurs, and the RV dilates and becomes fibrotic leading 
to impaired right heart function (Vonk-Noordegraaf et al., 2013). Cardiomyocyte 
function is also thought to be impaired by this process as a result of extracellular 
matrix alterations, electrical remodelling and the production of reactive oxygen 
species (Bogaard et al., 2009; Piao et al., 2010). The response of the RV is one 
of the key factors which determines the clinical outcome of the patient (Vonk 
Noordegraaf and Galie, 2011). RV failure is the main cause of mortality in PAH 
patients (Chin et al., 2005).  
Although the role of the RV in determining prognosis for PAH is well understood, 
there is still a great need to develop our understanding of the pathological 
processes which occur in the RV. It is not appropriate to extrapolate findings 
from the investigation of pathological remodelling in the LV to the RV. It has 
been shown that the two ventricles exhibit key structural differences and 
differential responses to oxidative stress and activation of apoptotic processes 
which result in a more rapid progression of RV failure than LV failure (Reddy and 
Bernstein, 2015). A greater understanding of disease development can be gained 
from investigating how these maladaptive processes in the RV are influenced by 
factors known to be important in PAH such as sex and BMPR2 signalling. Recent 
clinical studies have identified a role for sex and BMPR2 in RV function in PAH 
patients (Jacobs et al., 2014; Kawut et al., 2009; Evans et al., 2016a; van der 
Bruggen et al., 2016). The poorer survival rates of male PAH patients are 
thought to be associated with a more rapid decrease in RV function (Jacobs et 
al., 2014; Kawut et al., 2009). Patients harbouring a BMPR2 mutation have been 
described as having poorer haemodynamic profiles at diagnosis (Evans et al., 
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2016a) and in particular a greater degree of RV impairment even when 
experiencing similar afterload (van der Bruggen et al., 2016). However, there 
are still very few studies that have been conducted in this area of research. 
Moreover, there are currently no therapies available to treat PAH patients that 
specifically target the RV. Current therapies are all targeted to the pulmonary 
vasculature and aim to counteract the vasoconstrictive environment. Although 
these therapies contribute to decreased RV afterload, they do not act directly 
on the RV and their effect on the clinical outcomes associated with the RV are 
likely to be limited  (Handoko et al., 2010). Therefore, there is a need to 
understand the effect of potential PAH therapies on the RV. 
The aims of this chapter were: 
To characterise the 5 week chronic hypoxia rat model with regard to the RV. 
To investigate the effect of FK506 treatment on right ventricular parameters of 
experimental PH.  
To investigate the effect of hypoxia and FK506 treatment on gene expression 
profiles in the male and female rat RV. 
To perform a direct comparison between the male and female gene expression 
profiles in the RV under normoxic and hypoxic conditions.  
To develop an in vitro model to study the effects of sex on cardiac fibroblasts 
and cardiomyocytes from RV of male and female rats and an in vivo model to 
investigate the role of sex in right heart dysfunction independent of pathological 
changes in the pulmonary vasculature.  
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4.2 Results 
As described previously, Sprague Dawley rats were housed in a hypobaric hypoxic 
chamber for 35 days. Subcutaneous pellets releasing FK506 at a dose of 0.05 
mg/kg/day or placebo were inserted at the back of the neck subcutaneously on 
day 14 of the study. Following recovery from this procedure, the rats were then 
returned to the hypobaric hypoxic chamber for the remainder of the study. 
Controls which were both age and sex matched were housed in normoxia and 
were treated with the same dosing protocol. The study ended on day 35 with 
haemodynamic assessment using the Millar PV loop system. Following this, the 
heart, lung and other tissue types were collected for protein, RNA and 
histological analysis (Figure 4.1).   
 
Figure 4.1 - Schematic diagram showing FK506 study protocol and dosing 
regimen.  
Male and female Sprague Dawley rats were kept in normoxic or hypoxic 
conditions for a period of 35 days. On day 14, FK506 pellets (0.05 mg/kg/day) or 
placebo pellets were administered, and the rats returned to normoxia or 
hypoxia. On day 35 haemodynamic measurements were collected and the 
animals humanely killed prior to tissue harvesting. 
114 
 
4.2.1 The effect of hypoxia and FK506 treatment on right 
ventricular hypertrophy in male rats 
 
Following haemodynamic assessment, the heart was removed and the right 
ventricle (RV) was finely dissected from the left ventricle + septum (LV+S). The 
RV and LV+S were weighed separately and the mass recorded. Hypoxia 
significantly increased RV mass (mg) in both the placebo and FK506 groups 
(placebo group 212.9± 8.7mg vs 478.3± 24.3 mg, ****p<0.0001, FK506 group 
209.3± 4.6 mg vs 395.1± 17.3 mg, ****p<0.0001, n=6) and RV mass corrected for 
body weight (RV mass/body weight (mg/g)) in male rats (placebo 
group 0.61± 0.01 vs 1.43± 0.07, ****p<0.0001, FK506 group 209.3± 4.6 vs 395.1± 
17.3, ****p<0.0001, n=6)  (Figure 4.2). The effect of FK506 treatment 
(0.05mg/kg/day) on RV mass and RV mass/body weight was also investigated. 
FK506 significantly reduced RV mass (478.3± 24.3 mg vs 395.1± 17.3 mg, *p<0.05 
n=6) and RV mass/body weight (1.43± 0.07 vs 1.22± 0.03, *p<0.05, n=6) in 
hypoxic male rats. The standard measurement for right ventricular hypertrophy 
in experimental models within the pulmonary hypertension field is the Fulton’s 
index (RV mass/LV+S mass) (Fulton et al., 1952). When Fulton’s index was 
calculated hypoxia significantly increased RV/LV+S in male rats (placebo 
group 0.28± 0.01 vs 0.55± 0.02, ****p<0.0001, FK506 group 0.27± 0.01 vs 0.50± 
0.01, ****p<0.0001, n=6). However, FK506 treatment had no significant effect on 
RV/LV+S in the hypoxic group. It was thought that this could be associated with 
a change in LV+S mass across the different experimental groups. Comparison of 
LV+S mass (mg)/body weight (g) showed LV+S mass/body weight is significantly 
increased in hypoxic male rats treated with placebo (2.2± 0.1 vs 2.6± 0.1, 
*p<0.05, n=6) but not in those treated with FK506. 
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Figure 4.2. The effect of hypoxia and treatment with FK506 on right and left 
ventricular mass in male rats. 
Male rats were housed in normoxia or hypoxia and treated with placebo or 
FK506 (0.05 mg/kg/day). A) RV mass (mg). B) RV mass/body weight (mg/g). C) 
RV/LV+S. D) LV+S mass (mg) E) LV+S mass/body weight (mg/g). n=6, *p<0.05, 
****p<0.0001.  Statistical analysis was performed using one-way ANOVA followed 
by Bonferroni post-hoc test. Data is displayed with the bar representing the 
mean ± S.E.M. The measurement from each individual animal is also 
represented.  
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4.2.2 The effect of hypoxia and FK506 treatment on right 
ventricular hypertrophy in female rats 
The same investigation was carried out on the RV and LV+S tissue collected from 
female rats. As was identified in the male rats, hypoxia significantly increased 
RV mass (mg) in both placebo and FK506 groups (placebo group 176.4± 7.3 mg vs 
331.6± 25.8 mg, ****p<0.0001, FK506 group 160.3± 5.7 mg vs 285.2± 13.9 mg, 
***p<0.001, n=6) and RV mass corrected for body weight (RV mass/body weight 
(mg/g)) in female rats (placebo group 0.68± 0.02 vs 1.31± 0.09, ****p<0.0001, 
FK506 group 0.62± 0.03 vs 1.22± 0.06, ****p<0.0001, n=6) (Figure 4.3). FK506 
treatment had no significant effect on RV mass or RV mass/body weight in 
female rats. The Fulton’s index (RV mass/LV+S mass) showed hypoxia 
significantly increased RV/LV+S (placebo group 0.30± 0.01 vs 0.52± 0.02, 
****p<0.0001, FK506 group 0.28± 0.01 vs 0.51± 0.02, ****p<0.0001, n=6). FK506 
treatment had no significant effect on RV/LV+S. There were no significant 
differences in LV+S mass or LV+S mass/body weight (mg/g) across the 4 
experimental groups of female rats.  
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Figure 4.3. The effect of hypoxia and treatment with FK506 on right and left 
ventricular mass in female rats. 
Female rats were housed in normoxia or hypoxia and treated with placebo or 
FK506 (0.05 mg/kg/day). A) RV mass (mg). B) RV mass/body weight (mg/g). C) 
RV/LV+S. D) LV+S mass (mg) E) LV+S mass/body weight (mg/g). n=6, ***p<0.001, 
****p<0.0001.  Statistical analysis was performed using one-way ANOVA followed 
by Bonferroni post-hoc test. Data is displayed with the bar representing the 
mean ± S.E.M. The measurement from each individual animal is also 
represented.  
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4.2.3 Sex differences in right ventricular remodelling in 
experimental pulmonary hypertension    
The finding that treatment with FK506 (0.05 mg/kg/day) reduced RV mass and 
RV mass/body weight in male rats but not female rats highlighted a potential 
sex-specific effect of FK506 in the RV. As a result, it was important to 
investigate potential sex-dependent signalling within the RV which could 
influence RV remodelling in response to hypoxia and FK506 treatment. It was 
determined that initial investigations should involve a gene expression study as 
changes in gene expression may highlight signalling pathways that play a key role 
in the response of the RV. Candidate signalling pathways were selected based on 
genes and pathways known to be important in PAH and cardiac remodelling and 
the expression of genes within these pathways were investigated. The genes 
selected included those in the BMPR2 and transforming growth factor-β (TGFβ) 
pathway as well as those involved in cardiac hypertrophy and fibrosis. Initially, 
the effect of hypoxia on gene expression was investigated in male and female RV 
to understand the response to hypoxia at a mRNA level. Secondly, the effect of 
FK506 treatment on gene expression in the male and female rat RV was studied 
to identify a potential pathway involved in the action of FK506 which could lead 
to the reduction of RV mass in male rats. Finally, there was a direct comparison 
between the data collected from male and female rat RV under normoxic or 
hypoxic conditions. This comparison allowed identification of sex specific 
differences in gene expression. The data is displayed as part of the separate 
male and female studies and then again as part of the male vs female direct 
comparison.  
4.2.4 Identification of an appropriate housekeeping gene for RV 
gene expression analysis 
After the mass of the RV and LV tissue had been recorded, the tissue was snap 
frozen in liquid nitrogen to allow it to be used for gene expression analysis. 
Firstly, the most consistent housekeeping gene across the different experimental 
groups had to be determined. A stable housekeeping gene is required in order to 
normalise the gene of interest with regard to the concentration of cDNA added 
to the experimental set up and the efficiency of the PCR reaction. It is possible 
that hypoxia, sex or treatment with FK506 could influence the expression of a 
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housekeeping gene and therefore this had to be determined prior to beginning 
the experiment. Three housekeeping genes - β2-microglobulin (B2m), Peptidyl-
prolyl cis-trans isomerase B (Ppib) and β-actin - were investigated by measuring 
the mRNA expression from RV tissue across all the experimental groups using 
TaqMan quantitative real-time PCR (qRT-PCR) method. The cycle threshold (CT) 
values and the standard deviation across the CT values was assessed across all of 
the study groups (Figure 4.4). B-actin showed the most variation across the 
groups with standard deviation of 0.73. B2M and Ppib showed similar standard 
deviation across the groups at 0.68 and 0.67 respectively. B2M showed lower CT 
values which was deemed more appropriate for a housekeeping gene. Therefore, 
B2M was selected as the housekeeping gene for all further gene expression 
analysis work. 
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Housekeeper gene Standard Deviation of CT values  
B2M 0.683888 
Ppib 0.670941 
B-actin 0.72657 
 
Figure 4.4 . Identification of the most appropriate housekeeping gene for 
qRT-PCR analysis of RV tissue.  
TaqMan qRT-PCR was performed on RV tissue collected from each of the study 
groups to measure the mRNA expression of 3 potential housekeeping genes B2M, 
Ppib and B-actin. A) B2M CT values B) Ppib CT values. C) B-actin CT values D) 
Standard deviation of the CT values across all the samples for each of the 
housekeeper genes. n=4 per group repeated in triplicate. Data is displayed with 
the bar representing the mean ± S.E.M. The measurement from each individual 
animal is also represented. No statistical analysis was performed. N = normoxic 
group, H = hypoxic group. 
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4.2.5 The effect of hypoxia on the expression of genes involved in 
Bmpr2 and Tgfβ pathway in RV tissue from male rats 
The first pathways to be investigated were the BMPR2 and TGFβ pathways. The 
expression of Bmpr2, Smad 1, Id1, Id3, Tgfβ1 and TgfβR1 genes was investigated 
by qRT-PCR. Firstly, the aim was to assess the effect of hypoxia on the 
expression of these genes (Figure 4.5). RV tissue from male rats treated with 
placebo was selected for this analysis. qRT-PCR showed that hypoxia 
significantly decreased the expression of Bmpr2 (0.042± 0.003 vs 0.025± 0.003, 
**p<0.01, n=4) and Id3 (0.032± 0.004 vs 0.017± 0.002, **p<0.001, n=4). 
Additionally, hypoxia significantly increased expression of Tgfb1 (0.035± 0.002 vs 
0.049± 0.005, *p<0.05, n=4). However, hypoxia had no significant effect on the 
expression of Smad1, Id1 or transforming growth factor β Receptor 1 (TgfbR1).  
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Figure 4.5. The effect of hypoxia on the gene expression of Tgfβ pathway 
and Bmpr2 pathway in the male RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male rats 
maintained in normoxia or hypoxia and treated with placebo. A) Bmpr2 gene 
expression. B) Smad1 gene expression C) Id1 gene expression D) Id3 mRNA 
expression. E) Tgfβ1 gene expression F) TgfβR1 gene expression. Data is 
displayed as 2-ΔCT and data was normalised to the expression of B2M. n=4 per 
group, repeated in triplicate. Statistical analysis was performed using an un-
paired t test *p<0.05, ** p<0.01. Data is displayed to show each individual n 
number and the bar represents the mean ± S.E.M.  
  
123 
 
4.2.6 The effect of hypoxia on the expression of genes involved in 
cardiac remodelling in RV tissue from male rats 
Assessment of the effect of hypoxia on the expression of genes associated with 
cardiac remodelling was also conducted. Collagen type 1 alpha 1 chain (Col1a1), 
collagen type 3 alpha 1 chain (Col3a1) and connective tissue growth factor (Ctgf) 
were used as gene expression markers of cardiac fibrosis. Natriuretic Peptide A 
(Nppa), Natriuretic Peptide B (Nppb) and Myosin heavy chain 7 (Myh7) were used 
as gene expression markers of cardiac hypertrophy. These results show that 
hypoxia significantly increased the expression of Ctgf (0.045± 0.005 vs 0.192± 
0.043, *p<0.05, n=4), Nppb (0.065± 0.022 vs 0.233± 0.050, *p<0.05, n=4) and 
Myh7 (0.219± 0.011 vs 1.291± 0.205, ** p<0.01, n=4) in RV of male rats treated 
with placebo (Figure 4.6). Hypoxia also significantly decreased the expression of 
Col3a1 (0.848± 0.012 vs 0.571± 0.078, *p<0.05, n=4). These results suggest that 
at the end point of this study (35 days), hypoxia significantly affects the 
expression of markers of cardiac fibrosis and hypertrophy in male rats.   
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Figure 4.6. The effect of hypoxia on the expression of gene involved in 
cardiac hypertrophy and cardiac fibrosis in the male RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male rats 
maintained in normoxia or hypoxia and treated with placebo. A) Col1a1 gene 
expression. B) Col3a1 gene expression C) Ctgf gene expression D) Nppa gene 
expression. E) Nppb gene expression F) Myh7 gene expression. Data is displayed 
as 2-ΔCT and data was normalised to the expression of B2M.  n=4 per group, 
repeated in triplicate. Statistical analysis was performed using un-paired t test 
*p<0.05, ** p<0.01. Data is displayed to show each individual n number and the 
bar represents the mean ± S.E.M.   
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4.2.7 The effect of hypoxia on the expression of genes involved in 
Bmpr2 and Tgfβ pathway in RV tissue from female rats 
The same investigation was performed in RV tissue harvested from female rats 
housed in normoxic and hypoxic conditions and treated with placebo. Hypoxia 
significantly reduced the gene expression of Bmpr2 in the RV of female rats also 
(0.046± 0.004 vs 0.027± 0.003, *p<0.05, n=4) (Figure 4.7). Hypoxia did not 
significantly affect the expression of any of the other genes of interest – Smad1, 
Id1, Id3, Tgfβ1 or TgfβR1.   
  
126 
 
 
Figure 4.7. The effect of hypoxia on the gene expression of Tgfβ pathway 
and Bmpr2 pathway in the female RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from female rats 
maintained in normoxia or hypoxia and treated with placebo. A) Bmpr2 gene 
expression. B) Smad1 gene expression C) Id1 gene expression D) Id3 gene 
expression. E) Tgfβ1 gene expression F) TgfβR1 gene expression. Data is 
displayed as 2-ΔCT and data was normalised to the expression of B2M. n=4 per 
group, repeated in triplicate. Statistical analysis was performed using un-paired 
t test *p<0.05. Data is displayed to show each individual n number and the bar 
represents the mean ± S.E.M.   
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4.2.8 The effect of hypoxia on the expression of genes involved in 
cardiac remodelling in RV tissue from female rats 
The effect of hypoxia on genes associated with cardiac remodelling were also 
investigated in the female RV. In the RV of female rats, hypoxia only 
significantly increases the expression of the hypertrophy marker Myh7 (0.134± 
0.030 vs 0.577± 0.098, **p<0.01, n=4) (Figure 4.8). Therefore, hypoxia had no 
significant effect on the expression of any of the genes associated with cardiac 
fibrosis at day 35 of hypoxia exposure.  
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Figure 4.8. The effect of hypoxia on the expression of gene involved in 
cardiac hypertrophy and cardiac fibrosis in the female RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from female rats 
maintained in normoxia or hypoxia and treated with placebo. A) Col1a1 gene 
expression. B) Col3a1 gene expression C) Ctgf gene expression D) Nppa gene 
expression. E) Nppb gene expression F) Myh7 gene expression. Data is displayed 
as 2-ΔCT and data was normalised to the expression of B2M. n=4 per group, 
repeated in triplicate. Statistical analysis was performed using un-paired t test, 
** p<0.01. Data is displayed to show each individual n number and the bar 
represents the mean ± S.E.M.   
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4.2.9 The effect of FK506 treatment on the expression of Bmpr2 
and Tgfβ1 in RV tissue from male and female rats 
This study showed that FK506 treatment significantly reduced RV mass in male 
rats independent of a reduction in RVSP suggesting that FK506 could have been 
acting directly on the myocardium. The expression of Bmpr2 and Tgfβ1 was 
assessed in order to identify the effect of FK506 treatment. Figure 4.5 showed 
Tgfβ1 was significantly increased in the male RV under hypoxia. FK506 
treatment (0.05 mg/kg/day) significantly reduced the expression of Tgfβ1 in the 
male RV (0.049± 0.005 vs 0.030± 0.002, *p<0.05, n=4) (Figure 4.9). This finding 
was specific to the male RV, which could be linked to the male specific 
reduction in RV mass as a result of FK506 treatment. There was no significant 
effect of FK506 on Bmpr2 expression in the male or female RV. 
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Figure 4.9. FK506 treatment significantly reduces expression of Tgfβ1 in the 
male hypoxic RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male and female 
rats maintained in hypoxia and treated with FK506 (0.05 mg/kg/day) or 
placebo. A) Tgfβ1 gene expression in the male RV. B) Tgfβ1 gene expression in 
the female RV. C) Bmpr2 gene expression in the male RV. D) Bmpr2 gene 
expression in the female RV. Data is displayed as 2-ΔCT and data was normalised 
to the expression of B2M. n=4 per group, repeated in triplicate. Statistical 
analysis was performed using unpaired t test *p<0.05. Data is displayed to show 
each individual n number and the bar represents the mean ± S.E.M. 
  
0 .00
0 .02
0 .04
0 .06
0 .08
0 .00
0 .02
0 .04
0 .06
Tg
fβ
1 
m
R
N
A 
ex
pr
es
si
on
 
(2
^-
ΔC
T)
Tg
fβ
1 
m
R
N
A 
ex
pr
es
si
on
 
(2
^-
ΔC
T)
Hypoxia
Placebo
FK506 (0.05mg/kg/day)
A. B.
*
Tgfβ1Tgfβ1
Hypoxia
0.00
0.02
0.04
0.06
0.00
0.02
0.04
0.06
0.08
0.10
B
m
pr
2 
m
R
N
A 
ex
pr
es
si
on
 (2
^-
ΔC
T)
Hypoxia
C. D.
Bmpr2Bmpr2
Hypoxia
B
m
pr
2 
m
R
N
A 
ex
pr
es
si
on
 (2
^-
ΔC
T)
131 
 
4.2.10 The effect of FK506 treatment on the expression of 
cardiac remodelling associated genes in the male RV 
Having identified that FK506 treatment significantly reduced the expression of 
Tgfb1 in the hypoxic male RV, the aim was to assess the expression of genes 
involved in cardiac remodelling. It was hypothesised that a reduction in Tgfb1 
expression may result in changes in expression of Col1a1, Col3a1, Ctgf, Nppa, 
Nppb and Myh7. However, the expression of these genes was not significantly 
affected by FK506 treatment (Figure 4.10). Although, there was a trend that 
FK506 treatment reduced the expression of Ctgf with the reduction close to 
statistical significance (0.192 ± 0.043 vs 0.069 ± 0.015, n=4, p= 0.0583). 
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Figure 4.10 FK506 treatment has no significant effect on the expression of 
genes involved in cardiac remodelling. 
TaqMan qRT-PCR was performed on RV tissue harvested from male rats 
maintained in hypoxia and treated with FK506 (0.05 mg/kg/day) or placebo. 
Male RV gene expression A) Col1a1. B) Col3a1. C) Ctgf. D) Nppa. E) Nppb. F) 
Myh7. Data is displayed as 2-ΔCT and data was normalised to the expression of 
B2M. n=4 per group, repeated in triplicate. Statistical analysis was performed 
using unpaired t test. Data is displayed to show each individual n number and 
the bar represents the mean ± S.E.M. 
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4.2.11 Differential gene expression between the male and 
female normoxic RV. 
The gene expression study had identified changes in gene expression as a result 
of hypoxia that appeared to be specific to the male RV. It was important then to 
perform a direct comparison between the male and female RV in order to 
interrogate and further understand how these changes in gene expression are 
related to sex. The data used for this comparison was displayed in previous 
figures when investigating the effect of hypoxia and FK506 on gene expression. 
Firstly, a comparison between RV tissue from male and female rats housed in 
normoxia and treated with placebo would highlight any sex-specific differences 
in gene expression under basal conditions (Figure 4.11).  Expression of genes 
associated with the Bmpr2 pathway - Bmpr2, Smad1, Id1 and Id3 - were not 
differentially expressed between male and female RV. However, Tgfβ1 was 
significantly increased in the male RV compared to the female RV (0.035± 0.002 
vs 0.024± 0.003, *p<0.05, n=4). Additionally, genes involved in cardiac 
remodelling Col1a1 (0.158± 0.012 vs 0.055± 0.008, ***p<0.001, n=4) and Col3a1 
(0.848± 0.12 vs 0.378± 0.039, ****p<0.0001, n=4) displayed significantly increased 
gene expression in the male RV. None of the genes associated with cardiac 
hypertrophy – Nppa, Nppb and Myh7 were differentially expressed between the 
male and female RV.  
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Figure 4.11. Differential gene expression between the male and female 
normoxic RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male and female 
rats maintained in normoxia and treated with placebo. Gene expression of A) 
Bmpr2. B) Smad1. C) Id1. D) Id3. E) Tgfβ1. F) TgfβR1. G) Col1a1. H) Col3a1. I) 
Ctgf. J) Nppa. K) Nppb. L) Myh7. Data is displayed as 2-ΔCT and data was 
normalised to the expression of B2M. n=4 per group, repeated in triplicate. 
Statistical analysis was performed using unpaired t test *p<0.05, *** p<0.001, 
**** p<0.0001. Data is displayed to show each individual n number and the bar 
represents the mean ± S.E.M. 
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4.2.12 Differential gene expression between the male and 
female hypoxic RV. 
The final aim of the gene expression study was to compare the hypoxic male and 
female RV directly. Again, this data has been displayed in previous figures when 
investigating the effect of hypoxia and FK506 on gene expression. Similar to the 
normoxic RV, expression of Bmpr2, Smad1, Id1 and Id3, genes involved in Bmpr2 
signalling, were not differentially expressed between male and female. Again, 
there were differences in the level of Tgfβ1 expression between the male and 
female RV. Tgfβ1 expression was significantly increased in the hypoxic male RV 
compared to the female RV (0.049± 0.005 vs 0.031± 0.004, *p<0.05, n=4). 
Furthermore, genes associated with cardiac hypertrophy and cardiac remodelling 
were also significantly increased in the hypoxic male RV, specifically - Col1a1 
(0.111± 0.015 vs 0.043± 0.005, **p<0.01, n=4), Ctgf (0.192± 0.043 vs 0.048± 
0.004, *p<0.05, n=4), Nppa (1.139± 0.385 vs 0.102± 0.029, *p<0.05, n=4) and 
Myh7 (1.291± 0.205 vs 0.577± 0.098, *p<0.05, n=4) (Figure 4.12). 
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Figure 4.12. Differential gene expression between the male and female 
hypoxic RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male and female 
rats maintained in normoxia and treated with placebo. Gene expression of A) 
Bmpr2. B) Smad1. C) Id1. D) Id3. E) Tgfβ1. F) TgfβR1. G) Col1a1. H) Col3a1. I) 
Ctgf. J) Nppa. K) Nppb. L) Myh7. Data is displayed as 2-ΔCT and data was 
normalised to the expression of B2M. n=4 per group, repeated in triplicate. 
Statistical analysis was performed using unpaired t test *p<0.05, ** p<0.01. Data 
is displayed to show each individual n number and the bar represents the mean 
± S.E.M. 
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4.2.13 Development of in vitro models to investigate the role 
of sex in the right ventricle.  
The results from the in vivo study highlighted that there is a need to develop our 
understanding of the role of sex in signalling pathways within the RV. Identifying 
an appropriate in vitro model would allow further studies to be conducted and 
these pathways to be investigated in more detail. Gene expression studies in the 
male and female rat RV had highlighted sex-specific differences in normoxic, 
basal conditions as well as sex-specific differences in response to hypoxia. In 
vitro models could also help to determine if these sex-specific differences were 
exclusive to cardiac fibroblasts or cardiomyocytes.  
4.2.14  Investigation of neonatal rat cardiac fibroblasts 
Neonatal rat cardiac fibroblasts (NRCFs) were considered as an in vitro model for 
these studies. The isolation of NRCFs was a protocol that was well established 
within the lab. Therefore, the initial aim was to investigate key signalling 
pathways in NRCFs isolated from Wistar Kyoto (WKY) rats. To briefly describe the 
isolation protocol, at 3-5 days both male and female neonatal rat pups were 
culled and the hearts collected. Sexing of the pups was not possible at the 
neonatal stage so male and female pups were combined for the purposes of this 
investigation. The ventricles were carefully dissected and enzymatically 
digested. NRCFs were then isolated by plating the cells on poly-l-lysine coated 
cell culture dishes for 1 hour before washing the dish to remove the neonatal 
cardiomyocytes that had not adhered. This method can result in low level 
contamination with cardiomyocytes, however, the subsequent DMEM media used 
promotes proliferation of the NRCFs and not the cardiomyocytes. 
As it was not possible to isolate male and female NRCFs, initially, the aim was to 
investigate the effect of estrogen on the expression of genes in key signalling 
pathways in NRCFs. Estrogen acting via ER- β has been shown to inhibit Ang II 
stimulated cardiac fibrosis and cardiac hypertrophy in vivo and in vitro models 
(Pedram et al., 2010; Hoa et al., 2018). In mouse models, estrogen has also been 
shown to inhibit Ang II stimulated increases in Tgfβ1 (Pedram et al., 2010).   
Prior to beginning cell culture stimulations, cells were serum starved in phenol 
red free media. Phenol red can act as a weak estrogenic mimic therefore in all 
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cell culture stimulations involving estrogen, phenol red free media was used 
from the quiescence stage onwards. Angiotensin II (Ang II) (100nM) was used as a 
pathological stimulus in the NRCFs and the effect of β-estradiol (E2) at 1 nM or 
10 nM concentrations was investigated. As the in vivo study had highlighted sex-
specific differences in Tgf-β1 expression under normoxic and hypoxic conditions, 
the expression of Tgf-β1 was the first to be investigated (Figure 4.13). 
Stimulation with Ang II did not affect the expression of Tgf-β1 in NRCFs. 
Furthermore, the addition of E2 at 1 nM or 10 nM had no significant effect on the 
gene expression of Tgf-β1. An extension of these studies was planned within the 
NRCFs, however, further investigation was required to characterise these cells 
and their responses before the effect of estrogen on pathological responses 
could be determined.    
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Figure 4.13 The effect of estrogen on Tgf-β1 gene expression in Ang II 
stimulated NRCFs.  
Neonatal rat cardiac fibroblasts (NRCFs) were isolated and cultured from 
neonatal rat ventricles. Cells were stimulated by Ang II 100 nM ± E2 at 10 nM or 
1 nM for 24 hr. Tgf-β1 gene expression was assessed using TaqMan qRT-PCR. 
Data is displayed as 2-ΔCT and data was normalised to the expression of B2M. 
n=3, repeated in triplicate. Data is displayed to show each individual n number 
and the bar represents the mean ± S.E.M. EtOH = ethanol, E2 = 17β-estradiol. 
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4.3 Discussion 
The first aim of this study was to investigate the effect of hypoxia on the RV in 
the 5-week chronic hypoxia model. The results showed hypoxia significantly 
increased RV mass, RV mass/body weight and RV/LV+S in male and female rats. 
This finding completed the investigation of the 5 week chronic hypoxia model 
carried out in Chapter 3 and confirms its success as an experimental model of 
PH.  
The next aim was to investigate the sex dependent effects of treatment with 
FK506 on RV remodelling. The previous in vivo studies were only completed in 
male models of the disease (Spiekerkoetter et al., 2013). It was hypothesised 
that females may respond differently to FK506 induced increases in BMPR2 
expression as their basal levels could be lower. The findings discussed in Chapter 
3 showed RVSP and pulmonary artery remodelling were not significantly affected 
by FK506 treatment in male or female rats. The RV investigation highlighted a 
sex-specific response in the effect of FK506 on RV mass independent of changes 
in RVSP. RV mass and RV mass/body weight were significantly reduced by FK506 
treatment in male rat RV but not female RV. Treatment did not significantly 
alter the Fulton’s index (RV/LV+S) which is the standard measure of RVH within 
the PH research field (Fulton et al., 1952). However, this was thought to be 
associated with an increase in LV+S mass/body weight within the hypoxic 
placebo treated male rats which affected the ratio measurement. This may be 
why FK506 treatment significantly reduces RV mass and RV mass/body weight in 
male rats but does not significantly affect the Fulton’s index. This also suggests 
that hypoxia had induced LV remodelling either independently or secondary to 
RV remodelling. If tibial length had been measured during this study, a more 
appropriate measurement of RVH would have been RV mass (mg)/tibia length 
(mm) as this would have removed any potential interference of LV remodelling 
(Li et al., 2016b; Hardziyenka et al., 2011). However, this result does suggest 
that FK506 treatment has the potential to effect RV remodelling in male rats 
only, highlighting a possible sex-dependent effect of FK506.       
The recent Spiekerkoetter et al. study (Spiekerkoetter et al., 2013) showed 
FK506 treatment significantly improved parameters of experimental pulmonary 
hypertension in several different male models of the disease via BMPR2 
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activation. Right ventricular hypertrophy (RVH) was reduced following a 3 week 
dosing period with FK506 (0.05 mg/kg/day). The group also completed a phase II 
clinical trial with compassionate use of low dose FK506 in 3 patients 
(Spiekerkoetter et al., 2015). This preliminary study showed increased cardiac 
function in the patients treated with FK506 as well as a reduction in the time 
spent in hospital due to RV failure. However, it is not understood if the improved 
RV function is secondary to FK506 effects on the pulmonary vasculature or if 
FK506 directly targets the RV.  
Following these findings, it was important to further investigate the sex-specific 
effects of hypoxia and FK506 treatment on the RV. This was performed by 
assessing gene expression within the RV. It was hypothesised that significant 
changes in gene expression could highlight key pathways involved in sex-specific 
hypoxia-induced remodelling of the RV and sex-specific effects of FK506 on the 
RV. The gene expression study identified that hypoxia significantly increased 
Tgfβ1 gene expression in the male RV. FK506 treatment significantly reduced 
Tgfβ1 expression under hypoxic conditions. A finding which was not replicated in 
the female RV tissue. Tgfβ1 is known to play a role in the development of 
cardiac fibrosis and cardiac hypertrophy and therefore a reduction in the 
expression of Tgfβ1 could be associated with a reduction in cardiac hypertrophy 
and therefore RV mass. However, further characterisation of the effect of FK506 
on the TGFb pathway is required. Studies in human foreskin fibroblasts cultured 
have shown that treatment with FK506 can reduce the expression of Tgfb1 and 
this leads to a reduction in collagen production (Lan et al., 2014). FK506 did not 
significantly reduce the expression of the genes associated with collagen and 
fibrosis - Col1a1, Col3a1 or Ctgf in this study. However, the expression of many 
of the collagen genes are time dependent (Manabe et al., 2002; Friddle et al., 
2000; van den Bosch et al., 2006) and it could be hypothesised that at another 
time point during the dosing period that FK506 treatment would have 
significantly affected gene expression. Furthermore, in future it would be 
important to also examine the protein expression as this would provide a better 
indication of collagen levels within the tissue at that time. 
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Another key finding of this study was that hypoxia significantly reduced the 
expression of Bmpr2 in both the male and female RV. To our knowledge this is 
the first time this has been shown in male and female chronic hypoxia rats. 
Mutations in the BMPR2 gene are one of the most well established genetic risk 
factors for developing PAH (Machado et al., 2009). Despite dysfunctional BMPR2 
signalling being well characterised in the lung, the downstream effects in the RV 
are not as well understood. A recent clinical study suggested BMPR2 mutation 
carriers have poorer RV function despite similar cardiac adaptation in mutation 
carrier and non-carrier groups (Van Der Bruggen et al., 2016). Unfortunately, 
this study did not stratify the results depending on gender. It does suggest, 
however, that BMPR2 signalling influences RV function. Furthermore, a 
transgenic mouse model expressing RV specific mutant BMPR2 displays impaired 
hypertrophy of the RV in response to increased RVSP (Hemnes et al., 2014). This 
suggests that in the absence of functional BMPR2, the RV’s ability to compensate 
for increased afterload is diminished. FK506 treatment had no significant effect 
on Bmpr2 expression in the male or female RV, therefore, further work is 
required in order to assess if FK506 treatment affects Bmpr2 signalling in the RV 
and consequently how this affects RV function in a PH model.  
This study also highlighted several sex-specific differences in gene expression in 
the RV under hypoxic conditions. Interestingly these differences in expression 
were in Tgfβ1 and genes associated with cardiac fibrosis and cardiac 
hypertrophy. These processes that are known to be highly influenced by Tgfβ1 
(Khan and Sheppard, 2006) (Rosenkranz, 2004). Col1a1, Ctgf, Nppa and Myh7 
were all significantly increased at a gene expression level in the male hypoxic RV 
compared with the female hypoxic RV. These results suggest that the male and 
female RV have differential responses to hypoxia. In order to further validate 
this finding, it would be important to examine the protein expression of each of 
these genes. Estrogen acting via estrogen receptor β (ER-β) has been shown to 
inhibit Ang II and endothelin-1 (ET-1) stimulated increases in Tgfβ1 and cardiac 
fibrosis in mouse models (Pedram et al., 2010).  Additionally, estrogen acting via 
ER-β has also been shown to reduce Ang II stimulated cardiac hypertrophy in 
neonatal cardiomyocyte cell models and female rodent models (Hoa et al., 
2018). The published study showed cardiac hypertrophy was inhibited by the 
action of estrogen maintaining expression of transcription factor Krüppel-like 
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factor 15 (Klf15). However, studies investigating the action of estrogen 
specifically in the RV are lacking. The initial aim of the in vitro studies was to 
investigate the effects of E2 and estrogen metabolites on gene expression in Ang 
II stimulated neonatal rat cardiac fibroblasts. Previous studies had shown that 
Ang II increases the expression of Tgfb1 in rat cardiac fibroblasts (Pedram et al., 
2010; Lee et al., 1995) therefore it was expected that Tgfb1 expression would 
have been increased. However, Ang II stimulation did not increase expression of 
Tgfβ1 in this experiment and therefore, further characterisation of these cells 
has to be carried out before investigations can continue. 
Currently, there are no treatments available that target RV dysfunction in PAH 
despite it being the main cause of mortality in PAH patients. Therefore, there is 
a real need to develop our understanding of the molecular mechanisms 
underlying RV dysfunction in order to identify potential therapeutic targets. 
Poorer male patient survival rates are thought to be associated with increased 
and accelerated RV dysfunction compared to females (Jacobs et al., 2014; Kawut 
et al., 2009). Clinical studies in control groups have suggested that higher 
estrogen levels are associated with increased RV function (Ventetuolo et al., 
2011; Ventetuolo et al., 2016b). However, the role of estrogen in PAH is 
controversial as it has been shown to play a pathogenic role in both 
experimental animal studies (White et al., 2011; Mair et al., 2014b) and clinical 
studies (Ventetuolo et al., 2016a). This therefore adds to the complexity of 
identifying potential estrogen-associated therapeutic targets as therapies would 
have to be targeted to the RV specifically. Investigations into the effect of sex 
and estrogen on the RV could help develop our understanding of why females 
tend to have better RV function and perhaps even identify new RV-specific 
therapeutic targets.
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Chapter 5 
 
5 The role of sex and estrogen in the development 
of experimental pulmonary hypertension and 
their effect in the RV 
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5.1 Introduction 
The most significant risk factor in the development of PAH is the female sex. 
Although more women develop PAH, males who do develop the disease tend to 
have poorer outcomes (Shapiro et al., 2012). This is thought to be associated 
with a quicker decline in RV function (Jacobs et al., 2014; Kawut et al., 2009). 
Therefore, the role of sex hormones, particularly estrogen, in the development 
and progression of PAH remains one of high interest within pre-clinical and 
clinical studies. Experimental studies investigating the role of estrogen in PAH 
have produced conflicting results. In vivo studies have shown estrogen to be 
protective in the pulmonary vasculature in chronic hypoxia (Xu et al., 2010; 
Lahm et al., 2012) and monocrotaline models of disease (Farhat et al., 1993). 
However, the opposing theory is that estrogen exacerbates disease progression 
within the lungs and reduced levels of estrogen could prevent or reverse the 
pathophysiology of disease (Mair et al., 2014b; White et al., 2011; Wright et al., 
2015). This hypothesis was investigated in the Smad 1 (+/-) mouse model in 
which the females spontaneously develop a PH phenotype at approximately 6 
months of age. Ovariectomy in the Smad1 (+/-) mouse model prevented an 
increase in RVSP and RV/LV+S, however, the same study also showed that 
ovariectomy in wild-type mice resulted in increased RVSP and RV/LV+S (Mair et 
al., 2015). The contradictory evidence surrounding the role of estrogen is known 
within the field as the “estrogen paradox” (Lahm et al., 2014).  
Therapies that could manipulate endogenous estrogen production have also been 
utilised to investigate the role of estrogen. Anastrozole, a drug which was 
initially developed as a therapy for hormone receptor positive breast cancer, 
reduces the production of endogenous estrogen by inhibiting the action of the 
enzyme aromatase (Baum et al., 2002; Geisler et al., 1996). Aromatase catalyses 
the production of 17β-estradiol from the male sex hormone testosterone as well 
as the production of estrone (E1) from androstenedione (Grodin et al., 1973). 
Aromatase was found to be expressed in the PASMCs of both female animal 
models and female PAH patients (Mair et al., 2014b; Wright et al., 2015). This 
finding added more weight to the hypothesis that treatment with Anastrozole 
could improve parameters of PH. Inhibition of aromatase within the chronic 
hypoxia mouse model and the SuHx rat model reversed the PH phenotype 
associated with these models (Mair et al., 2014b). This involved reduced RVSP 
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and RVH as measured by RV/LV+S. This finding was specific to female mice and 
rats. Male chronic hypoxia mice and SuHx rats showed no improvement in these 
parameters when treated with the same dose of anastrozole (Mair et al., 2014b). 
Inhibition of endogenous estrogen has also been shown to improve metabolic 
dysfunction associated with disease in the BMPR2 mutant mouse model (Chen et 
al., 2017).  
Anastrozole safety and tolerability studies have now been conducted in PAH 
patient populations including male and female patients (Kawut et al., 2017). 
This Phase II clinical trial suggested Anastrozole was well tolerated and safe 
within the PAH patient populations and it was capable of reducing 17β-estradiol 
levels by approximately 40% after 3 months of treatment. Anastrozole treatment 
improved 6 min walk distance, a measure which indicates exercise tolerance of 
the patients and has been recognised as the primary clinical outcome used 
during the assessment of PAH patients (Demir and Küçükoğlu, 2015). However, it 
was not capable of improving any of the other clinical parameters of PAH such as 
functional class or the number of adverse events experienced by the patient 
group. The results were also not stratified based on sex. Given the sex-specific 
responses identified in pre-clinical models, this could have been an interesting 
measurement. Importantly, treatment with anastrozole had no detrimental 
effect on parameters of RV function. Although reversal of the pathophysiological 
state in the lungs could result in reduced afterload and therefore improved RV 
parameters, there is also the risk that inhibiting endogenous estrogen production 
could have direct detrimental effects in the RV as estrogen has been shown to 
be cardioprotective (Iorga et al., 2017). The outcomes of the small clinical study 
did justify a larger and longer Phase II clinical trial known as PHANTOM 
(NCT03229499) which is currently recruiting patients.  
As well as a role for the production of 17β-estradiol, the metabolism of estrogen 
has also been shown to be important in PAH animal models and patient groups. It 
is thought that the estrogen metabolite 16α-OHE1 is the most potent of the 
estrogen metabolites as it binds the receptor covalently (Swaneck and Fishman, 
1988). Furthermore, PAH patients have been shown to exhibit estrogen 
metabolism that tends to produce 16α-OHE1 (Austin et al., 2009; West et al., 
2008; Dempsie et al., 2013).   
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The RV-associated outcomes of inhibiting estrogen production are still not fully 
elucidated. It is important to understand the effect of Anastrozole on the RV as 
RV function is thought to determine clinical outcomes for PAH patients. 
Furthermore, an understanding of the inhibition of estrogen production in the 
pulmonary circulation and the RV may help to uncover the “estrogen paradox” 
that exists in PAH.  
The aims of this chapter include: 
To investigate the effect of treatment with Anastrozole (3 mg/kg/day) on the 
right ventricle in male and female chronic hypoxia mice.  
To compare RV gene and protein expression profiles in male and female mice. 
To investigate the effect of estrogen on the migration of PASMCs explanted from 
male and female rats.   
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5.2 Results 
C57Bl/6 male and female mice were recruited to this study at 6-8 weeks old. 
Mice were housed in the hypobaric hypoxic chamber maintained at 550 mbar for 
28 days. On day 14 of the study, administration of Anastrozole (3 mg/kg/day) or 
the equivalent volume of vehicle (1% CMC) was initiated. Anastrozole (3 
mg/kg/day) or vehicle (1% CMC) was administered by daily i.p. injections for the 
last 14 days of the study. Age and sex-matched controls animals were housed in 
normoxic conditions and followed the same dosing regimen of Anastrozole (3 
mg/kg/day) or vehicle (1% CMC). On day 28 of the study the male and normoxic 
animals were humanely culled and a tissue harvest was performed. 
Haemodynamic assessment was performed on the female hypoxic mice before 
the mice were humanely culled and tissue harvested (Figure 5.1). Initially, the 
main aim of this study was to assess the effects of Anastrozole in the female RV 
as Anastrozole had been shown to be effective in reducing RV/LV+S in female 
mice only (Mair et al., 2014b). For this reason, full haemodynamic assessment 
was performed in the female hypoxic mice only. In future, haemodynamic 
assessment would be performed on male and female normoxic and hypoxic 
animals.  
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Figure 5.1- Schematic diagram showing Anastrozole study protocol and dosing 
regimen. 
Male and Female C57Bl/6 mice were kept in normoxia or hypoxia for a period of 
28 days. On day 14 daily intra-peritoneal (i.p.) injections of Anastrozole 
(3mg/kg/day) or vehicle (1% CMC) began in normoxic and hypoxic mice for the 
remainder of the 28 days. On day 28 tissue was harvested from the normoxic 
group and the male hypoxic group. Haemodynamic assessment and tissue 
harvest were completed for the female hypoxic group.  
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5.2.1 Investigation of the effect of Anastrozole on RVSP and 
BMPR2 expression in the female mouse lung 
A previous study by the group had shown treatment with Anastrozole (3 
mg/kg/day) significantly reduced RVSP (mmHg) as well as RVH in female chronic 
hypoxia mouse model (Mair et al., 2014b). Therefore, the aim was to confirm 
this finding in the current study and investigate the effect of anastrozole 
treatment on the RV.  
All mice were humanely culled on day 28 and tissue was harvested from all 
animals. Only the hypoxic mice were haemodynamically assessed at day 28 prior 
to cull, haemodynamic assessment was not performed on normoxic mice. 
Haemodynamic measurement of RVSP in the female hypoxic vehicle treated and 
anastrozole treated groups showed no significant difference in RVSP between the 
2 groups (Figure 5.2A).  
A previous study had shown that chronic hypoxia significantly reduced the 
expression of BMPR2 in the lung at both a gene and protein level and BMPR2 
expression was restored with Anastrozole treatment (Mair et al., 2014b). 
Therefore, to investigate the differential effect of treatment with anastrozole (3 
mg/kg/day) in the current study, gene expression and protein expression of 
BMPR2 was investigated by TaqMan qRT-PCR and western blot, respectively. 
Gene expression analysis showed BMPR2 was significantly lower in the hypoxic 
vehicle treated group in comparison with the normoxic group (0.224 ± 0.020 vs 
0.341 ± 0.023, n=4, *p<0.05) (Figure 5.2B). However, Anastrozole was not able to 
restore gene expression of BMPR2 as there was no significant difference in 
expression between hypoxic vehicle and anastrozole treated groups. 
Densitometric analysis of the western blot was used to compare BMPR2 protein 
expression in each of the groups (Figure 5.2D). There was no significant 
difference in BMPR2 protein expression across the groups.  
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Figure 5.2. RVSP and lung BMPR2 expression in the female chronic hypoxia 
mouse model.  
Female mice were maintained in normoxia and hypoxia and treated with 
Anastrozole (3 mg/kg/day) or vehicle (1% CMC). A) RVSP (mmHg) in female 
hypoxic mice treated with Anastrozole or vehicle. n=5-8. B) BMPR2 gene 
expression. TaqMan qRT-PCR was performed on lung tissue harvested from 
normoxic and hypoxic female mice treated with Anastrozole or vehicle. Data is 
displayed as 2-ΔCT and data was normalised to the expression of B2M. n=4 per 
group, repeated in triplicate. Statistical analysis was performed using one-way 
ANOVA followed by Bonferroni post-hoc test. C) BMPR2 protein expression in 
the lung. Representative immunoblots. D) Densitometric analysis of BMPR2 
protein expression in the lung. a-tubulin was used as a loading control. n=3 per 
group. Data is displayed to show each individual n number and the bar 
represents the mean ± S.E.M. 
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5.2.2 Treatment with Anastrozole had no significant effect on RV 
or LV+S mass in the chronic hypoxia female mouse model 
The previous study also showed that Anastrozole treatment significantly reduced 
RVH as measured by RV/LV+S in female chronic hypoxia mice (Mair et al., 
2014b). Therefore, the heart was harvested at the end of the study. The atria 
and vessels were removed, and the RV carefully dissected from the LV+S. The RV 
and LV+S mass was recorded. Hypoxia significantly increased RV mass (20.04 ± 
1.40 vs 27.39 ± 0.84 mg, n=5, **p<0.01) and RV mass corrected for body weight 
(RV mass/body weight) (1.02 ± 0.07 vs 1.46 ± 0.03 mg/g, n=5 ***p<0.001) in the 
vehicle group only (Figure 5.3). However, there was no significant difference 
between the vehicle and anastrozole treated hypoxic groups. RV/LV+S ratio was 
significantly increased in both hypoxic treatment groups compared to their 
normoxic controls (vehicle treated: 0.26 ± 0.02 vs 0.41 ± 0.01, n=5, 
****p<0.0001, Anastrozole treated: 0.28 ± 0.01 vs 0.38 ± 0.01, n=4-5, ***p<0.001). 
However, within the vehicle treated group, LV+S mass was significantly lower in 
the hypoxic animals (78.52 ± 2.23 vs 67.25 ± 2.34 mg, n=5, *p<0.05) and within 
the anastrozole treated group LV+S mass/body weight was significantly 
decreased in the hypoxic animals (4.09 ± 0.21 vs 3.45 ± 0.08, n=4-5, *p<0.05). 
LV+S mass was not significantly different between the hypoxic vehicle and 
hypoxic anastrozole groups.   
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Figure 5.3. The effect of hypoxic and treatment with Anastrozole 
(3mg/kg/day) on RV and LV+S mass in female C56Bl/6 mice.  
Mice were housed in normoxic or hypoxic conditions for 28 days and 
administered Anastrozole (3mg/kg/day) or vehicle (1% CMC) for the final 14 
days. A) RV mass (mg) B) RV mass/body weight (mg/g). C) RV/LV+S. D) LV+S 
mass (mg) E) LV+S mass/body weight (mg/g). n=4-5, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  Statistical analysis was performed using one-way 
ANOVA followed by Bonferroni post-hoc test. Data is displayed to show each 
individual n number and the bar represents the mean ± S.E.M. 
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5.2.3 Anastrozole does not significantly affect RV or LV+S mass 
in male chronic hypoxia mice 
The protocol at the end of the 28-day study varied slightly for the male mice. 
After the body weight was recorded, the mice were humanely culled, and tissue 
harvested. The heart was dissected in the same manner as the female mice - RV 
was finely dissected from the LV+S. RV mass and LV+S mass was recorded (Figure 
5.4). Hypoxia did not significantly increase RV mass in the vehicle or anastrozole 
treated groups. However, when RV mass was corrected for body weight (RV mass 
(mg)/body weight (g)), hypoxia had a significant effect in the vehicle treated 
group (0.91 ± 0.03 vs 1.26 ± 0.05 mg/g, n=5, *p<0.05). The Fulton’s index 
RV/LV+S was significantly increased in both hypoxic groups compared to their 
normoxic counterparts (vehicle treated: 0.24 ± 0.01 vs 0.37 ± 0.01, n=5, 
****p<0.0001 anastrozole treated: 0.23 ± 0.004 vs 0.39 ± 0.01, n=4-5, 
****p<0.0001). However once again, hypoxia significantly affected the LV+S. LV+S 
mass measurements showed that LV+S mass and LV+S mass corrected for body 
weight was significantly decreased in the Anastrozole treated hypoxic group 
compared to normoxia (LV+S mass: 117.88 ± 10.60 vs 87.18 ± 2.80 mg, n=4-5 
**p<0.01, LV+S mass/body weight 4.48 ± 0.36 vs 3.40 ± 0.08 mg/g, n=4-5, 
**p<0.01). There was no significant difference in LV+S mass between the 
different treatment groups.  
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Figure 5.4. The effect of hypoxic and treatment with Anastrozole 
(3mg/kg/day) on RV and LV+S mass in male C56Bl/6 mice.  
Mice were housed in normoxic or hypoxic conditions and administered 
Anastrozole (3/mg/kg/day) or vehicle (1% CMC). RV mass (mg) B) RV mass/body 
weight (mg/g). C) RV/LV+S. D) LV+S mass (mg) E) LV+S mass/body weight 
(mg/g). n=4-5, *p<0.05, **p<0.01, ****p<0.0001.  Statistical analysis was 
performed using one-way ANOVA followed by Bonferroni post-hoc test. Data is 
displayed to show each individual n number and the bar represents the mean ± 
S.E.M. 
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5.2.4 Expression studies in the male and female mouse RV. 
As described, the previous study by the lab group had shown treatment with 
Anastrozole (3 mg/kg/day) was capable of significantly decreasing RVSP and RVH 
in the female chronic hypoxia mouse model (Mair et al., 2014b). Therefore, the 
aim prior to commencing the study was to investigate the effect of Anastrozole 
on the RV. However, in this current study Anastrozole had no significant effect 
on RVSP or RV/LV+S. For this reason, it was determined that the effect of 
Anastrozole on the RV was not the most informative investigation at this stage. 
Sex-specific expression profiles in the rat RV had been identified during the rat 
RV investigation. Therefore, the aim was to conduct a similar analysis in this 
mouse model in order to identify if these findings were apparent in different 
rodents.      
5.2.5 Protein expression of Id1 and Id3 is significantly different 
between the male and female normoxic RV 
BMPR2 dysfunction is the strongest risk factor in the development of PAH (Fessel 
et al., 2011) and recent studies have also shown that increased RV dysfunction is 
associated with BMPR2 mutation (van der Bruggen et al., 2016) indicating that 
BMPR2 signalling in the RV could influence clinical outcomes. Therefore, 
investigation of BMPR2 signalling in the RV could develop our understanding of 
how this could impact clinical outcomes. The gene expression of Bmpr2, Smad1, 
Id1 and Id3 gene expression was compared in male and female normoxic RV.  
There were no significant differences in the gene expression of the BMPR2 
pathway components between the male and female normoxic RV (Figure 5.5). 
When the protein expression was compared, analysis showed that expression of 
ID1 and ID3 was significantly downregulated in the female RV compared to the 
male RV (ID1 0.00073 ± 0.00032 vs 0.00330 ±0.00041, n=5, **p<0.001, ID3 
0.00189 ± 0.00044 vs 0.00380 ± 0.00029, n=5, **p<0.001) (Figure 5.6).   
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Figure 5.5. Differential gene expression between the male and female 
normoxic mouse RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male and female 
mice maintained in normoxia and treated with vehicle (1% CMC). A direct 
comparison between normoxic male and normoxic female RV is carried out for 
each of the genes investigated. A) Bmpr2 gene expression. B) Smad1 gene 
expression C) Id1 gene expression D) Id3 gene expression. E) CYP1b1 gene 
expression. Data is displayed as 2-ΔCT and data was normalised to the expression 
of B2M. n=4-5 per group, repeated in triplicate. Statistical analysis was 
performed using un-paired t test *p<0.05. Data is displayed to show each 
individual n number and the bar represents the mean ± S.E.M. 
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Figure 5.6 Protein expression of BMPR2, ID1 and ID3 in the normoxic male 
and female mouse RV. 
Male and female mice were maintained in normoxia and treated with vehicle 
(1% CMC). Protein expression in the RV was investigated by western blot. A) 
Representative immunoblot. Densitometric analysis of B) BMPR2 C) ID1 and D) 
Id3 protein expression in the RV. a-tubulin was used as a loading control. n=5 
per group, 1 technical replicate. Statistical analysis was performed using un-
paired t test **p<0.01.  Data is displayed to show each individual n number and 
the bar represents the mean ± S.E.M. 
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5.2.6 CYP1b1, ER-α and Aromatase are expressed in the male and 
female mouse RV but expression is not significantly 
different between males and females 
Next the expression of proteins involved in the production and metabolism of 
estrogen as well as the estrogen signalling pathway were investigated. The gene 
expression of Cyp1b1 was compared in normoxic male and female mouse RV by 
TaqMan qRT-PCR. There was no significant difference in Cyp1b1 expression 
between males and females (Figure 5.7). Following this, the protein expression 
of CYP1B1, ER-α and Aromatase were all investigated by western blot in the 
male and female RV. The key finding was that both the male and female mouse 
RV express each of these proteins (Figure 5.8). However, densitometric analysis 
did not show any significant difference in the expression of CYP1b1, ER-α or 
aromatase between the male and female mouse RV.    
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Figure 5.7. Cyp1b1 gene expression in the male and female normoxic mouse 
RV.  
TaqMan qRT-PCR was performed on RV tissue harvested from male and female 
mice maintained in normoxia and treated with vehicle (1% CMC). A direct 
comparison between normoxic male and normoxic female RV was carried out. 
A) CYP1b1 gene expression. Data is displayed as 2-ΔCT and data was normalised 
to the expression of B2M. n=4-5 per group, repeated in triplicate. Statistical 
analysis was performed using un-paired t test *p<0.05. Data is displayed to show 
each individual n number and the bar represents the mean ± S.E.M. 
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Figure 5.8 Protein expression in the male and female mouse normoxic RV. 
Male and female mice were maintained in normoxia and treated with vehicle 
(1% CMC). Protein expression in the RV was investigated by western blot. A) 
CYP1b1 expression - representative immunoblot B) Densitometric analysis of 
CYP1b1 protein expression in the RV. C) ER-a expression – representative 
immunoblot. D) Densitometric analysis of ER-a protein expression in the RV. a-
actin was used as a loading control. n=4 per group. E) Aromatase expression – 
representative immunoblot. Positive control (+) – mouse uterus tissue. F) 
Densitometric analysis of Aromatase protein expression in the RV. a-tubulin was 
used as a loading control, n=5 per group, 1 technical replicate. Data is displayed 
to show each individual n number and the bar represents the mean ± S.E.M. 
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5.2.7 Investigation of the effect of estrogen on the migration of 
pulmonary artery smooth muscle cells 
5.2.7.1 The expression of ER-a and ER-b in male and female rat PASMCs.     
The final aim of this chapter was to investigate the effect of estrogen on the 
migration of PASMCs. Briefly, the left lung lobe was removed from male and 
female rat post-mortem and the main pulmonary artery (PA) dissected from the 
lung. The PA was digested using a solution including elastase and collagenase 
and the resultant cells were filtered and plated for cell culture purposes.  
Prior to investigating the effect of estrogen, it was necessary to confirm 
expression of estrogen receptors ER-a and ER-b in male and female rat PASMCs 
under basal conditions. Protein was extracted from the cells and the expression 
of the estrogen receptors was confirmed using western blot (Figure 5.9). Both 
male and female rat PASMCs expressed ER-a and ER-b.      
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Figure 5.9. Expression of ER-a and ER-b in male and female rat PASMCs.  
The protein expression of ER-a and ER-b in male (M) and female (F) rat PASMCs 
under basal conditions was assessed by western blot. A) Representative 
immunoblot showing the expression of ER-a and ER-b. Uterus (U) was used as a 
positive control. This was performed by Dr. Katie Harvey. 
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5.2.7.2 The effect of varying serum conditions on the migration of rat 
PASMCs.  
The aim of this assay was to assess PASMC migration in response to stimulation 
with 17b-estradiol and estrogen metabolite, 16a-OHE1. As estrogens were being 
added to these cells as a stimulant the DMEM and serum used in the cell culture 
experiments had to be optimised. Fetal bovine serum has been shown to contain 
estrogens (Reynolds et al., 1982) therefore, a charcoal stripping process can be 
performed on FBS to remove any endogenous estrogenic compounds from the 
serum. Charcoal is used to strip non-polar compounds from FBS including 
hormones. Additionally, phenol red present in most DMEM has been shown to act 
as a weak estrogenic mimic (Welshons et al., 1988). Consequently, FBS and 
phenol red media can influence cell culture estrogen stimulations and it is 
favourable to use charcoal stripped FBS in phenol red free DMEM when 
performing hormone stimulations. Therefore, prior to beginning cell stimulations 
with estrogen the effect of varying DMEM media and serum conditions on cell 
migration was tested.  
First, cells were allowed to reach full confluence before a physical scratch was 
induced in the cell monolayer. Images at 0 hr (the time the scratch was induced) 
and at 24 hr were captured. The bottom of the well was marked to ensure the 
same area of the scratch was captured at each time point. The area of a small 
section of the scratch indicated by the line drawn on the bottom of the well was 
measured at 0 hr and 24 hr and the % wound closure calculated 0 -24 hr area/0 
Hr*100.  
The migration assay showed that 10% FBS in phenol red free DMEM induced the 
greatest migratory response in male PASMCs (78% wound closure, n=1) (Figure 
5.10, Figure 5.11). Both 10% charcoal stripped serum in phenol red free DMEM 
and 10% FBS in phenol red DMEM were capable of inducing a migratory response 
(44%, 57% wound closure, n=1), however, this was to a lesser extent. The 1% 
serum controls were similar across the 3 different groups (22%, 20% and 27% 
wound closure, n=1).  
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Figure 5.10. The effect of serum and DMEM on the migration of male rat 
PASMCs.   
Rat PASMCs were grown to a confluent monolayer and serum starved for 24 Hr 
before a scratch was induced in the monolayer. Cells were grown in varying 
conditions – 1% fetal bovine serum (FBS), 10% FBS, 1% charcoal stripped serum 
(CSS), 10% CSS, 1% FBS in phenol red media (PRM) and 10% FBS in PRM for 24 hr. 
The area of a section of the scratch was measured at 0 hr and again at 24 hr. 
The % wound closure is calculated by 0 hr -24 hr area/0 hr*100. n=1. A) 
Representative images highlighting the area of the scratch at 0 hr and 24 hr 
times points.   
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Figure 5.11. The effect of serum and DMEM on the migration of male rat 
PASMCs.   
Rat PASMCs were grown to a confluent monolayer and serum starved for 24 Hr 
before a scratch was induced in the monolayer. Cells were grown in varying 
conditions – 1% fetal bovine serum (FBS), 10% FBS, 1% charcoal stripped serum 
(CSS), 10% CSS, 1% FBS in phenol red media (PRM) and 10% FBS in PRM for 24 hr. 
The area of a section of the scratch was measured at 0 hr and again at 24 hr. 
The % wound closure is calculated by 0 hr -24 hr area/0 hr*100. n=1. A) % wound 
closure for each of the conditions. Data is displayed to show the individual n 
number.  
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5.2.7.3 The effect of 17b-estradiol and 16a-OHE1 on the migration of 
PASMCs 
Having confirmed that the use of phenol red free DMEM and charcoal stripped 
serum should not prevent the migration of PASMCs, the subsequent aim was to 
stimulate male and female PASMCs with E2 and 16a-OHE1 at physiologically 
relevant concentrations and assess the migration of the cells. Male and female 
PASMCs were stimulated with 17b-estradiol (E2) at 1 nM and 10 nM and 16a-
OHE1 at 1 nM and 10 nM for 24 hr (Figure 5.12). Similar to the previous assay, a 
scratch was induced in the cell monolayer at 0 hr and the area of a section of 
the scratch at 0 hr and 24 hr measured from images captured and the % wound 
closure calculated. However, the 10% charcoal stripped serum positive control 
did not induce an increased % wound closure as was expected in either the male 
or the female PASMCs. Furthermore, there was no significant effect of E2 or 
16a-OHE1 on % wound closure in the female PASMCs. Migration analysis was only 
carried out in n=1 for the male PASMCs and therefore, it is not possible to 
comment on statistically significant results.  
As investigation of the effect of FBS vs charcoal stripped serum had shown FBS 
was capable of inducing migration of PASMCs to a greater extent than charcoal 
stripped serum, the experiment was repeated utilising FBS (Figure 5.13). Cell 
stimulations were carried out in 1% FBS and 10% FBS was used as a positive 
control. 10% FBS significantly increased % wound closure compared to the 1% FBS 
basal control in female PASMCs (female 13.89 ± 2.02 vs 81.82 ± 3.65 %, n=3, 
****p<0.0001). The success of the positive control confirmed the cells were 
capable of migration and the assay design was able to detect % wound closure. 
However, both E2 (1 nM) and 16a-OHE (1 nM) did not affect % wound closure in 
female PASMCs. The ethanol (EtOH) vehicle control was not significantly 
different from the 1% FBS control indicating that the EtOH vehicle does not 
affect the migration of these cells.  
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Figure 5.12. The effect of 17β-estradiol and 16α-OHE1 on the migration of 
male and female rat pulmonary artery smooth muscle cells in charcoal 
stripped serum.  
Rat PASMCs were grown to a confluent monolayer and serum starved for 24 Hr 
before a scratch was induced in the monolayer. Cells were stimulated for 24 Hrs 
with 16a-OHE1 1nM, 16a-OHE1 10nM, 17β-estradiol (E2) 1nM or E2 10nM for 
24hours in 2.5% charcoal stripped serum (CSS) DMEM. The area of a section of 
the scratch was measured at 0 hr and again at 24 hr. The % wound closure is 
calculated by 0 hr -24 hr area/0 hr*100. A) Female rat PASMCs. n=2. B) Male rat 
PAMSCs. n=1.  Data is displayed to show each individual n number and the bar 
represents the mean ± S.E.M. 
169 
 
 
Figure 5.13. The effect of 17β-estradiol and 16α-OHE1 on the migration of 
male and female rat pulmonary artery smooth muscle cells in charcoal 
stripped serum and FBS.  
Rat PASMCs were grown to a confluent monolayer and serum starved for 24 hr 
before a scratch was induced in the monolayer. Cells were stimulated for 24 hr 
with 16a-OHE1 1nM, 16a-OHE1 10nM, 17β-estradiol (E2) 1nM or E2 10nM for 24 
hr in 2.5% charcoal stripped serum (CSS) DMEM. The area of a section of the 
scratch was measured at 0 hr and again at 24 hr. The % wound closure is 
calculated by 0 hr -24 hr area/0 hr*100. A) Female rat PASMCs. n=3 
****p<0.0001. B) Male rat PAMSCs n=2. Statistical analysis was performed using 
one-way ANOVA followed by Bonferroni post-hoc test. Data is displayed to show 
each individual n number and the bar represents the mean ± S.E.M.  
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5.3 Discussion  
Despite an increasing number of studies in the area, the role of estrogen in the 
development and progression of PAH is still not fully elucidated. Recent 
literature has indicated a pathogenic effect of estrogen in the pulmonary 
vasculature (Mair et al., 2014b; White et al., 2012; Rajkumar et al., 2010). 
Further complexity is added to interrogating the role of estrogen as studies have 
also shown contradictory effects in the lung and the right ventricle. Animal 
studies have highlighted a protective effect of estrogen in the RV with females 
of the SuHx rat model displaying improved cardiac output and RVEF (Liu et al., 
2014; Frump et al., 2015). Inhibiting the production of endogenous estrogens 
with the use of aromatase inhibitors, such as Anastrozole, is being investigated 
as potential therapeutics for the treatment of PAH. The effect of these 
therapies on the RV has to be carefully monitored as ultimately RV dysfunction is 
the main cause of mortality in the PAH patient population.  
In this chapter, the key aim was to investigate the role of estrogen in the 
development of PH and in the RV. Initially, the effect of Anastrozole on PH 
phenotype was assessed. The chronic hypoxia mouse model was utilised as 
Anastrozole was effective at reducing RVSP and RVH in female mice of this 
rodent model (Mair et al., 2014b). In the current study, treatment with 
Anastrozole (3 mg/kg/day) did not significantly reduce RVSP or RVH in female 
mice. RVH in male mice was not influenced by the administration of Anastrozole 
similar to the finding by Mair et al. (2014). The chronic hypoxic model and the 
dosing protocol were identical between the 2 studies. However, the current 
study involved lower n numbers in each of the groups compared to the 8-10 
animals per group in the previous study. There was a slight trend emerging in 
the female hypoxic group that the Anastrozole treated group had lower RV/LV+S 
compared to the vehicle treated group. An increase in n numbers in this study 
may have been able to statistically confirm or refute this trend. Although, the 
RVSP in both the vehicle and Anastrozole treated female mice was similar. In an 
attempt to identify if Anastrozole had been effective in these mice, lung BMPR2 
expression levels were investigated. Previous studies have shown hypoxia 
decreases lung BMPR2 expression and Anastrozole is capable of restoring 
expression (Mair et al., 2014b). Gene and protein expression analysis did not 
provide evidence to confirm this effect of Anastrozole. Measuring circulating 
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estrogen levels within the plasma of the female mice at the end of the study 
would have allowed confirmation that Anastrozole treatment was effective at 
inducing a reduction in endogenous estrogen production.    
The hypothesis at the beginning of this study was that Anastrozole treatment 
would significantly reduce RVH in the female mice and the studies following 
would further investigate the effect of Anastrozole on RV signalling pathways. 
However, as Anastrozole had no significant effect on RVH the aim of the study 
was adapted to focus on sex-specific differences in gene and protein expression 
in the normoxic RV. This investigation combined with the data produced in the 
rat model (Chapter 3), would confirm if sex-specific differences were apparent 
across multiple rodent models. An understanding of the male and female RV 
under normal conditions could identify key differences in signalling pathways 
that may account for the differing responses in the diseased state.  
Once again, the BMPR2 pathway was selected as a candidate pathway as 
mutations in the BMPR2 gene is one of the most well-established risk factors for 
developing PAH. Despite dysfunctional BMPR2 signalling being well characterised 
in the lung, the downstream effects in the RV are not so well understood. The 
results of the current study showed that although there was no significant 
difference in the gene expression of the BMPR2 pathway, at a protein level Id1 
and Id3 were significantly reduced in the female mouse RV. These results 
suggest that under normal physiological conditions BMPR2 signalling 
is downregulated in the female RV. Downregulation of the BMPR2 signalling 
pathway has been identified in female PASMCs compared to male PASMCs (Mair 
et al., 2015). It was suggested this could be related to the predisposition of the 
female sex to develop PAH.  This finding is concordant in that female RV also 
showed downregulation of the downstream components of the BMPR2 signalling 
pathway and therefore could also contribute to female susceptibility. 
Additionally, the disparity between gene expression and protein levels 
suggests that there could be differential post-translational modifications in male 
and female RV. Further studies would be required to confirm and fully 
understand the significance of this finding however it does highlight that there 
are significant, gender-specific differences between the male and female RV. 
Importantly, these changes occur in a pathway that has been identified as having 
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a key role in the development of PAH. To further develop this hypothesis, key 
assessments would involve a comparison of the BMPR2 pathway expression in 
male and female RV in the chronic hypoxia mouse model. Additionally, it may 
also be beneficial to assess RV function in male and female mutant BMPR2 
transgenic mice with conditional KO in lung vs heart.  
The ability of the RV to synthesise and metabolise estrogen and also the 
potential for estrogen signalling within the RV was assessed. In order to do this, 
the expression of CYP1B1, ER-α and aromatase was investigated. Gene 
expression analysis showed the expression of Cyp1b1 was similar between male 
and female RV. Expression of aromatase, CYP1b1 and ER-α proteins confirmed 
the potential for the synthesis, metabolism and signalling of estrogens with the 
male and female mouse RV. The protein expression was not significantly 
different between the sexes. Currently, estrogen synthesis, metabolism and 
signalling in the right ventricle specifically are largely unexplored. Additionally, 
the effect of treatment with Anastrozole on the RV of PAH patients is not fully 
elucidated. Although, the Phase II clinical trials conducted by Kawut et al. 
(2017) did show that Anastrozole treatment did not negatively impact the 
parameters of RV functionality assessed (Kawut et al., 2017). The ongoing 
clinical trial being carried out by the same group, will provide a larger patient 
group in which this can be confirmed. Having highlighted the potential for 
differential BMPR2 signalling in the male and female mouse RV, the effect of 
Anastrozole on BMPR2 signalling in the RV of pre-clinical models of disease could 
be an interesting focus for future studies.  
Finally, the ability of E2 and 16α-OHE1 to stimulate migration of male and 
female rat PASMCs was assessed. Preliminary studies highlighted 
that 10% CSS media was able to stimulate migration of male or female rat 
PASMCs but not to the same extent as 10% FBS. Initial cell culture stimulations 
were carried out in CSS but assessment of the migration of these cells showed no 
difference across any of the conditions including the 10% CSS which was included 
as a positive control. The effect of the positive control differed from the 
preliminary investigations, however it does perhaps suggest that the charcoal 
stripping process removes factors from the FBS that contribute to the migratory 
potential of cells. The process removes lipophilic molecules from the serum such 
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as growth factors (Tu et al., 2018). Although it is preferable that cell culture 
experiments involving estrogen be carried out in CSS, the final stimulations were 
performed using FBS to supplement the DMEM. This could be a limitation of this 
work as we do not know how any endogenous hormones in the FBS will influence 
the effect of E2 and 16a-OHE1. 
When supplementing the DMEM with 1% FBS, E2 (1 nM) and 16α-OHE1 (1 nM) had 
no significant effect on the migration of female RPASMCs. Although statistical 
analysis could not be completed on the male RPASMCs data, the trend is the 
same in that E2 and 16α-OHE1 had no effect on migration. These concentrations 
of E2 and 16a-OHE1 were selected as they are physiologically relevant. E2 
circulating levels in pre-menopausal women range from 30-400 pg/mL depending 
on the stage of the menstrual cycle (Becker, 2008), however levels are much 
lower in posts-menopausal women at < 10pg/mL (Modugno et al., 2006). 16a-
OHE1 circulating levels range from 295 pg/mL in post-menopausal women to 360 
pg/mL in pre-menopausal women (Arslan et al., 2014; Modugno et al., 2006; 
Jernstrom et al., 2003). E2 and 16α-OHE1, at the same concentration used in 
this study (1 nM), induce proliferation of PASMCs (Wright et al., 2015; White et 
al., 2012), however, there is very little known about the effect of estrogen or 
estrogen metabolites on the migration of PASMCs. In vascular smooth muscle 
cells E2 at a concentration of 10 nM reduces TNF-α induced proliferation and 
migration (Li et al., 2016a). E2 at 10 nM concentration has also been shown to 
inhibit lipopolysaccharide induced vascular SMC migration and serum induced 
migration in rat aortic VSMCs (Jiang et al., 2010; Zheng et al., 2015). PASMCs 
have a different phenotype and behaviour to other vascular beds with regards to 
proliferation and therefore it is possible their migratory response is also 
different (Frid et al., 1997). E2 (10 nM) has been shown to stimulate migration in 
other cell types such as endometriotic epithelial cells (Qi et al., 2018). Future 
studies could follow to assess whether E2 and 16α-OHE1 have an inhibitory effect 
on the migration of PASMCs.    
In summary, this data highlighted sex-dependent differences in the protein 
expression of ID1 and ID3, the downstream proteins involved in BMPR2 signalling. 
Although these findings are preliminary, they do fit with the hypothesis that 
basal differences in BMPR2 signalling may contribute to the susceptibility of 
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females to the development of PAH. Moreover, investigation of rat PASMCs 
highlighted that E2 and 16α-OHE1 are not capable of stimulating migration in 
either male or female cells under the conditions utilised. As therapeutics 
targeting BMPR2 and estrogen synthesis are currently under investigation for the 
treatment of PAH, it is important to enhance our understanding of their 
potential effects in the pulmonary vasculature and RV. 
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6 General Discussion 
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6.1 General Discussion 
PAH is a devasting and currently incurable disease which results from 
pathological remodelling of the pulmonary vasculature. These pathological 
changes lead to an increased afterload experienced by the RV which eventually 
results in right heart dysfunction and ultimately right heart failure. PAH 
registries have identified key characteristics of the patient population which 
have influenced the study of this disease. The REVEAL registry highlighted 
approximately 80% of the PAH population are female (Badesch et al., 2010). This 
suggested that females were more susceptible to disease and indicated a role for 
female sex hormones in the development of disease. Subsequent research has 
followed which has uncovered pathogenic effects of estrogen in the pulmonary 
vasculature (Mair et al., 2014b; White et al., 2012; Rajkumar et al., 2010). 
However, there have been contradictory studies which have indicated a 
protective effect for estrogen in the lung (Xu et al., 2010; Lahm et al., 2012; 
Umar et al., 2011). The effect of estrogen on the RV is largely unexplored.  
The other major risk factor in the development of PAH is abnormal BMPR2 
signalling (Fessel et al., 2011). Mutations in BMPR2 have been identified in both 
heritable and idiopathic versions of the disease (Machado et al., 2009). Patients 
harbouring BMPR2 mutations are more likely to present with worse disease 
progression at a younger age (Evans et al., 2016a). Aberrant BMPR2 signalling 
results in a decrease in anti-proliferative ID1 and ID3 which act as inhibitors of 
DNA binding preventing differentiation and proliferation (Morrell et al., 2009). 
BMPR2 dysfunction is better understood in the lung where it is known to lead to 
increased proliferation of PASMCs. Sex differences in the expression of BMPR2 
have been identified which could also be related to increased susceptibility in 
females (Mair et al., 2015). However, the role of BMPR2 in the RV is not well 
understood.  
Current therapies are all targeted towards the increased vasoconstriction 
present in the PAH lung (Ryan et al., 2015). There is a real need to identify new 
therapeutic targets which are capable of reversing the pathological remodelling 
of the pulmonary vasculature or the dysfunction of the RV.  
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The key aims of this thesis were to investigate the sex-dependent and RV-
specific effects of potential PAH therapies that are undergoing clinical trials. It 
is more common in rare, orphan diseases such as PAH that drugs licensed for 
another uses are considered as potential therapies. A recent study identified 
that FK506, an FDA approved drug currently licensed for use as an 
immunosuppressant in organ transplantation, was able to increase the expression 
of BMPR2 (Spiekerkoetter et al., 2013). Investigations in three different rodent 
models showed FK506 treatment improved the key parameters of PH disease 
phenotype. However, there was a need to identify the sex-dependent effects of 
this therapy as this had not yet been investigated. Published studies have 
identified sex-specific differences in the BMPR2 pathway in rodent models as 
well as human PASMCs with females displaying lower levels of expression (Mair 
et al., 2015). Although this sex difference has not been fully elucidated in the 
chronic hypoxia rat model it was hypothesised that female rats may respond 
differently to FK506-induced increases in BMPR2 expression as their basal levels 
could be lower. 
Chapter 3 investigated the effects of FK506 treatment on the development of 
PAH. During this investigation the 5-week chronic hypoxia rat model was 
characterised as this model had not previously been used within the lab group. 
This model was confirmed as an appropriate model for the investigation as all 
the PH phenotype parameters measured corresponded to previous models 
utilised by the lab (Docherty et al., 2019; Mair et al., 2014; Dean et al., 2018). 
Treatment with FK506 had not previously been investigated in this rodent model. 
FK506 was not capable of reducing RVSP or pulmonary artery remodelling. The 
slow releasing pellets which were utilised to administer FK506, released the drug 
at a dose appropriate to their weight at the beginning of the study. One 
limitation of this study was that the concentration of FK506 did not increase 
with the weight gain of the animals throughout the 3-week dosing period. 
Additionally, weight gain was lower in the female rats across the 3-week dosing 
period as a result it would not be appropriate to directly compare males and 
females as it is likely the doses were not equivalent. This could have been 
further investigated had plasma FK506 concentrations have been monitored at 
the end of the study. Other studies by the lab group have utilised slow releasing 
pellets for the administration of 2-methoxyestradiol in male and female rats and 
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effects have been apparent in males and females regardless of the inevitable 
greater weight gain in male animals (Docherty et al., 2019).  
Chapter 4 focused on a cardiac-specific investigation of the sex specific effects 
of FK506 treatment. It is currently unknown if FK506 treatment affects BMPR2 
signalling in the RV and consequently how this affects RV function in a PH model. 
RV/LV+S significantly increased in hypoxia, however, treatment with FK506 did 
not influence RV/LV+S measurements. When RV mass was assessed in isolation, 
there was a significant decrease in the FK506 treated hypoxic group in males 
only. This finding was also apparent when the RV mass was corrected for body 
weight. Although RV/LV+S is the standard measure within the field, it may have 
more been appropriate to measure tibial length in this study to confirm the 
effects of FK506 on the male RV (Yin et al., 1982). This reduction in RV mass was 
also independent of any significant changes in RVSP, which could suggest a 
direct effect of FK506 on the RV. Furthermore, this was a sex-dependent effect 
as FK506 had no significant effect on RV mass, RV mass/body weight or RV/LV+S 
in the female hypoxic rats. Treatment with FK506 also significantly reduced the 
expression of Tgfβ1 in the male hypoxic RV. As the role of Tgfb1 in cardiac 
fibrosis and cardiac hypertrophy is well established (Khan and Sheppard, 2006; 
Rosenkranz, 2004), the effect of FK506 on the gene expression of markers of 
hypertrophy and fibrosis was investigated. FK506 treatment did not alter gene 
expression of these markers, however, it is understood that the expression of 
these genes is time dependent (Manabe et al., 2002; van den Bosch et al., 2006; 
Friddle et al., 2000) and therefore further investigations are required. To further 
elucidate the effect of FK506 on the RV, cellular hypertrophy measured by 
wheat germ agglutinin staining and collagen deposition measured by picrosirius 
red staining could be utilised (Fattah et al., 2016; McCarroll et al., 2018).  
The investigations in this chapter also involved a comparison between the RV 
gene expression profiles in normoxia vs hypoxia and male vs female. There were 
several key differences identified, consequently, it was important to identify 
patterns in gene expression which could influence the response of the RV in 
disease. Hypoxia significantly reduced Bmpr2 gene expression in the male and 
female RV, a finding which is important in the study of PAH. A recent clinical 
study showed BMPR2 mutation carriers have poorer RV function despite similar 
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cardiac adaptation in mutation carrier and non-carrier groups (van der Bruggen 
et al., 2016) suggesting that BMPR2 signalling has an effect on RV function. 
Furthermore, mutations in BMPR2 have also been shown to impair RVH in a 
transgenic mouse model (Hemnes et al., 2014). Reduced expression of BMPR2 in 
the hypoxic RV may also contribute to impaired function.  
Next, Tgfβ1 emerged from the expression profiles as a gene influenced by 
hypoxia and sex. Tgfβ1 expression was significantly higher in males under 
normoxic and hypoxic conditions. Hypoxia induced expression of Tgfβ1 in the 
males only. This could be related to the FK506 dependent reduction in RV mass 
and Tgfb1 expression previously discussed. Investigations of genes involved in 
cardiac hypertrophy and fibrosis were once again conducted. In normoxia, 
Col1a1 and Col3a1 were significantly upregulated in males and Col1a1, Ctgf, 
Nppa and Myh7 were increased in males following exposure to hypoxia. Although 
these are very preliminary investigations, they begin to identify potential 
differential Tgfβ1-mediated effects in the male RV that are not present in the 
female RV. Our understanding of the significance of this finding is limited as only 
changes in gene expression have been identified. This hypothesis would have to 
be further investigated in isolated male and female cardiac myocytes and 
fibroblasts through investigation of Tgfβ1 signalling.  
The final results chapter aimed to investigate the effect of endogenous estrogen 
on the development of PH. Published studies showed treatment with Anastrozole 
was capable of reversing the PH phenotype in female mice (Mair et al., 2014b; 
Chen et al., 2017). In contrast, Anastrozole treatment in the current study did 
not significantly affect RVSP or RVH. The expression of the BMPR2 pathway was 
investigated in normoxic mice similar to the previous study in rats (Chapter 4). 
Similar to the rat study, Bmpr2, Smad1, Id1 and Id3 gene expression were not 
significantly different between males and females. However, the mouse study 
presented in Chapter 5 also investigated protein expression. This showed that 
ID1 and Id3 were significantly down-regulated in the female RV. Protein 
expression analysis should also be carried out in the rat tissue to confirm this 
finding across different species. Protein investigations also showed that proteins 
involved in estrogen synthesis, metabolism and signalling (Aromatase, CYP1B1 
and ER-a) are all expressed in both the male and female mouse RV. Finally, the 
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ability of E2 and 16α-OHE1 to induce migration of male and female rat PASMCs 
was assessed. The conclusion of this work was that E2 and 16α-OHE1 did not 
stimulate migration of PASMCs. One limitation of the migration assay design was 
that proliferation of the PASMCs was not inhibited. Therefore, it would not have 
been possible to differentiate between the effects of PASMCs proliferation and 
migration on % wound closure. As there was no significant effect on % wound 
closure, the role of proliferation was not considered. E2 at a concentration of 10 
nM has been shown to inhibit migration of smooth muscle cells in other vascular 
beds (Li et al., 2016a; Jiang et al., 2010; Zheng et al., 2015). These 
investigations should be extended in the future to investigate a potential 
inhibitory effect of E2 and 16α-OHE1 on cell migration in response to classical 
agonists such as TGFb.  
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6.2 Future perspective 
The need to develop our understanding of the RV encouraged the development 
of the surgical pulmonary artery banding (PAB) rat model during these 
investigations. The method development is described in Appendix 7.2. The 
surgical procedure was particularly challenging and only sham surgeries have 
been performed successfully. The major challenges associated with this surgery 
are that the pulmonary artery is very thin walled and fragile and the RV is 
unable to withstand stress while the pulmonary artery is being manipulated 
during surgery (Tarnavski et al. 2004). The aim of developing this model was to 
compare RV function and RV phenotype in male and female rats, allowing the 
influence of sex and estrogen on the response of the RV to increased afterload 
to be investigated. This RV dysfunction model would provide a unique 
opportunity to investigate the pulmonary-independent effects of increased 
afterload and the pulmonary independent effects of estrogen on the RV. Using 
other rodent models, it would prove difficult to decipher the effect of estrogen 
on RV structure and function as it could be secondary to effects on the 
pulmonary vasculature or as the result of a direct effect on the RV.  
Initial in vitro investigations were carried out in neonatal rat cardiac fibroblasts 
which were routinely used in the lab (Flores-Munoz et al., 2012). However, 
studies that could be carried out in these cells were limited due to the inability 
to culture the cells based on sex or to isolate and culture RV cells. Therefore, a 
protocol for the isolation of adult rat RV cardiomyocytes was another method 
under development during this PhD thesis. The development of this model is 
described in Appendix 7.1. The isolation of viable adult myocytes is more 
challenging than neonatal cardiac cells. The isolation of neonatal cells is 
technically less demanding and the cells are more suited to culturing (Louch et 
al., 2011). Isolation of adult RV cardiomyocytes presented a challenge as current 
protocols within the lab were optimised to the successful isolation of LV 
cardiomyocytes. Isolation of adult RV cardiomyocytes results in a lower cell yield 
than that of the LV, maximising the number of viable isolated cardiomyocytes 
was one of the key aims during method development. Successful development 
would have provided a model which allowed investigation of cardiomyocytes in a 
sex-specific manner. Key investigations that could have been conducted 
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included: investigation of the sex-dependent effects of Tgfb1 and the effect of 
FK506 treatment on isolated cardiomyocytes.   
Currently, there are no treatments available that target RV dysfunction in PAH, 
despite this being the main cause of mortality in PAH patients. There is a real 
need to develop our understanding of the molecular mechanisms underlying RV 
dysfunction in order to identify potential therapeutic targets. Poorer male 
patient survival rates are thought to be associated with increased and 
accelerated RV dysfunction compared to females (Jacobs et al., 2014; Kuwat et 
al., 2009). Investigations into the effect of estrogen on the RV could help 
develop our understanding of why females tend to have better RV function and 
identify new RV-specific therapeutic targets. Clinical studies in control groups 
have suggested that higher estrogen levels are associated with increased RV 
function (Ventetuolo et al., 2011; Ventetuolo et al., 2015b). However, there is 
added complexity to estrogen-targeted therapeutics as estrogen has been shown 
to play a pathogenic role in both experimental animal studies (Mair et al., 
2014b; White et al., 2011) and clinical studies (Ventetuolo et al., 2015). 
Targeting therapies specifically to the pulmonary vasculature or the RV could be 
a solution.  
This thesis highlights that there are key differences between the male and 
female RV under basal conditions and in response to hypoxia which require 
further investigation. It is possible that sex-specific RV signalling contributes to 
the differences in disease progression in males and females. In the development 
of new PAH therapeutics, it is essential the sex-specific responses are 
investigated. In future, it may be beneficial to the clinical outcomes of PAH 
patients to stratify therapy depending on sex and to develop therapies that 
selectively target the lung or RV to reduce disease morbidity and mortality. 
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7 Appendices 
7.1 Development of a protocol to isolate cardiomyocytes 
from the adult rat right ventricle  
Initial investigations were performed in neonatal rat cardiac fibroblasts (NRCFs). 
This cell type was selected for early stage studies as they are technically easy to 
work with. Also, NRCFs have increased proliferative potential compared to adult 
cells due to their neonatal rat heart origin (Porrello et al., 2011; Zogbi et al., 
2014; Alkass et al., 2015). Although, it was understood that NRCFs were not the 
most appropriate model as it was not possible to isolate male and female cells or 
RV and LV cells. Sexing of neonatal pups is challenging and cell yields from the 
neonatal RV would have been low for complete in vitro investigations. The lab 
had developed successful protocols for the isolation of adult rat LV 
cardiomyocytes. The aim of this work was to adapt this protocol to successfully 
isolate viable RV cardiomyocytes. This would allow a model in which RV-derived 
cardiomyocytes could be investigated. It would also allow studies in male and 
female cells to be carried out in order to investigate sex-specific effects. The 
key challenge with this protocol development was ensuring that an appropriate 
number of cells were isolated that were still viable.  
To summarise the isolation protocol, Wistar Hans rats were culled and the hearts 
rapidly excised and transferred to a chilled Krebs solution. A Langendorff 
perfusion was set up and the hearts were cannulated via the aorta. An enzymatic 
digestion involving Collagenase Type I (0.7 mg/mL) and protease (0.06 mg/mL) 
in Krebs solution was performed.  Following digestion, a 0.5% BSA in Krebs 
solution was perfused through the heart which acted to halt the enzymatic 
digestion. Optimising the protocol involved identifying and selecting the most 
appropriate time periods for both the enzymatic digestion and the 0.5% BSA 
solution perfusion. Often the enzymatic activity of the collagenase Type I is 
batch dependent. The batch used in this current study was 260 units/mg. 
Following the perfusion step, the heart was cut down from the Langendorff set 
up and the RV dissected from the LV. It was from this point forward that the RV 
and LV cells were isolated. The tissue was then gently agitated to release the 
cells from the tissue mass. This was performed in a step by step process which 
involved removing the cell suspension and adding further 0.5% BSA solution. The 
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cells were then examined under the microscope to identify the number of viable 
rod-shaped cardiomyocytes. The viable rod-shaped cells and the non-viable ball 
shaped cells (Powell and Twist, 1976) in the field of view were counted (Figure 
7.1). A haemocytometer was not used for cell counting due to the size of 
cardiomyocytes. A representative cell population was not seen in the 
haemocytometer.  
The aim of this protocol development was to alter the time period of the 
enzymatic digestion and the 0.5% BSA perfusion step in order to determine the 
time period that resulted in the highest yield of viable cardiomyocytes to allow 
further downstream studies to be carried out. Table 12 shows the development 
of the protocol using cells derived from the RV of male Wistar Hans rats. As the 
protocol had not been optimised for RV cells it was important to vary the 
protocol significantly in order to identify the best time periods for the perfusion 
steps. The enzymatic digestion time period was varied between 3.5 mins and 10 
mins. The 0.5% BSA perfusion step was varied between 0 mins and 4 mins. This 
approach identified a 5.5 mins enzymatic digestion followed by 2 mins 0.5% BSA 
perfusion resulted in the highest percentage of rod cells (Table 12). Protocol 
development was initially carried out in male RV cells. Once the optimal 
perfusion times had been identified, the protocol was repeated in cells derived 
from female rat RV (Table 13). This protocol resulted in a similar percentage of 
rod-shaped viable cardiomyocytes and therefore these perfusion time periods 
were deemed appropriate. The next steps in this protocol development would 
have been to begin the addition of calcium chloride (CaCl2) in incremental stages 
and assess the percentage of viable cells when 1mM CaCl2 was reached. It is 
necessary to increase the calcium concentration within the cells in order to 
culture the cells for further experimentation.   
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  Figure 7.1 Representative image showing the rod shaped and ball shaped 
cells following adult rat RV cardiomyocyte isolation protocol.  
The resulting rod and ball shaped cardiomyocytes isolated from the RV of adult 
Wistar Hans rats.  
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Enzyme 
time (mins) 
BSA time 
(mins) 
Mean no. 
of rods 
Mean no. 
of Balls 
Mean Total 
no. of cells 
Mean Rod 
% 
03:30 04:00 8.5 55.5 64.0 13.2 
04:00 04:00 13.5 136.0 149.5 8.9 
04:30 02:00 19.0 104.0 123.0 15.7 
04:30 02:00 1.0 74.0 75.0 0.8 
05:00 00:00 9.1 79.6 88.7 10.3 
05:15 00:00 41.0 150.0 191.0 21.5 
05:30 02:00 27 49 76.0 35.5 
05:30 02:00 17.4 91.6 109.0 16.2 
05:30 03:00 19.0 90.4 109.4 17.7 
10:00 00:00 8.0 98.5 106.5 7.5 
 
Table 12. Development of adult rat RV cardiomyocyte isolation in Wistar Hans 
male rats. 
Cardiomyocyte isolation experiments were performed in male Wistar Hans rats. 
The time of the enzyme perfusion (0.7 mg/mL collagenase and 0.06 mg/mL 
protease in Krebs solution) on the Langendorff set up was varied in each 
isolation experiment to optimise the protocol. The time of the 0.5% BSA 
solution perfusion on the Langendorff set up was also varied in each isolation to 
optimise the protocol. Cells from the RV were dropped onto a microscope slide 
and the cells in a field of view were counted. The number of rod-shaped and 
ball shaped cells were counted and the rod % was calculated. Several fields of 
view were counted and the mean values calculated.  Cells were counted at 0mM 
calcium chloride (CaCl2).  
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Enzyme 
time (mins) 
BSA time 
(mins) 
Mean no. 
of rods 
Mean no. 
of Balls 
Mean Total 
no. of cells 
Mean Rod 
% 
05:30 02:00 36 88 124.0 29.0 
 
Table 13. Development of adult rat RV cardiomyocyte isolation in Wistar Hans 
female rat. 
Cardiomyocyte isolation experiment performed in a female Wistar Hans rat. 
05:30 mins enzyme perfusion (0.7 mg/mL collagenase and 0.06 mg/mL protease 
in Krebs solution) and 02:00 mins 0.5% BSA solution perfusion on the 
Langendorff set up. Cells from the RV were dropped onto a microscope slide and 
the cells in a field of view were counted. The number of rod-shaped and ball 
shaped cells were counted and the rod % was calculated. Several fields of view 
were counted and the mean values calculated.  Cells were counted at 0 mM 
calcium chloride (CaCl2).  
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7.2 Development of the pulmonary artery banding rat 
model 
As the study developed the central focus was on the effect of sex, BMPR2 and 
potential PAH therapies on the RV. There was a need to investigate changes in 
the RV in isolation rather than secondary to the pulmonary vasculature. For this 
reason, we began to work towards developing a pulmonary artery banding (PAB) 
rat model at the University of Glasgow. This model would allow investigation of 
the pulmonary-independent effects of sex on the development of right heart 
dysfunction developing our understanding of some of the sex paradoxes that 
exist in pulmonary hypertension. Additionally, it provides an experimental model 
to investigate the cardiac-specific effects of PH therapies and could help 
identify therapies that would improve right heart function. This could ultimately 
contribute to improving mortality rates within the PAH population.  
The early stages of model development were carried out as part of this study. A 
study by Tarnavski et al. in 2004 describes the PAB surgical procedure in a mouse 
model (Tarnavski et al., 2004). The PAB rat model protocol we aimed to develop 
was based on this method. The sham surgery also underwent development to act 
as a control. The protocol which was under development is detailed in Table 14. 
Briefly, the rat was intubated and positioned on the sterile, surgical table. A left 
lateral thoracotomy at the second intercostal space was performed in order to 
expose the pulmonary artery. The pulmonary artery was bluntly dissected from 
the aorta. This step was technically challenging as it was important to ensure 
extreme care was taken not to damage to pulmonary artery or the aorta. A 
suture was then positioned under the pulmonary artery with the use of a ligation 
aid before the suture was tied to constrict the artery. A 19G blunted needle 
positioned alongside the pulmonary artery was used to determine the diameter 
of the constriction. The sham surgery involved the same process of positioning 
the suture under the pulmonary artery, but the suture was then removed 
without being tied. Finally, the wound was closed before the intubation tube 
was removed and the animal was transferred to a recovery cage.  The recovery 
of the animal was closely monitored.
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Step  Description  
Preparation  Prepare sterile field and sterile instruments.   
Anaesthetics  Intubate and ventilate - approx. 3% isoflurane in oxygen. Ventilator – 60 breaths per min with 4ml tidal volume.  
Analgesics  Prior to the beginning of surgery – Subcutaneous injection of: Buprenorphine (0.05mg/kg) 
and Rimadyl (8mg/kg). Rib injections: Ropivacaine (4.5mg/kg).  
Thoracotomy  Left thoracotomy at the second intercostal space to expose the top of the heart, aorta and pulmonary artery.   
Isolation of 
PA 
Isolate the pulmonary artery from the aorta by blunt dissection. Position the ligation aid with the piece of suture in 
between the aorta and pulmonary artery. Using forceps stretch the connective tissue over the tip of the ligation aid until 
the ligation aid breaks the through the connective tissue.    
Banding  Pull the suture through the ligation aid and remove the ligation aid ensuring that the suture remains under the 
pulmonary artery. Place blunted 19G needle on top of the artery and tie the suture around the artery to the diameter of 
the needle. 
Suturing   Intercostal layer, muscle layer, subcutaneous layer (x2) and skin.  
Recovery  Turn off isoflurane and continue to administer oxygen. Once the rat can breathe on its own, disconnect from ventilator 
while keeping the intubation tube in place.  When convinced the rat is able to make a full recovery remove intubation 
tube.   
Post-Surgery  
care  
Maintain in heated box post-surgery. When the rat has fully recovered it can be return to the cage. Post-surgery – for 2 
days administer Buprenorphine (0.05mg/kg) in Nutella (am and pm).  
  
Table 14. Development of the pulmonary artery banding rat model protocol.   
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Unfortunately, due to other constraints with the project, only 2 sham surgeries 
were carried out. 1 male Wistar rat and 1 male Sprague Dawley rat successfully 
recovered from the sham surgery. Both animals had a satisfactory recovery and 
incisions that healed well post-surgery. The male rats were haemodynamically 
assessed post-surgery as an assessment of model development. One rat was 
assessed at 4 weeks and the other at 6 weeks post-surgery. RVSP, LVSP and SAP 
were recorded (Table 15). RV mass was recorded and RVH calculated using the 
standard measure in the pulmonary hypertension field RV/LV+S. The RVH 
measurements were consistent with male rats housed in normoxic conditions 
(Dean et al., 2016; Docherty et al., 2019) suggesting that the surgical procedure 
had not resulted in right ventricular hypertrophy. However, the RVSP of the 
male sham rats was slightly elevated in comparison with normoxic rats, previous 
studies have shown normoxic rats with RVSP of approximately 30 mmHg 
(Docherty et al., 2019; Mair et al., 2014b). This suggests that manipulation of 
the pulmonary artery during the surgical procedure could have induced a 
physiological response associated with the trauma which lead to an increase in 
RVSP, however, further sham surgeries would have to be carried out in order to 
investigate this fully. The pulmonary artery was not collected following 
haemodynamic assessment, however, in future it may be possible to 
histologically analyse the PA in the sham animals to try and identify any damage 
or remodelling. 
During the development of this model, it was identified that the method by 
which the pulmonary artery was constricted could be improved. Although the 
study by Tarnavski et al. (2004) described a method of using a blunted needle 
placed alongside the pulmonary artery as a guide for the diameter of the 
constriction, it was thought there would be variability in the constriction 
diameter using this method. Another method is to use a surgical clip to constrict 
the artery. Investigations of right heart dysfunction after pulmonary artery 
banding with a clip either 0.5 mm and 0.6 mm in diameter showed that 0.1 mm 
of a difference in the diameter of the clip was the difference between severe 
right heart failure and right heart dysfunction (Andersen et al., 2014). It is 
unlikely that this level of accuracy could be achieved by tying a suture and 
therefore the surgical clip would allow the most reproducible results.  
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  Sham Rat 1  Sham Rat 2 
Weeks post-surgery 
haemodynamic assessment 
was carried out 
4 6 
Strain Sprague 
Dawley 
Wistar 
Weight at PAB surgery (g)  300  259 
Weight at haemodynamic 
measurements (g)  
350.9  364.8 
 
RVSP (mmHg)  40.96 35.19 
Mean Systemic Arterial 
Pressure (mmHg)  
56.69  97.54 
LVSP (mmHg)  87  109.8 
RV mass (mg) 221.25 139.3 
RVH (RV/LV+S) 0.26 0.23 
  
Table 15. Summary of the phenotype and haemodynamic measurements of 
Pulmonary Artery Banding Sham surgery model. 
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